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Increasingly, drug-induced liver injury is one of the main reason for drugs to be withdrawn 
from the market even after passing toxicity studies in pre-clinical and clinical trials because 
of risks of toxicity and ineffective treatments. Human immortalised hepatocyte cell lines 
used in drug testing are widely available, inexpensive and easy to culture. However, these 
cell lines are commonly known to have poor predictive capabilities and improved in vitro 
hepatic models are required for predicting hepatotoxicity of large numbers of compounds in 
drug discovery.  
In this study, the primary goal was to develop an improved in vitro human hepatic model 
using a combination of the C3A human hepatic cell line and human umbilical vein 
endothelial cells (HUVECs), for prediction of acetaminophen (APAP) hepatotoxicity. Initial 
experiments showed that co-culture of HUVEC:C3A in EGM-2, an endothelial medium, was 
essential to support both cell types, and that co-cultures maintained the initial cell seeding 
ratio of 1:1 (HUVEC:C3A) after 3 days. Phenotyping of co-cultured cells using platelet 
endothelial cell adhesion molecule (PECAM-1/CD31) for HUVECs, and hepatic epithelial 
(EpCAM) markers for C3As demonstrated that at ratio 1:1 (HUVEC:C3A), there is cross-
talk between HUVECs and C3As and cells in co-culture showed properties of self-
organisation. This interaction resulted in improved hepatic metabolic activity in vitro in 
respect of albumin synthesis and cytochrome P450 activity.  
Treatment with low (5 mM), intermediate (10 mM) and high doses (20 mM) of APAP, 
showed that prediction of hepatotoxicity using specific kits for cell viability and 
mitochondria function, was significantly improved in C3As in the presence of HUVECs, 
thus demonstrating an in vitro human hepatic co-culture could be an invaluable model for 
drug toxicity studies. We observed that the intermediate APAP dose had no effect on cell 
viability and mitochondrial function in co-cultures, whilst by comparison both lactate levels 
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and oxidative stress were perturbed in mono-cultures. Co-cultures also up-regulated 
expression of vascular endothelial growth factor receptor-2 (VEGFR-2) in HUVECs 
following APAP exposure, which may be important in modulating the toxic effect of APAP 
on C3As.  
To further improve the in vitro liver-like model, Matrigel™ was incorporated to promote 
vascular formation by HUVECs and support hepatic organization, migration and function of 
C3As. 
In HUVEC mono-cultures, Matrigel™-promoted vascularization, haptotaxis and self-
organization and in HUVEC:C3A co-cultures formation of structures reminiscent of liver 
sinusoids and maintenance of hepatic albumin synthesis and CYP3A4 activity. Time-lapse 
imaging showed haptotactic migration of hepatocytes towards endothelial cells, with 
Matrigel™ likely having a chemotactic effect on HUVECs and C3As, resulting in 
interconnected vascular network. APAP inhibited angiogenesis in HUVEC mono-cultures 
whereas APAP had no effect in HUVEC:C3A co-cultures. 
In conclusion, the development of an in vitro human organotypic co-culture model of 
HUVECs and C3As significantly enhanced hepatic function, demonstrated by significant 
improvement in hepatic metabolism, evidence of greater resistance to APAP toxicity, and 
improved cell-cell communication. Co-cultures markedly modulated APAP hepatotoxicity 
compared with C3A mono-cultures. Furthermore, co-culture of HUVECs and C3As using a 
complex basement membrane biomatrix (Matrigel™) produced a self-assembling 
interconnected vascular network, improved hepatocyte function as well as reproducibility of 
responses to APAP toxicity. The application of the described co-culture models may 
improve the accuracy, efficacy and predictive power of drug toxicity testing strategies in 
drug development.  
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1 Chapter 1: Introduction  
 
Replace, Reduce and Refine 
In 1959 W.M.S. Russell and R.L. Burch published “The Principles of Humane Experimental 
Technique”, describing the principle of the three Rs: Replace, Reduce and Refine. This 
concept promotes the replacement, reduction and refinement of animal testing, encouraging 
scientists to find alternatives to using animals in experimentation and drug testing to 
demonstrate the same hypothesis (Flecknell, 2002).  
Prediction of drug toxicity in vitro is a major challenge for pharmaceutical companies. In 
spite of drug toxicology studies using in vitro animal or human-derived hepatic models, data 
from these models does not correspond accurately to the same effects or mimic side effects 
that would be expected to be observed in the equivalent human trials. This is especially the 
case when drugs are tested in animals, as responses of non-human species are often not 
representative or predictive of human drug responses (O'Brien et al., 2006, Gomez-Lechon et 
al., 2010).  
As the liver is one of the principal organs involved in drug metabolism, the development of a 
more representative in vitro human hepatic model of in vivo would be an ideal alternative to 
predict drug toxicity and provide information regarding dosing while ensuring efficacy 
(Jetten et al., 2013, Gomez-Lechon et al., 2010).  For example, hepatotoxicity is a significant 
common side effect for drugs to be withdrawn from the market following successful trials, 
which is not anticipated using the in vitro models or human trials (Arrowsmith and Miller, 
2013, Kaplowitz, 2005).  
In vitro hepatic models aim to meet three key elements for marketing a new chemical entity: 
efficacy, safety and rigorous testing of toxicity (Temple and Himmel, 2002, Yoon et al., 
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2014). New cell lines and novel technologies have been developed in recent years to improve 
the prediction of different aspects of hepatotoxicity using in vitro hepatic models, 
particularly in replicating human dose-responses, gene expression and morphological change 
in response to drug treatment (Donato et al., 2013), but they still do not fully mimic human 
physiological responsiveness (Soldatow et al., 2013). Animal cell lines and in vivo animal 
testing are costly and are not always representative of human metabolism (Shuey and Kim, 
2011). Using primary human hepatocytes (PHH) for an in vitro human hepatic model would 
show inter individual variation which may increase the difficulty to understand drug toxicity 
studies. One alternative is to use human hepatoblastoma cell lines to investigate how 
culturing in a more modulated and improved physiological environment could reveal 
important elements required for improvement of in vitro hepatic models. 
Indeed, human hepatocytes cultured with other non-parenchymal cells in two (2D) and three 
dimensions (3D) culture have been widely considered to be a reasonable approach to 
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1.1 Liver structure and composition 
 
The liver is the largest organ in the human body, weighing approximately 2% to 3% of the 
total weight, located in the upper right quadrant of the abdominal cavity and covered by the 
capsule of Glisson (Abdel-Misih and Bloomston, 2010).  
The liver is connected to the human body via the vascular system. The hepatic blood flow is 
divided in to two blood flows: the hepatic artery and the portal vein. The hepatic artery 
supplies oxygenated blood to the liver and the portal vein is responsible for the transfer of 
nutrients and drugs absorbed in the intestine to be metabolised in the hepatocytes. The portal 
vein also facilitates clearance of toxics and waste in the liver (Godoy et al., 2013).   
Most of the liver consists of parenchymal cells (hepatocytes) and the rest of the liver 
comprises non-parenchymal cells: liver sinusoidal endothelial cells (LSECs), hepatic stellate 
cells (HSC), also called ‘Ito cells or fat-storing cells’, Kupffer cells. The liver synthesises 
essential proteins to maintain vital functions including synthesis of albumin, blood 
coagulation factors II, V, VII, VIII, protein S and antithrombin as well as immune factors, 
bile, cholesterol and storage of glycogen, vitamins and nutrients as well as removing toxins 
(Biron-Andreani et al., 2010, Godoy et al., 2013, Elvevold et al., 2008, Fomin et al., 2013). 
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Table 1-1 Composition and function of liver cells. 
Several different liver cell types contribute to overall hepatic function and their strategic 
location allows them to perform metabolic activities key to the maintenance of homeostasis 
in the liver. Information adapted from (Godoy et al., 2012, Blouin et al., 1977, Wisse et al., 
1996, Elvevold et al., 2008, Fomin et al., 2013). 
Liver cells  % liver 
cells 
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1.1.1 Liver cells 
 
Hepatocytes are 10–20 µM in size and are characterised by having apical (canalicular) and 
basolateral poles (sinusoidal) which are directly related to their hepatic functionality 
(LeCluyse et al., 2012). This is the result of their strategic location in sheets which allows 
them to perform liver metabolic functions, drug metabolism and communication between 
parenchymal and non-parenchymal cells (NPC) (Figure 1-2). 30% of the liver comprises 
NPC; including 20% of LSECs and 10% Kupffer and hepatic stellate cells (HSC) (Table 1-1) 
(Godoy et al., 2012, Blouin et al., 1977).  
Hepatocytes and LSECs are separated by the space of Disse (10–15µM). The space of Disse 
contains the extracellular matrix (ECM), which mainly contains fibronectin and collagen-I, 
but also some laminin and collagen-III (Godoy et al., 2013). Its composition maintains 
hepatocyte phenotype and supports HSC which usually exist in a quiescent state. HSC store 
vitamin A and the interaction between endothelial cells and the extracellular matrix collagen 
receptors (α1b1, α2b1), laminin (α3b1, α6b1) and fibronectin receptors (α4, α5) has been 
associated with the promotion of vasculogenesis and cell migration (Hynes, 2007).  
Another important characteristic of hepatocytes is their capacity to regenerate in healthy 
adults and after hepatectomy (Diehl and Rai, 1996). The mechanism of hepatocyte 
regeneration and differentiation is influenced by LSECs. Hepatic growth factor and vascular 
endothelial growth factor (VEGFR-2) expressed in bone marrow progenitors cells of LSECs, 
which are associated to VEGFR1 pathways in vivo, play an important role in hepatocytes 
regeneration (DeLeve, 2013). 
LSECs are smaller in size than hepatocytes (6.5 µM) and they are characterised by an open, 
porous fenestrated endothelium (~100-150 nm) with no basement membrane or diaphragm 
(DeLeve, 2014). The fenestrae filter and distribute proteins, carbohydrates or fats from the 
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space of Disse to hepatocytes for their metabolism. LSECs main function is the clearance of 
waste of macromolecules, including low-density lipoproteins (DeLeve, 2013, Simon-
Santamaria et al., 2010, Li et al., 2011) and they also participate in lipid metabolic functions 
(Salerno et al., 2011). The three main receptors for endocytosis in LSECs are; mannose, 
scavenger receptor and Fcγ receptor IIb2 (DeLeve, 2013, Simon-Santamaria et al., 2010, Li 
et al., 2011).  
As mentioned previously in Section 1.1, the hepatic sinusoid microcirculation is responsible 
for the exchange of nutrients and drugs from the blood flow to the hepatocytes through the 
perisinusoidal space of Disse (McCuskey, 2008). In the absence of a membrane in the 
hepatic sinusoid, any disruption in the fenestrae can affect the permeability, the filtration of 
nutrients, the concentration of oxygen and hepatic function (LeCouter et al., 2003). Damage 
in the hepatic vascular system can also precede the activation of quiescent cells (DeLeve, 
2014) and lead to liver diseases such as non-alcoholic fatty liver disease (NAFLD), alcoholic 
liver diseases, fibrosis (Zhang et al., 2014). In hepatotoxicity, disturbances in the vascular 
system and in the fenestrae can interfere with blood vessel formation, potentially leading to 
the infiltration of erythrocytes into the space of Disse in liver drug toxicity, swelling of 








Figure 1-1 Architecture of the liver and liver cells location in the liver 
The liver is composed of 80% of hepatocytes (parenchymal cells) and 20% of non-
parenchymal cells (LSECs, HSC and Kupffer cells). In the parenchymal area, hepatocytes 
and LSECs are separated by the space of Disse, which contains the ECM. Although in 
indirect contact, LSECs filter through the fenestrations nutrients and drugs to be 
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1.2 Hepatic lobule: acinus 
 
The liver is organised by parenchymal (hepatocytes) and non-parenchymal cells dividing the 
liver into hexagonal lobules of 1mm in diameter and 2mm in thickness. Their functional 
subunit is the acinus, a mass of hepatocytes surrounding the sinusoids formed by blood 
vessels (Figure 1-2). The expanse of the acinus ranges from the terminal portal venule and a 
terminal hepatic arteriole, delivering blood into the hepatic sinusoid, to the central vein, 
which ultimately delivers blood to the hepatic vein (Jungermann and Kietzmann, 1996). 
Oxygen delivery to hepatocytes therefore depends on their proximity to the sinusoid and the 
size of the fenestrae (DeLeve, 2014), dividing the acinus into three major zones (Figure 1-3): 
Zone 1 or the periportal area (PP) receives approximately 75% of the oxygen supply and it is 
where regulation and synthesis of bile, metabolism of urea from ammonia, oxidative 
metabolism and gluconeogenesis occurs. Zone 2 or pericentral (PC) and Zone 3 or 
perivenous (PV) areas each receive approximately 25% of oxygen and it is where processes 
such as detoxification of ammonia into glutamine, metabolism of xenobiotics and glycolysis 
occur (Jungermann and Kietzmann, 1996).  
Cholangiocytes and hepatocytes have their origin in the intrahepatic bile ductules from oval 
cells (Yovchev et al., 2013) and both are characterised by a polarized structure. The bile 
canaliculus collects bile secreted by hepatocytes to the gut and the bile is an important way 
of drug excretion via canalicular transporters such as multidrug resistant-associated protein 
(Raynaud et al., 2011, Mottino and Catania, 2008).   




Figure 1-2 Liver lobule; acinus 
The liver hexagonal lobules contain the acinus, a microcirculatory functional unit. The 
acinus is exposed to hepatic blood flow through sinusoids from the portal vein to the central 
vein and, depending on the quantity of oxygen, the acinus can be divided into three zones 
with each performing specified functions: 
Zone 1 or the periportal area (PP) receives approximately 75% of the oxygen and it is the 
closest to the portal triad where bile synthesis, β-oxidation, cholesterol synthesis, and 
glycogen synthesis from lactate and ureogenesis occurs. Zone 2 or pericentral (PC) and 
Zone 3 or perivenous (PV) areas receive approximately ~25% of oxygen. Glycogen synthesis 
from glucose, glycolysis, lipogenesis, glutamine and heme synthesis, as well as metabolism 







   
10 
 
1.3 Intracellular organelles 
 
The intracellular organelle targets involved in drug metabolism are mainly mitochondria, 
endoplasmic reticulum and lysosomes. However, the mitochondrion is the main organelle in 
regulating cell death via apoptosis and necrosis. Mitochondrial dysfunction is significantly 
associated with drug toxicity or non-alcoholic fatty liver disease (Sassi et al., 2014, Lockman 
et al., 2012).   
1.3.1 Mitochondrial structure and function 
 
Mitochondria are approximately between 0.5µm and 10µm in size per cell. Mitochondria are 
essential in cellular respiration and their main function is to generate most of the adenosine 
triphosphate (ATP) as the main source of energy (Yehuda-Shnaidman et al., 2013, Ribeiro et 
al., 2014). 
Mitochondria are characterised by a double membrane separated by the intermembrane 
space: the external membrane and the inner membrane. The inner membrane is characterised 
by cristae, which provide a larger surface area for the mitochondrial function. In terms of 
their content, mitochondria have DNA, RNA and ribosomes, which encode 13 polypeptides. 
Mitochondrial DNA (mtDNA) has a very high genomic density which makes it more 
susceptible to mutation and reduces the capacity to repair mechanism in the mitochondria 
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1.3.2 Mitochondrial respiration and membrane integrity 
 
Mitochondria oxidise fatty acids via the β-oxidation pathway, synthesise heme, steroids and 
regulate calcium concentration, which is crucial in several cellular mechanisms such as cell 
death and the regulation of the mitochondrial permeability transition (MPT) (Pivovarova and 
Andrews, 2010, Ribeiro et al., 2014).   
Glycolysis and oxidative phosphorylation (OXPHOS) are the main mechanisms in ATP 
production and the amount produced is determined by the type of metabolism: aerobic (high 
ATP levels) or anaerobic (low ATP levels).  
1.3.2.1 Glycolysis metabolism 
 
Glycolysis transforms glucose, taken up by the glucose transporters (GLUTs) in the cytosol. 
In the liver, the glucose transporter is GLUT2 which transports glucose into the hepatic 
cytosol to start a chain of reactions and transforms glucose into glucose-6-phosphate by the 
hexokinase enzyme followed by a series of reactions, to produce pyruvate and lactate as end 
products (Marin-Juez et al., 2014, Adeva et al., 2013). The balance between pyruvate and 
lactate is a reversible mechanism that depends on the oxidative state of the cell. This 
glycolytic pathway can be disrupted, (e.g. in drug toxicity) increasing the conversion from 
pyruvate to lactate. Pyruvate is transported into the mitochondria and the pyruvate 
dehydrogenase complex catalyses conversion of pyruvate to acetyl-CoA (Adeva et al., 
2013). Then, acetyl-CoA is oxidised by enzymes in the Krebs or tricarboxylic acid. During 
the Krebs cycle, reduced nicotinamide adenine dinucleotide/flavin adenine dinucleotide 
(NADH/FADH2) are produced and transported to the electron transport chain (ETC) in 
oxidative phosphorylation mechanism to finally produce ATP (Sekine et al., 2013).  
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High levels of lactate can lead to lactate acidosis, which is observed in acetaminophen 
(APAP) toxicity (Schneider et al., 2014). DILI can lead to reduction in the quantity of ATP 
formation in the mitochondria and stress in hepatocytes, and thus can cause a reduction in 
energy and lead to mitochondrial necrosis or apoptosis (Han et al., 2013). This is because 
ATP levels contribute in a direct way to mitochondrial function. Mitochondria need energy 
to maintain essential activities including in drug metabolism.   
1.3.3 Oxidative phosphorylation (OXPHOS) 
 
Oxidative phosphorylation (OXPHOS) is the series of enzymatic Red-Ox reactions used to 
produce ATP as a source of energy in the mitochondria. The electron transport chain (ETC) 
is located in the inner mitochondrial membrane and is composed of five enzyme complexes, 
complex I (NADH dehydrogenase), complex II (succinate dehydrogenase), complex III 
(cytochrome bc1 complex), complex IV (cytochrome oxidase) and complex V (ATP 
synthase) where ATP is generated. Cytochrome C and coenzyme Q are transporters 
(Feichtinger et al., 2014, Ribeiro et al., 2014). In this mechanism, the proton pump (complex 
I, III and IV) generates an electrochemical gradient across the mitochondrial membrane (pH 
gradient and membrane potential ΔΨ) (Ribeiro et al., 2014) from the Red-Ox reactions, in 
which the enzyme complexes act successively as donors (reduction) and acceptors of 
electrons (oxidation) from bio-products of Krebs cycle and β-oxidation.  
In the mitochondria, during the metabolic process of the Krebs cycle, NADH and FADH2 co-
factors are generated. NADH is transferred into complex I, and FADH into complex II, to be 
oxidised. The electrons generated are transferred into complex III by the electron carrier 
ubiquinone or coenzyme Q and electron carrier cytochrome c makes the transfer to complex 
IV where the electrochemical gradient is used to generate ATP  (Ribeiro et al., 2014) (Figure 
1-3). 




Figure 1-3 Mitochondrial structure and metabolism. 
- During the glycolysis, the glucose is broken down to pyruvate, itself potentially reduced 
into lactate, depending on the cytosolic redox potential (or NAD/NADH ratio). The 
glycolysis produces 2 molecules of ATP per molecule of glucose oxidised, as well as NADH. 
- The pyruvate is transferred into the mitochondria and serves as substrate of the pyruvate 
dehydrogenase to produce acetyl-coA before it enters the Krebs cycle - also known as 
tricarboxilic acid cycle or citric acid cycle - generating NADH. 
- The NADH, but also FADH2 generated from the oxidation of fatty acids, are reoxidised by 
the ETC, which transfers protons into the intermembrane space, generating the proton-
motive force, while channeling electrons, finally accepted by O2 at complex IV to form H2O.  
- The proton motive force, created by the accumulation of protons in the intermembrane 
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1.4 Drug metabolism: Phase I and Phase II 
 
Hepatocytes metabolise drugs by transforming them from lipophilic to hydrophilic 
molecules to facilitate subsequent metabolism and excretion. These drug biotransformations 
are carried out in two main phases, namely Phase 1 in which changes in drug polarity are 
achieved through oxidation, reduction and hydrolysis reactions catalysed principally by 
Cytochrome P450 enzymes (CYP450) and Phase 2 in which drug molecules and 
biomolecules from phase I are conjugated to increase solubility and facilitate excretion 
(Deenen et al., 2011).   
1.4.1 Cytochrome P450 enzymes (CYP450) 
 
Approximately 90% of drugs are oxidised and reduced by the cytochrome P450 enzymes 
(CYP450) (Zhu, 2010). CYP450 are heme proteins and the majority of them are located in 
the human liver but some varieties can be also found in the human small intestine and other 
organs. There are a number of different CYP450 divided into families and subfamilies (Paine 
et al., 2006). In the liver, most functional CYP450 enzyme families are CYP1, 2 and 3 and 
their subfamilies CYP3A4, 2C9, 2C8, 2E1 and 1A2. Most of these are expressed on the 
endoplasmic reticulum in hepatocytes (Zanger and Schwab, 2013). The most important are 
CYP3A and subfamily 3A4/5 (Zanger and Schwab, 2013). In drug toxicity, CYP450 activity 
can be compromised by the volume of drug administered which can reduce efficacy and 
induce toxicity. Indeed, Phase I metabolism can lead to the formation of highly toxic 
molecules, the lack of detoxification of which can result in alteration in Ca2+ homeostasis, 
mitochondrial function and oxidative stress in hepatocytes (Gomez-Lechon et al., 2010). 
These reactive bio molecules can be detoxified by phase II metabolism. For example, in 
acetaminophen (APAP) mechanism, CYP2E1/CYP3A4/CYP2A1 enzymes transform APAP 
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into a reactive N-Acetyl-p-Benzoquinone Imine (NAPQI) which is detoxified by glutathione 
(GSH).  
Furthermore, co-administration of different drugs at the same time can cause unfavourable 
drug-drug interactions, leading to further drug toxicity and compromising CYP450 activity 
(Kamel and Harriman, 2013).  
Phase II reactions include glucuronidation, acetylation, s-methylation, glutathione 
conjugation and sulfo and amino acid conjugation (Deenen et al., 2011). In this phase, drug 
intermediate compounds such as NAPQI in APAP metabolism, are mainly detoxified by the 
glutathione S-transferase enzyme family and impairment in their function is associated with 
hepatotoxicity. The main transferases are UDP-glucuronosyltransferases (UGTs), 
Glutathione S-transferases (GSTs), and  sulfotransferases (SULTs) (Jancova et al., 2010).  
In drug toxicity, hepatic membrane transport proteins plays an important role in the 
absorption of drugs, drug-drug interactions, and excretion of drugs into the biliary and 
sinusoidal system (Le Vee et al., 2006, Kunze et al., 2012, Shukla et al., 2014). Hepatic 
membrane transport proteins can regulate the accumulation of drugs in the system, 
influencing the development of liver failure, and can alter the prediction of the plasma 
concentration-time curve (Yoshida et al., 2012). Receptors present in the sinusoids and 
canaliculi such as multidrug-resistance-associated proteins are associated with drug toxicity 
resistance. Multidrug-resistance-associated proteins receptors can adapt to APAP or carbon 
tetrachloride toxicity and can up-regulate their expression and increase waste removal in 




   
16 
 
1.5 Drug induced liver injury (DILI)  
 
Drug-induced liver injury (DILI) is a major issue in drug discovery. Approved drugs can 
cause DILI even after successfully passing pre-clinical drug toxicity studies in animals and 
humans trials (Kaplowitz, 2005). For example, in 2011 approximately 86% of drugs did not 
achieve  efficacy and safety standards (Arrowsmith and Miller, 2013).  
As the liver is the principal organ in detoxifying the vast majority of external agents, there is 
a need to develop a more physiologically-relevant human hepatic in vitro model to predict 
drug toxicity and produce more relevant pre-clinical data. And in particular to evaluate the 
pathways involved in the activation of the cellular mechanisms in apoptosis and necrosis in 
drug toxicity (McGill et al., 2011, Xie et al., 2014b). This is greatly important for 
pharmaceutical companies who invest in developing highly effective in vitro human models 
and in vitro assays for drug testing (Tourovskaia et al., 2014). These studies are principally 
based on the importance of improving in vitro human models to represent in vivo liver-like 
function, and additionally in an attempt to reduce the use of animal models (Xie et al., 
2014b).  
 
Drug toxicity in the liver mainly occurs as a sequential chain of events and is linked to the 
regulation of nuclear receptors, including pregnane X receptor, constitutive androstone 
receptor or hepatocyte nuclear factor-4. Those mechanisms regulate the CYP450 enzyme 
activity which is crucial in the metabolism of most of drugs and a reduction in their activity 
can determine the accumulation of toxins inside cells (Hoekstra et al., 2013, Zanger and 
Schwab, 2013, Wang et al., 2004, Sahi et al., 2009, Ulvestad et al., 2013). Accumulated 
toxins can then perturb mitochondrial function and enhance reactive nitrogen species (RNS) 
and reactive oxygen species (ROS) formation (Nel et al., 2006). 
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When a drug is associated with organ failure, a warning is displayed on the label requiring 
the notification of patients by a health professional; alternatively the drug can be directly 
withdrawn from the prescribing list (Shah et al., 2013). The list of hepatotoxic drugs is 
getting longer with the constant addition of drugs associated with liver injury.  
Alcohol or APAP are examples of external agents causing major induced liver injury 
(Jaeschke et al., 2013). Therefore, APAP is a typical example of a hepatotoxic drug used in 
in vivo and in vitro hepatic models. APAP can be obtained over the counter and it is safe at 
therapeutic doses for treatment of pain and fever. However, adults should not exceed 1g of 
APAP per dose and 4g per day because APAP can be highly hepatotoxic when taken at 
doses > 4 g/day (Schafer et al., 2013).  
Primary human hepatocytes (PHH) became necrotic at 24hr in acetaminophen (APAP) 
overdose (Xie et al., 2014b). This mechanism is the result of the activation of C-Jun N-
terminal kinase following mitochondrial dysfunction, and causes a rise in ROS formation in 
the mitochondria (Xie et al., 2014b). However, there are additional mechanisms which can 
also be activated through mitochondrial dysfunction, leading to cell death. For example, 
cysteine proteases (caspases 3, 8, 10) are additionally activated by the mitochondria-
apoptosis mechanism (Xiong et al., 2014).  
APAP has been widely investigated in rodents (Agarwal et al., 2012, Kato et al., 2011) and 
conventional in vitro hepatic models (McGill et al., 2011, Aritomi et al., 2014). However, its 
mechanism of action in the liver not only affects hepatocyte function, but may also have 
deleterious effects on the endothelium, especially in the early stages of hepatotoxicity 
(DeLeve et al., 1997, Ito et al., 2003). Prediction of APAP toxicity using an in vitro hepatic 
model using a combination of parenchymal and non-parenchymal cells might therefore be 
valuable in determining unknown APAP toxicity mechanisms and also cell-cell interaction in 
the activation of drugs in the liver, not revealed in mono-culture (Ito et al., 2003, Toyoda et 
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al., 2012). APAP is often used as a model to understand cytotoxicity in vitro, but a model of 
DILI to fully predict human drug toxicity is still lacking (Jaeschke et al., 2013). In humans, 
APAP can be toxic at high doses and only rarely at normal doses does toxicity arise due to 
an idiosyncratic reaction (immune response) depending on race, age and sex (Han et al., 
2013). 
1.6 Drug induced mitochondrial dysfunction 
 
As described previously, mitochondria are a critical target in the activation of intracellular 
mechanisms of hepatotoxicity.  
Drug toxicity can specifically affect mitochondrial permeability transition (MPT), integrity 
of the mtDNA, and function of glutamate dehydrogenase, reducing the probability of cell 
survival (McGill et al., 2014). When drug toxicity affects mitochondria, the MPT pore 
opening increases its permeability, increasing exposure to reactive nitrogen species (RNS) 
and reactive oxygen species (ROS) (Pessayre et al., 2010).  
Mitochondria are one of the main organelles responsible for the formation of ROS as by 
products during ATP production. However, the formation of reactive oxygen molecules from 
drug activation can increase the ROS formation and often leads to mitochondrial dysfunction 
and susceptibility to lipid peroxidation in hepatocytes, resulting in widespread necrosis 
(Agarwal et al., 2012, Jaeschke et al., 2013).  
Under normal conditions, the principal antioxidant superoxide dismutase, glutathione 
peroxidase and catalases neutralise ROS formed during ATP generation or drug metabolism 
via CYP450 activity (Knight et al., 2002, Jaeschke et al., 2003). Oxidants such as hydrogen 
peroxide, formed from the superoxide anion radical, are produced in low concentrations and 
can be detoxified by antioxidants in the mitochondria. However, when oxidants are at high 
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concentrations, the electron transport chain can be disrupted and the mtDNA can become 
fragmented (Maharjan et al., 2014).  
ROS and RNS are not only generated in the mitochondria, they can also be generated in the 
endoplasmic reticulum or by peroxisomes (Fransen et al., 2012). The disruption of the 
mechanism of β-oxidation of fatty acids can cause accumulation of lipid peroxides in the 
mitochondria (steatosis). Liver disease such as steatosis can also cause liver failure 
(Germano et al., 2014). 
Drugs such as APAP or tamoxifen (TAM) can compromise mitochondrial function (Ribeiro 
et al., 2014, Jaeschke et al., 2012b). APAP at high doses, can compromise mitochondrial 
respiratory function and form superoxide anion radicals (O2·-) which are associated with the 
excess of NAPQI formation (McGill and Jaeschke, 2013, Pessayre et al., 2010, Martin et al., 
2003). The O2·- in contact with nitric oxide can form ROS and RNS, including the 
peroxynitrite anion (ONOO-). The formation of ROS and cytokines such as tumour necrosis 
factor-α (TNF-α), is not restricted to hepatocytes and also occurs in NPC liver cells such as 
Kupffer cells (Kojima et al., 2014) or hepatic stellate cells (Hsieh et al., 2014) leading to 
enhanced mtDNA fragmentation. In the absence of ROS, an increase in nitric oxide (NO) 
output by LSECs can play a protective role, inducing vasodilation, whilst its reduction is 
associated with endothelial dysfunction (Zhang et al., 2014).  
Under standard conditions, levels of oxidative stress are low compared to the relatively high 
levels of antioxidants such as GSH. In cytotoxicity, GSH levels are low and oxidants high 
(ROS and RNS formation).  
In hepatotoxicity, there are many mitochondrial apoptosis mechanisms induced by cell 
signalling which remain unknown. However, one of the most important activation 
mechanisms in apoptosis is the caspases pathway (Xiong et al., 2014) which, in contact with 
TNF-α, can cause cell death (Feldstein et al., Ray and Jena, 2000).  
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During drug induced oxidative stress, mitochondria respond with the activation of 
antioxidant pathways, including transcription factor erythroid 2-related factor 2 or hypoxia-
inducible factor 1-α antioxidant defence (Pullikotil et al., 2012, Aleksunes et al., 2008). 
However when these cellular mechanisms and antioxidants are not sufficient to cope with the 
oxidants produced in drug metabolism, cells can activate apoptosis pathways. One of the 
early mechanisms leading to this is mitochondrial dysfunction (Nel et al., 2006, McGill et 
al., 2014). For example, this could be triggered when NAPQI depletes mitochondrial GSH 
content, which would normally inhibit formation of ROS and peroxynitrite in the 
mitochondria (Jaeschke et al., 2003).  
The activation of caspases, which contribute to the apoptosis mechanism, can be inhibited by 
the addition of small molecule inhibitors such as small molecules or inhibitor such as 2-
aminoethoxy-diphenyl-borate or Bcl-2 (anti-apoptotic protein) (Du et al., 2013, Xie et al., 
2014b).  
The administration of APAP can disrupt the respiratory chain with ATP depletion and 
increase ROS formation, overwhelming antioxidants systems and thus causing mitochondrial 
dysfunction and cell death (Panatto et al., 2011). To reduce APAP-induced liver injury, 
antioxidants can be administered, including glutathione (GSH) or n-acetylcysteine (NAC) 
(Saito et al., 2010). However, NAC seems to be most effective, when is administrated within 
48hr after APAP exposure (Martin et al., 2003). Otherwise, in later stages ROS will already 
have activated apoptosis mechanisms resulting in liver cell damage (Badmann et al., 2012, 
Du et al., 2013). Between GSH and NAC, it seems that GSH is more effective in increasing 
ATP levels than NAC (Saito et al., 2010).   
Tamoxifen (TAM) also can cause idiosyncratic DILI. Although TAM is not a dose-
dependent drug, long-term therapy can cause an increase in lipid production and reduction in 
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superoxide dismutase activity (antioxidant) within the mitochondria, resulting in 
steatohepatitis (Ribeiro et al., 2014). 
Both APAP and TAM can raise the hepatic enzyme release, which become measurable in the 
patients' blood, such as aspartate aminotransferase (AST) or alkaline phosphatase (ALP) 
(Agarwal et al., 2012, Ribeiro et al., 2014, Aleksunes et al., 2008).  
The study of those two drugs demonstrate the importance of mitochondrial dysfunction in 
the development of hepatotoxicity and the need to focus on mitochondrial function in studies 
with new drugs to minimise and avoid drug toxicity.      
1.7 In vitro hepatic models for drug metabolism studies 
 
As mentioned previously, the liver metabolises most of the drugs and the majority of in vitro 
hepatic models are based on mono-culture of animal or human hepatocyte cell lines. 
However, despite several significant advances, drug-induced liver injury is still a major 
difficulty to predict in those models. Using a more physiological in vitro human hepatic 
model could help in predicting drug toxicity before drugs are tested in human trials and may 
also reduce animal testing (Jetten et al., 2013). Development of a high throughput screening 
compatible in vitro hepatic model, combining hepatocytes and endothelial cells, would 
improve the study of drug metabolism by the liver.   
  
Significant hepatic functions such as drug metabolism or albumin synthesis, are difficult to 
maintain in hepatocytes when they are cultured in vitro, and this makes the available hepatic 
models, (which include liver slices, microsomes and liver S9 fractions) not ideal for 
hepatotoxicity studies (Gomez-Lechon et al., 2014, Soldatow et al., 2013). The main reason 
for thus is the short-viability of these models and the lack of the major phase I or phase II 
enzymes (Gomez-Lechon et al., 2004). Since the use of in vitro animal hepatic models lead 
to unreliability in extrapolating data to humans, the selection and combination of different 
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cells lines to achieve a more physiological model is the principal difficulty (Jetten et al., 
2013).  
PHH are considered the gold standard because they contain the main enzymes and hepatic 
membrane transport proteins for drug metabolism analysis and can be used as a potential 
model to evaluate new drugs (Rotroff et al., 2010). However, their isolation from liver tissue 
is complex and with a low percentage of success (Bhogal et al., 2011) and their stability is 
limited with considerable reductions in drug metabolising enzyme activity occurring during 
isolation and short term culture (Jetten et al., 2013). The other main disadvantage of PHH is 
the inter-individual differences in the expression of drug metabolizing enzymes between 
donors (Zhou et al., 2009, Jetten et al., 2013). A number of alternatives have been developed 
during the last decade to address these problems. One of these uses immortalized 
hepatocytes cell lines. 
 
Immortalized hepatocytes cell lines are a valuable alternative for in vitro hepatotoxicity 
studies as they provide an unlimited supply, are reproducible, easily maintained and 
inexpensive models (Tsiaoussis et al., 2001).  
One of the cell lines most used by the pharmaceutical industry is the C3A clonal derivative 
of the HepG2 cell line selected for strong contact inhibition of growth, high albumin 
production, high production of alpha fetoprotein (AFP) and ability to grow in glucose 
deficient medium (Seeland et al., 2013, Ramaiahgari et al., 2014, Choucha Snouber et al., 
2013). C3As are metabolically active and mostly used for drug toxicology studies (Gomez-
Lechon et al., 2014), bio artificial liver supports systems (Filippi et al., 2004, Yang et al., 
2013b) or for the development of in vitro non-alcoholic fatty liver disease models (Lockman 
et al., 2012). Other immortalized cell lines, which include Huh 7 for example, lack 
expression of important Phase I or Phase II metabolising enzymes, when compared with 
PHH (Guo et al., 2011, Sjogren et al., 2014).  
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Recent approaches have emerged to improve current in vitro hepatic models. Novel hepatic 
cell lines are being exploited to predict drug toxicity in vitro. Gripon et al have described the 
novel HepaRG hepatic cell line (Gripon et al., 2002), which shows promise for 
pharmaceutical applications, and may be comparable to PHH for drug metabolism and 
hepatotoxicity studies (Parent et al., 2004, McGill et al., 2011, Lübberstedt et al., 2011, 
Aninat et al., 2006). HepaRG cell cultures are bipotential comprising a combination of 
hepatocyte-like and biliary-like epithelial cells and possess a variable percentage of each cell 
line between passages, thus representing the natural variability observed in a hepatic co-
culture system (Gripon et al., 2002, Jetten et al., 2013).   
Human hepatocyte surrogates such as HepaRG or primary hepatocytes have been used to 
determine drug metabolism and drug-drug interactions as they are more representative of 
predicting drug toxicity in vivo than microsomes or liver slides (Ferreira et al., 2014, Gomez-
Lechon et al., 2004).  
These cells are therefore used for High Throughput Screening (HTS) become of their high 
reproducibility for investigation of hepatotoxicity (Kostadinova et al., 2013, Gomez-Lechon 
et al., 2014, Aritomi et al., 2014). HTS is a technique that allows the screening of thousands 
of compounds candidates to identify those with therapeutically efficacy and lack of drug 
toxicity. The use of HTS allows investigation drug-drug interactions and multi doses. A 
human model for HTS may represent an alternative for animal drug testing (Ramaiahgari et 
al., 2014). However, despite their advantages in drug discovery, cell lines such as HepG2 
have shown lower CYP450 expression than PHH or HepaRG (Jetten et al., 2013) and 
improvements in cell culture are needed to characterise drug toxicity in vitro. 
 
However, as mentioned in Section 1-2, drug toxicity can also affect hepatic non-
parenchymal cells such as endothelial cells (Badmann et al., 2012, Toyoda et al., 2012). 
These limitations may be overcome with the addition of different cell lines using co-cultures 
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to promote hepatic function and vascularization in vitro. The reproduction of liver cell-cell 
interactions in in vitro hepatic models will be essential in the understanding of intercellular 
protective mechanisms in drug metabolism.  
 
In vitro co-cultures models combining primary hepatocytes (rat, mouse or human) with a 
type of endothelial cells have shown important advantages in supporting hepatocyte 
function, including albumin synthesis in the long term and hepatic vascularization in vitro 
(Ohno et al., 2009, Nahmias et al., 2006, Soto-Gutierrez et al., 2010).  Most of the in vitro 
co-culture studies concluded that secretion of different cytokines and soluble factors from 
non-parenchymal cells enhance hepatocyte differentiation and hepatic function  (Bale et al., 
2014a, Leong et al., 2013, Soto-Gutierrez et al., 2010, Kim et al., 2012, Ohno et al., 2009, 
Salerno et al., 2011). 
 
Endothelial cells activate significant cytoprotective signals which lead to important functions 
including angiogenesis, migration, vasodilation, ROS formation in repair liver injury and 
result in reduced cell death (Donahower et al., 2010). In these mechanisms, endothelial cells 
secrete and express cytokines and adhesion molecules, which are essential to regulate the 
aforementioned pathways. For example, platelet endothelial cell adhesion molecule 
(PECAM-1), also known as cluster of differentiation CD31, expressed on different 
endothelial cells can regulate vascularization, superoxide dismutase formation and caspase 
activation (Liu et al., 2006, Saragih et al., 2014, Tsuneki and Madri, 2014).  
Vascular endothelial growth factor expressed in hepatocytes can regulate endothelial 
receptors such as vascular endothelial growth factor receptor-1 and receptor-2 (VEGFR-1 
and VEGFR-2 (Hwa et al., 2007). VEGFR-2 regulates the generation of anti-oxidants such 
as NO which is highly important in the regulation of vasodilation, migration, angiogenesis 
and has a cytoprotective effect in mitochondria, inhibiting the PI3K apoptosis mechanism 
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(Aharoni-Simon et al., 2012, Cox et al., 2014, Jaeschke et al., 2012b, Alva et al., 2013, 
Saraswati et al., 2013, Zachary and Gliki, 2001). Hepatic VEGF signalling is essential in 
restoring the hepatic vascular system in injury (Wang et al., 2012a, Stolz et al., 2007) and 
also in liver organogenesis in the embryo (Matsumoto et al., 2001).   
The appropriate selection of endothelial cells to reconstruct an accurate in vitro hepatic 
model is complex, as LSECs are difficult to obtain and to conserve their phenotype in vitro 
(Elvevold et al., 2008, DeLeve et al., 2004, March et al., 2009). However, published studies 
have addressed this disadvantage using cell lines such as HUVECs (Inamori et al., 2009, 
Salerno et al., 2011). HUVECs share properties to LSECs such as the expression of CD31 
(Elvevold et al., 2008, Kjaergaard et al., 2013) or von Willebrand factor (Shahidi et al., 
2014). Furthermore, HUVECs have been used in combination with hepatocytes to reproduce 
better the hepatic sinusoid and investigate paracrine signalling (Nahmias et al., 2006, Ho et 
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1.8 In vitro hepatic model in two-dimensional and three-dimensional culture  
 
Hepatocytes cultured in two-dimensional (2D) static culture rapidly lose polarity and 
differentiated function, and have poor levels of viability and gene expression for drug 
metabolism and toxicity assays (Nelson et al., 2010, Donato et al., 2013). Meanwhile, 
hepatic and endothelial cultures in more physiological extracellular matrix have been shown 
to maintain proliferation and promote hepatic and endothelial differentiation, allowing the 
establishment of a better hepatic drug metabolising model for drug toxicity studies (Godoy et 
al., 2013, Tourovskaia et al., 2014, Toyoda et al., 2012).  
A further advantage of this approach is to be able to culture hepatocytes in three dimensions 
(3D). Hepatic activity of albumin synthesis, urea synthesis and expression of drug 
metabolising enzymes (CYP3A4 activity) improve when hepatocytes are cultured in a more 
liver-like environment using novel technologies like 3D culture using scaffolds or 
extracellular matrices (Kostadinova et al., 2013, Leong et al., 2013).  
Spinner flasks, perfusion systems, rotating wall vessels and microfluidic chips are widely 
used in tissue engineering and these systems could provide ‘proof-of-feasibility’ and more 
physiologically representation of the in vivo situation (Allen et al., 2005, Bhatia and Ingber, 
2014). Spheroids have demonstrated that collagen as an ECM results in a covered hepatic 
vascularised tissue in vitro (Inamori et al., 2009). Similar observations have been shown 
using endothelial and hepatocytes in hydrogel fibres (Leong et al., 2013), cell sheets 
(Harimoto et al., 2002) or using an open porous scaffold (Chou et al., 2013).  
Culturing cells in appropriate 3D micro environments allows for the development of more 
complex (and physiological) cell-cell and cell-matrix interactions and establishes gradients 
of growth factors to cultured cells better than using 2D systems (Tourovskaia et al., 2014). 
Moreover, recapitulation of the proper micro environment, is also important for encouraging 
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in vivo–like cell migration and characteristic paracrine signalling (Leong et al., 2013, 
Nahmias et al., 2006, Swartz and Fleury, 2007).  
Extracellular matrix (ECM) containing collagen, fibronectin, laminin and cell adhesion 
molecules plays an important role promoting cell differentiation and migration in liver 
organogenesis (Moir et al., 2012). For example, hyaluronic acid is an essential component of 
the ECM synthesized by hepatic stellate cells (HSC) and endothelial cells in rats during liver 
regeneration (Vrochides et al., 1996). Puramatrix maintains rat primary hepatocytes in a fully 
functional state for up to 90 days (Giri et al., 2013). However, compared to these available 
matrices, Matrigel™ provides a better 3D culture environment for stem cells differentiation 
(Rowland et al., 2013).  
The development of an in vitro vascularised model would allow understanding of the 
principles of vascularization and cell migration. To regenerate an accurate in vitro human 
hepatic model it is thus essential to be able to control mechanisms of vasculogenesis in two 
or three dimensional culture.   
Vasculogenesis and angiogenesis are two different processes both leading to vascularisation. 
Vasculogenesis refers to the formation of new vessels, whereas angiogenesis is the formation 
of vessels from existing vessels (Carmeliet, 2000). These two mechanisms can be initiated 
with or without stimulation of paracrine signalling (e.g. VEGF) during liver organogenesis in 
the embryo or in response to disease (Lee and Niklason, 2010, Matsumoto et al., 2001). 
Angiogenesis taking place in wound healing is regulated mainly by endothelial signalling, 
including VEGF, (Knudsen and Kleinstreuer, 2011). Endothelial cells can up-regulate 
VEGFR-1 and VEGFR-2, CD31 or VE-Cadherin receptors which act as regulators in 
differentiation, permeability, migration, wound healing, angiogenesis and maintenance of 
fenestrae (LeCouter et al., 2003, Matsumoto et al., 2001, DeLeve, 2014, Schmidt et al., 
2007).  VEGFR-2 stimulates endothelial mobilization in hypoxic conditions by activation of 
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hypoxia-inducible factors, resulting in an increase in permeability and vasodilation with 
participation of nitric oxide (NO), regulation of endothelial receptor such as CD31 
(Carmeliet, 2000) and maintenance of the phenotype in LSECs (DeLeve, 2014). The 
presence of NO also contributes in maintaining HSC in a quiescent state (DeLeve, 2014) and 
HSC can be activated in response to liver damage, becoming myofibroblast-like cells with 
induction of extracellular matrix synthesis, laminin or collagen synthesis, causing fibrosis 
(Godoy et al., 2012, Reichen, 1999, Schuppan et al., 2001, Vinken, 2013). 
The representation of an in vitro vascular system is fast becoming an important prerequisite 
in accurate representation of drug metabolism and maintenance of hepatic function. In liver 
injury, a phenomenon of “hepatocyte-sinusoid alignment” occurs, in which hepatocytes 
proliferate along the sinusoids when endothelial cells are still viable (Hoehme et al., 2010). 
The phenomenon emphasises the importance of keeping the vascular system healthy and in 
contact with hepatocytes, as when the distance between hepatocytes and the sinusoid 
increases hepatocytes lose function (Hoehme et al., 2010). There are several studies which 
focus on the importance of this aspect of cell-cell contact. For example Inamori et al. 
demonstrated in 2009 that HUVECs can attach to rat hepatocytes when they are covered by 
collagen-I to form spheroids, suggesting the importance of cell-extracellular matrix 
interaction. In in vitro hepatic co-culture models, LSECs contribute to hepatocyte viability in 
microfluidic systems (Maher et al., 2014) and co-cultures in bioreactors provides better 
understanding about paracrine signalling and the source of hepatic growth factors for further 
liver regeneration mechanisms (Schmelzer et al., 2009). The simulation of the blood flow 
can contribute to the regulation of the oxygen and the exposure to a shear stress to cells can 
improve function and improve interpretation of cell migration in drug studies (Bhatia and 
Ingber, 2014). Microfluidic systems simulates shear stress and induce paracrine signalling 
between hepatic cells. The dynamic flow distributes these chemokines, resulting in better 
metabolic and functional activities (Marrone et al., 2014).  





In this introduction, evidence has been presented on the current weaknesses in predicting 
drug toxicity using only hepatocytes alone as an in vitro hepatic model. Current in vitro 
hepatocyte models do not fully predict drug toxicity as they do not fully represent in vivo 
liver functions. Although hepatocytes have high plasticity, their metabolic capacity and 
morphology are compromised when cultured in conventional 2D mono-cultures. The reasons 
for their dysfunction and phenotype lose may be due to the lack of interactions between 
hepatocytes and non-parenchymal cells in an appropriate extracellular matrix (Godoy et al., 
2013).  
The improvement of in vitro hepatic models, combining hepatocytes and endothelial cells to 
more accurately represent in vivo, could thus reduce the unnecessary exposure of humans to 
unknown drug toxicities and ineffective drugs as well as reduce animal testing.  
To summarise, in vivo, hepatocytes can suffer a potential damage but also endothelial cells 
can be affected by drug toxicity (Ito et al., 2003). These are reasons to consider in an in vitro 
hepatic model, the use of endothelial cells in combination with hepatocytes to predict drug 
toxicity (Godoy et al., 2013, Ito et al., 2003).  
For example, in APAP toxicity, endothelial cells and hepatocytes act synergistically to 
activate cellular mechanism, including VEGF signalling to induce hepatic regeneration after 
APAP toxicity (Kato et al., 2011, Ito et al., 2003) and the lack of endothelial cells in an in 
vitro hepatic model probably makes more difficult to represent paracrine signalling 
happening in hepatotoxicity.   
This type of evidence reflects the significant contribution of endothelial cells to a hepatic 
model and the importance of maintaining an intact and functional vascular system in 2D or 
3D culture to accurately represent cell-cell interactions using endothelial and hepatocytes for 
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drug studies. As discussed previously, this is because when a drug is administered, other 
liver cells in addition to hepatocytes have an important effect on the metabolism of the drug 
including drug activation and metabolism (LeCluyse et al., 2012, Toyoda et al., 2012, 
Badmann et al., 2012). Development of a system which efficiently provides nutrients and 
distributes oxygen, simulating the acinus zonation and interstitial flow seen in vivo, may 
enhance current pharmaceutical drug evaluation strategies (Bhushan et al., 2013, Nelson et 
al., 2010, Bhatia and Ingber, 2014).  
Moreover, an in vitro human hepatic model should offer an improvement over animal-based 
cultures in predicting a large number of drug toxics compounds and the data should be able 
to be extrapolated to humans and used to establish the maximum tolerated dose. Finally, 
approaches to increase efficacy and to maximise the safety of human drugs can provide a 
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1.10 Thesis aims  
 
The major aim was to develop an improved in vitro human hepatic model for prediction of 
hepatic toxicity by exploring co-culture of hepatocytes with endothelial cells. Most of the 
available in vitro hepatic models use animal or human hepatocytes or cells lines in mono-
culture. The reproduction of hepatocyte and endothelial cell interactions may provide more 
reliable prediction of metabolic indicators of drug toxicity.  
To develop this in vitro human co-culture model, several key points needed to be 
investigated:  
1. Development of an in vitro human co-culture model using Human Umbilical 
Vein Endothelial Cells (HUVECs) and hepatocytes (C3As) (HUVEC:C3A) in 
conventional culture: Investigation of the biocompatibility, proliferation and culture 
conditions of an in vitro hepatic model using HUVECs and C3As. 
2. Morphological, phenotypic and functional characterization of an in vitro hepatic 
co-culture model: Comparison of morphology, phenotype and hepatic function 
including albumin synthesis and drug metabolism enzymes (CYP450) of hepatic and 
endothelial mono- and co-cultures for the pre-clinical assessment of new candidates 
for drug development. 
3. Drug toxicity studies: Investigation of the effect of the hepatotoxic model 
acetaminophen (APAP) on parameters of mitochondrial function and oxidative 
stress: Investigation of cellular mechanisms involved in hepatotoxicity using 
HUVEC and C3A in mono- and co-cultures.  
4. Cell migration studies: Investigation of cell migration and cross-talk between 
endothelial and hepatocytes using a rich extracellular matrix, to build an in vitro 
vascularised hepatic tissue.   
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2 Chapter 2: Heterotypic co-culture of HUVECs with the human hepatic cell 




Drug-induced liver injury (DILI) is a major ongoing challenge for the pharmaceutical 
industry. Pre-clinical investigation of new candidate drugs, using in vitro hepatic models 
which closely resemble human liver function, is highly desirable to mimic in vivo 
metabolism and reduce animal testing. Also, animal studies may be insufficient to predict 
human drug toxicity due to inter-species differences in drug metabolic pathways (O'Brien et 
al., 2006). Furthermore, current in vitro human hepatocyte mono-cultures models are limited 
by tissue availability and do not always accurately represent drug metabolic pathways that 
occur in vivo (Gomez-Lechon et al., 2014).  
Over the period 1991-2000, approximately 30% of licensed drugs were withdrawn from the 
market despite passing both in vitro and in vivo toxicity testing (Kola and Landis, 2004). 
With recent estimates for development of each new drug of between $868m to $1,241m 
USD, this represents a huge financial cost to the pharmaceutical industry and a disincentive 
to future drug development (Ciociola et al., 2014). 
Hepatic models using primary human hepatocytes (PHH) are currently preferred for in vitro 
drug testing; however, they have major limitations for prediction of drug toxicity. PHH are 
scarce and expensive, while they present batch variation in hepatic function, with CYP450 
activity declining rapidly in culture (Gomez-Lechon et al., 2014). Practical alternatives for 
PHH in drug testing include immortalized cell lines, such as C3A cells. Although C3As have 
somewhat limited CYP450 activity, they are inexpensive and easy to culture while 
maintaining stable metabolic activity and provide a reproducible and sustainable supply of 
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cells to model hepatic function. Indeed, C3As have been successfully applied previously in 
our laboratory, investigating non-alcoholic fatty liver disease (Lockman et al., 2012) and bio 
artificial liver systems (Filippi et al., 2004). 
For improved prediction of in vivo drug metabolism mechanisms using in vitro hepatic 
models, hepatocytes require an environment which reproduces in vivo interaction and cross-
talk with endothelial cells (Ohno et al., 2009, Soto-Gutierrez et al., 2010, Toyoda et al., 
2012).   
Endothelial cells have a significant role in clearance from the portal venous circulation 
(Smedsrod et al., 1990, DeLeve, 2013); and while hepatocytes are mainly responsible for 
hepatic drug metabolism and are the principal targets of hepatotoxic drugs, endothelial cells 
can be also affected by drug toxicity (Badmann et al., 2012, Ito et al., 2003, Deleve, 1994). 
To emphasise the contribution of endothelial cells in maintaining the hepatocyte phenotype, 
important interactions between hepatocytes and endothelial cells have also been observed 
during hepatocyte differentiation and hepatic organization for liver tissue development in 
vitro (Xin et al., 2001, Matsumoto et al., 2001, Bale et al., 2014a, Inamori et al., 2009, Soto-
Gutierrez et al., 2010, Nahmias et al., 2006).  
In vivo, the secretion of cytokines such as vascular endothelial growth factor (VEGF) and 
hepatic growth factor (HGF) from endothelial cells implicates vascular function in 
hepatocyte differentiation (Matsumoto et al., 2001, Soto-Gutierrez et al., 2010), regeneration 
and the maintenance of liver sinusoidal endothelial cell (LSECs) markers, including: CD31 
(March et al., 2009, Hwa et al., 2007). Expression of the endothelial cell marker, CD31, has 
been used to monitor the endothelial phenotype (Elvevold et al., 2008); whilst epithelial cell 
adhesion molecule (EpCAM) has been used as a marker for adult hepatocytes (Mitra et al., 
2012).  
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However, CD31 is not expressed by all types of endothelial cells, and its expression on rat 
liver sinusoidal endothelial cells can be suppressed in the presence of hepatocytes or stellate 
cells via paracrine and autocrine pathways (DeLeve et al., 2004, March et al., 2009). To date, 
this inhibition in CD31 expression has not been investigated in HUVECs co-cultured with 
other human hepatic cell types. 
Human LSECs differ from other vascular endothelial cells in the human body (Elvevold et 
al., 2008). They have also been shown to have different phenotype compared to mouse 
LSECs (e.g. immune-factors)(Fomin et al., 2013). LSECs have open fenestrations in their 
cytoplasm to allow nutrients transfer to hepatocytes and another characteristic is the lack of 
basal lamina underneath the endothelium. Amongst its function, LSECs have a strong 
endocytotic capacity not observed in other cell lines (Elvevold et al., 2008) and synthesis of 
Factor VIII  (Fomin et al., 2013). LSECs are, however, difficult to isolate and present an 
unstable phenotype (DeLeve et al., 2004, Salerno et al., 2011, Elvevold et al., 2008, Fomin et 
al., 2013). Published studies have therefore used macro-vascular endothelial cells, 
principally HUVECs, as hepatic sinusoid endothelial cell surrogates to demonstrate the 
importance of the interaction between endothelial and hepatocytes in drug metabolism 
(Toyoda et al., 2012, Salerno et al., 2011) and in liver tissue formation in vitro (Nahmias et 
al., 2006). 
One of the most relevant function of endothelial cells is the capacity to interact with other 
liver cells which implicates activation of endothelial receptors and mechanisms to maintain 
normal phenotype and functionality in vitro (DeLeve et al., 2004, March et al., 2009, 
Khodarev et al., 2003).  
My hypothesis was that the combination of HUVECs and C3As as ‘organotypic’ co-cultures 
in an in vitro hepatic model would promote cell-cell interactions as well as cell-matrix 
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interactions and improve hepatic function and endothelial phenotype to provide a better 
human liver function representation in vitro, particularly in the context of drug testing.  
Here, the aim was to develop an improved human hepatic in vitro organotypic co-culture 
model for use in drug toxicity studies in vitro. To achieve this, HUVECs and C3As were co-
cultured to test the hypothesis that endothelial cells could both improve functionality of 
C3As in co-cultures, and provide a more physiologically-relevant model for drug testing. 
The first step in developing the model was to define a suitable cell culture medium, which 
would provide trophic support for both cell types whilst maintaining their individual 
phenotypically differentiated functions. Next, we sought to identify the optimal ratio of 
HUVECs and C3As required to maintain growth and function in co-cultures; and to design 
protocols to optimise cell seeding and assay of hepatic function. To determine the effect of 
culture conditions on each cell type and the contribution of paracrine regulation, in each 
experiment co-cultures were phenotyped using cell type-specific markers. 
Experiments were designed to assess the following research questions:  
(i)        Characterization of hepatic and endothelial cell type-specific (HUVECs or 
C3As) phenotypic markers for identification of each cell line in co-cultures.  
(ii)        The selection of an optimal cell culture medium, either hepatic medium 
(MEME) or endothelial medium (EGM-2), suitable for maintenance of 
HUVECs and C3As in co-cultures, without altering their phenotype from that 
seen in standard mono-cultures. Monitoring the maintenance of specific-
endothelial (CD31) and hepatic adhesion molecule (EpCAM) expression, and 
cell morphology, which are vital in construction of an in vitro co-culture system 
because a reduction in their expression and morphology might reflect a 
reduction in function and viability. 
(iii) The period and relative ratio of HUVECs and C3A required in co-cultures was 
also tested. A titration was used to test alternative ratios (1:3; HUVEC:C3A), 
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1:1 (HUVEC:C3A), 3:1 (HUVEC:C3A) which were assessed on day 3 and day 
7 after plating, with proliferation rate and viability being used to determine the 
optimum ratio and culture period.  
(iv) Evaluation of the effect of HUVECs on C3As functionality included 
measurement of albumin synthesis, urea production and basal CYP3A4 activity 
in co-cultures as compared with mono-cultures. 
(v)         The extent of paracrine signalling between endothelial and hepatocytes cells 
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2.2 Materials and Methods 
2.2.1 Cell culture general maintenance  
 
Human hepatocellular carcinoma, C3A cells were obtained from the American Type Culture 
Collection (CRL-10741, USA) and cultured in Minimum Essential Medium Eagle (MEME 
Sigma). HUVECs were obtained from Lonza (C2519A) and cultured in endothelial basal 
medium-2 (Lonza, EGM-2) supplemented with SingleQuots (Lonza, CC-3162): containing 
proprietary concentrations of: hEGF, hydrocortisone, gentamicin, amphotericin-B, VEGF, 
hFGF, IGF-1, ascorbic acid, heparin and fetal bovine serum (FBS) (2% v/v). 
HUVECs and C3As were initially grown separately as mono-cultures, on tissue culture 
plastic flasks of 25 cm2 or 75 cm2 with 5 ml or 10 ml of each cell culture media, respectively. 
When cell were >80% confluent, culture medium was discarded, and flasks were rinsed with 
phosphate-buffered saline (PBS) to remove serum. Cells were detached using trypsin 
solution (0.05% (W/V) Trypsin + 0.53 mM EDTA) in 37ºC and 5% (v/v) CO2 for at least 5 
min. Then, trypsin solution was neutralised with the addition of an equal volume of cell 
culture medium containing 10% (v/v) FBS and the cell suspension centrifuged for 5 min at 
350g. The cell pellet was suspended in cell culture media and cell numbers counted using 
Neubauer haemocytometer and trypan blue was used to assess cell viability. Cell suspensions 
with cell viability of at least 85-90% were used for experiments or cell culture maintenance. 
For in vitro co-culture experiments, HUVECs were seeded into cell culture plates 4 hours 
before addition of C3A cells to allow HUVECs to adhere to the cell culture plastic in EGM-2 
for 3 days before the assessment of biocompatibility and hepatic function. Starting cell 
density was based on surface area at 21,000 cells/cm2 and modified for ratio 3:1 
(HUVEC:C3A) and 1:3 (HUVEC:C3A). Otherwise, except where clearly stated in the text. 
Media was changed every 48-72hr. 
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2.2.2 Cell culture maintenance: HUVECs cryopreservation 
 
HUVECs (between passages 3 to 7) were cryopreserved when they achieved 90% 
confluence. At least 0.5 x 106 HUVECs were suspended in 0.5 ml of EGM-2 containing 10% 
(v/v) of DMSO in cryogenic tubes (Thermo Scientific-Nunc, UK). Cryogenic tubes were 
maintained at -80ºC overnight before transferring to liquid nitrogen. 
 
2.2.3 Light and immunofluorescence Microscopy 
 
Cell morphology was assessed under phase contrast microscopy using an inverted 
microscope (Zeiss Axio-Observer A1, Germany) and images were captured with a mounted 
camera (Zeiss AxioCam MRm). Images were processed and merged using ImageJ 1.46r 
(National Institute of Health, USA). 
2.2.4 Immunocytochemistry  
2.2.4.1 Platelet endothelial cell adhesion molecule (PECAM-1/CD31) and epithelial cell 
adhesion molecule (EpCAM) 
Cells were fixed in situ with 4% (w/v) paraformaldehyde (Sigma-Aldrich, UK) for 30 min at 
room temperature (RT), washed with PBS, and treated with 0.1% (v/v) Triton X-100 in PBS 
for 1 hour at RT, then blocked with PBS containing 5% (w/v) BSA for 30 min. 
Cells were incubated with rabbit-anti-human CD31 (eBioScience) endothelial cell marker 
diluted at 1:50 and/or directly conjugated mouse anti-human APC-EpCAM (Biolegend) 
diluted 1:50 at 4ºC overnight. Cells were then treated with secondary anti rabbit-IgG Alexa 
Fluor 488 (Life Technologies, A11034) antibody (1:400) and goat anti-mouse IgG Alexa 555 
(Life Technologies, A21424) for 2hr at RT. Finally, cells were washed and stained with 
DAPI (Sigma) at 1/5000 for 5 min. 
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2.2.4.2 CYP3A4 and filamentous actin (F-actin) staining 
 
Fixed cells were treated with 0.1% (v/v) Triton X-100 in PBS for 1hr at RT and blocked with 
PBS containing 5% (w/v) BSA for 30 min. Subsequently, they were incubated with primary 
rabbit-anti-human Cytochrome P450 Enzyme CYP3A4 Antibody (AB1254, Chemicon, 
Millipore) (1:800) and F-actin was labelled using Tetramethylrhodamine Isothiocyanate 
Rhodamine phalloidin (Molecular Probes, R415) (1:100) at RT. After 90 min, cells were 
washed with PBS before addition of a secondary anti rabbit-IgG Alexa Fluor 488 (Life 
Technologies A11034) (1:400) for 45 min, then labelled with DAPI (Sigma) at 1/5000 
dilution for 5 min. This method was modified from a published method (Pernelle et al., 
2011). 
2.2.5 Flow cytometry sample preparation  
 
To assess hepatic- and endothelial-specific expression markers, cells were stained with 
combinations of directly conjugated fluorescent mouse anti-human antibodies: PerCP-CD31, 
(BD eBioscience, 46-0319-41), APC-EpCAM (BioLegend), PE-VEGFR-2 (R&D Systems) 
at 4ºC for 20 min: Cells were washed using 2 spin-wash cycles (centrifugation for 7 min at 
350g), before final re-suspension in 200µl of PBS supplemented with 0.1% (w/v) BSA and 
0.1% (w/v) sodium azide, for data acquisition.  
At least 10,000 live events per sample were collected using a FACS-Calibur flow cytometer 
and data analysed using both CellQuest (Becton Dickinson, UK) and FCS express 4 
Software (free version online - DeNovo Software). Dead cells and debris were excluded 
from the analysis based on scatter characteristics, so that expression of markers was assessed 
exclusively on live cells. Unstained HUVECs, C3As and co-cultured cells were used as 
controls for expression of VEGFR-2. In stained cells, endothelial markers and hepatic 
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markers were analysed using electronic gating for each cell population using CD31+ for 
HUVEC and EpCAM+ for C3As to assess Mean Fluorescence Intensity (MFI).  
MFI was used to quantify the relative level of fluoresence in samples (brightness) which 
indicate the relative expression of HUVECs and C3As for each antibody in mono-culture 
and co-cultures. The peak values were obtained from flow cytometry histograms, and 
calculated as follows: 
MFI= stained sample peak channel - negative control peak channel 
2.2.5.1 HGF receptor/C-met staining  
 
For intracellular staining to ensure c-met stability, cells were fixed using flow cytometry 
fixation buffer (R&D Systems, FC004) (100µl/sample), permeabilized with flow cytometry 
Permeabilization/Wash Buffer (R&D Systems, FC005) for 15 min at RT and stained with 
Human/Mouse Phospho-HRF R/C-met (Y1234/Y1235) antibody (R&D Systems, AF2480) 
at 2.5 µg/106 cells for intracellular staining by flow cytometry. Cells were washed and 
resuspended with permeabilization/wash buffer then stained with a secondary antibody anti 
rabbit-IgG Alexa Fluor 488 (Life Technologies A11034) at 1:50 dilution, at 4ºC for 20 min. 
Finally, cells were washed twice by centrifugation for 7 min at 350g, before re-suspension in 
200µl of PBS supplemented with 0.1% (w/v) BSA and 0.1% (w/v) sodium azide, for 
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2.2.6 Relative Growth Kinetics: Titration, cell growth and proliferation rate  
2.2.6.1 Growth rate, population doubling (PD) and population doubling time (PDT) 
 
Growth rate, population doubling (PD), and population doubling time (PDT) were calculated 
in HUVECs and C3As as a different ways for comparing cell proliferation from number of 
cells on day 0 (D0) to the number of cells harvested on the final day (Df) of culture, using the 
following formulas (Hastings et al., 2004):  
Growth rate (%) = Number of cells harvested on final day (Df)*100%/ Number of cells 
seeded on initial day (D0) 
Population doubling (PD) = log [Df/ D0] / log2  
Population doubling time (PDT) = culture time /PD (time was expressed in hours) 
2.2.7 Hepatic functional assays 
 
For evaluation of hepatocyte function, C3As were seeded at the same density (12.500 cells 
per well in a 96 well plate) in mono- and co-cultures. 
2.2.7.1 Albumin synthesis  
 
Albumin synthesis was measured in cell culture supernatants taken on day 3 using Albumin 
Blue 580 Fluorescence Assay after 24hr in serum-free EGM-2 medium.  
On the second day of culture, HUVECs and C3A mono- and co-cultures at ratios 1:3 
(HUVEC:C3A), 1:1 (HUVEC:C3A) and 3:1 (HUVEC:C3A) were washed twice with PBS to 
eliminate bovine serum albumin from the EGM-2 media and replaced with endothelial 
serum-free media. It was important to measure albumin synthesis by cells in bovine serum 
albumin-free medium to avoid the possibility of overestimating albumin concentration. After 
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24hr, supernatants were collected and 80 µL per well of samples were added in duplicate 
into separate wells and mixed with 160 µL of working solution (Working solution: Albumin 
blue 580 (AB580) diluted in isopropanol at a final concentration of 30mg/l (stock solution). 
Then, stock solution was diluted in MOPS buffer (see Table 7.3).  
The solution and reagents were kept for a month in the dark at 4ºC. The plate was shaken for 
30 seconds before reading the fluorescence (excitation at 590nm and emission 645nm). Data 
were normalised to the number of viable C3A cells seeded on day 0. Samples were read in a 
96-well plate on a CytoFluor® series 4000 Fluorescence Multi-Well Plate Reader (Applied 
Biosystems). Albumin concentration was derived using an appropriate standard curve.  
2.2.7.2 Urea synthesis rate 
 
Urea synthesis was determined in cell culture supernatants of HUVECs and C3As in mono- 
and co-cultures at ratios 1:1 (HUVEC:C3A) and 3:1 (HUVEC:C3A) on day 3 of cell culture, 
using the Quantitative Colorimetric Urean Determination QuantiChromTM Urea Assay Kit 
(DIUR-500, BioAssay Systems). The principle of this method was to measure urea 
concentration in the cell culture supernatant using a chromogenic reagent that in contact with 
urea forms a coloured complex at 520nm.  In brief, on day 3, cells were washed twice with 
PBS and incubated with 2 mM ammonium chloride (NH4Cl) (Sigma, UK) for 2hr at 37ºC in 
5% (v/v) CO2. Supernatants were collected at two different time points, immediately after 
addition of the NH4Cl as a control (time 0) and after 2hr of incubation (time 2). Samples 
were stored at -80ºC for later analysis.  
For the urea measurement, samples were incubated for 50 min with working reagent in a 96-
well plate at RT, as recommended by the manufactures, and optical density read at 430nm 
using a GloMax®-Multi-Microplate Multimode Reader (Promega). The urea concentration 
of each sample was derived using an appropriate standard curve. Then, urea synthesis rate 
(USR) was calculated per hour by subtracting the urea concentration (C0) and the volume of 
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media (V1) taken at time 0 hours (t=0) values from the urea concentration (C1) and the 
volume of media (V2) taken at time 2 (t=2) and normalised by the number of hepatocytes 
(NH) and the time of exposure (T) where the equation is: 
USR = (C0*V1)-(C1*V2)/T*NH 
2.2.7.3  Cytochrome P450 3A4 assay (CYP3A4) 
 
CYP3A4 enzyme activity was measured directly in the cells on day 3 of co-culture at both 
ratio 1:1 (HUVEC:C3A) and ratio 1:3 (HUVEC:C3A) using a luminescence assay P450-
Glo™ CYP3A4 Assay with Luciferin-IPA (V9001, Promega). P450-Glo™ CYP3A4 Assay 
is a luminescent method designed to measured P450 activity. Cells take luciferin-based 
substrates and converted to luciferin by P450.  
On day 3, HUVECs and C3As in mono and co-cultures were washed and incubated for one 
hour with Luciferin-IPA diluted 1/1000 in EGM-2, and luciferin reagent added to the cells. 
Samples were transferred to a white-walled 96 well plate to be read by a luminometer 
GloMax Multi+ plate reader (Promega). Wells with medium alone were also incubated with 
Luciferin-IPA as background controls.  
2.3 Statistical Analysis  
 
Experiments were performed in triplicate culture wells (3 technical replicates were 
considered as n=1), in at least three independent biological experiments (n=3). GraphPad 
Prism®5 software was used for statistical analysis. Results were reported as mean ± standard 
error (SEM). Student’s unpaired t-test was used to compare all co-cultures to their 
appropriate HUVECs and C3As mono-culture controls (statistical significance was defined 
as: *p<0.05).  




2.4.1 Morphology and expression of endothelial and hepatic specific markers: 
Defining a biocompatible co-culture medium  
 
Standard mono-cultures of HUVECs and C3As are cultured in specialized hepatic growth 
medium (MEME) or endothelial medium (EGM-2), respectively. To develop an in vitro co-
culture model using HUVECs and C3As, biocompatibility of both cell types were tested in 
either endothelial or hepatic medium.  
Maintenance of surface marker expression 
Morphology and phenotype of cells through expression of cell type-specific endothelial 
(CD31 for HUVECs) and hepatic markers (EpCAM for C3As), were evaluated for each cell 
type, cultured in each medium, using phase contrast microscopy, flow cytometry and 
immunofluorescence techniques. 
Morphology 
In mono-cultures of HUVECs and C3As on polystyrene using MEME or EGM-2 for 3 days, 
HUVECs displayed significant abnormal changes in morphology dependent on culture 
medium (Figure 2-1A,B); whereas C3As maintained characteristic morphology regardless of 
culture medium. When HUVECs were cultured in MEME+ lost both morphology and 
viability (Figure 2-1A). However, when HUVECs were cultured in EGM-2, they formed 
characteristic cobblestone morphology (Figure 2-1B). C3As in MEME+ formed aggregates 
and maintained their epithelial morphology (Figure 2-1C), which was also maintained in 
EGM-2 following 3 days in culture (Figure 2-1D).  
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HUVECs and C3As expression surface markers 
Flow cytometry analysis revealed that EpCAM was expressed by C3As equally in culture 
with MEME or EGM-2 after 3 days. Endothelial adhesion molecule expression, CD31, was 
not detected on C3As. Due to the low cell viability observed for HUVECs in MEME+ it was 
only possible to stain those grown in EGM-2. Data showed that CD31 was highly expressed 
by HUVECs, while expression EpCAM was not detected (Figure 2-2).  
Immunohistochemistry photomicrographs show both morphology and phenotype of 
HUVECs and C3As grown in EGM-2 for 3 days. Cells were stained in situ and images 








Figure 2-1 Morphology of HUVECs and C3As in two different media; MEME and 
EGM-2. 
Morphology of HUVECs and C3As as mono-cultures on polystyrene in either hepatic 
medium (MEME) or endothelial medium (EGM-2) on day 3. Phase contrast image of 
HUVECs mono-cultured in MEME (A) and EGM-2 (B) and C3As mono-cultured in MEME 
(C) and EGM-2 (D). These images were taken using an inverted microscope (Zeiss Axio-









Figure 2-2 Expression of platelet endothelial cell adhesion molecule (CD31), and 
hepatic epithelial (EpCAM) in two different media; MEME and EGM-2. 
Phenotype of HUVECs and C3As as mono-cultures on polystyrene in either hepatic medium 
(MEME) or endothelial medium (EGM-2). Cells were stained with cell type-specific hepatic 
(EpCAM) or endothelial (CD31) antibodies for flow cytometry analysis and processed as 
described in Material and Methods in Section 2.2.6. CD31 and EpCAM cell surface 
expression was analysed in HUVECs and C3As using flow cytometry histograms: Grey is 
unstained, red is stained for HUVECs and blue for C3As.   
 
  




Figure 2-3 Immunofluorescence staining using cell type-specific hepatic and endothelial 
surface expression markers in HUVECs/CD31+ and C3As/EpCAM+ in EGM-2 
Morphological phenotype of HUVECs and C3As as mono-cultures on polystyrene in either 
hepatic medium (MEME) or endothelial medium (EGM-2). On day 3 of culture, HUVECs 
(A) and C3As (B) were labelled with DAPI (nuclei), EpCAM (red) and CD31 (green) 
antibodies. Fluorescence images were taken at magnification of 20x and respectively images 
of DAPI and CD31/EpCAM were taken using an inverted microscope (Zeiss Axio-
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2.4.2 Liver Extracellular Matrix: (ECM): Influence of collagen-I on cell culture 
phenotype 
 
In the liver, endothelial cells and hepatocytes are separated by the space of Disse, mainly 
composed of collagen, laminin or fibronectin. In vitro, ECM components influence 
phenotype and behaviour of liver cells. For examples, collagen-I is one of the most abundant 
ECM components in the liver and can maintain longer hepatocyte viability (De Kock et al., 
2011, LeCluyse et al., 2012). 
CD31 and EpCAM expression were evaluated in mono-cultures of EGM-2 medium on either 
collagen-I coated or polystyrene culture plates. Flow cytometry histograms (Figure 2-4) 
demonstrated no change in the levels of expression markers for HUVECs or C3A mono-











Figure 2-4 Expression of platelet endothelial cell adhesion molecule (CD31), and 
epithelial cell adhesion molecule (EpCAM) cultured on either collagen-I or polystyrene 
in EGM-2 media. 
Morphological phenotype of HUVECs and C3As as mono-cultures on either collagen-I or 
polystyrene in EGM-2. CD31 and EpCAM expression were analysed by flow cytometry in 
HUVECs and C3As as described in Material and Methods Section 2.2.6. The flow cytometry 
histograms show CD31 and EpCAM expression in HUVECs cultured in collagen-I, 
polystyrene; and C3As cultured in collagen-I and polystyrene (Grey is unstained and red 
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2.4.3 Optimization of HUVEC:C3A ratios in co-cultures based on cell proliferation 
 
Relative Growth Kinetics in Co-culture: Titration, proliferation rate and viability to 
determine the optimal ratio and culture period 
Following initial titration of HUVEC:C3A ratios used in co-culture experiments, derivation 
of the optimal ratio was also based upon assessment of growth rate, population doubling and 
population doubling time of HUVECs and C3As in mono and co-cultures, from day 0 to day 
3 (d3), and from day 0 to day 7 (d7).  
Growth rate 
At day 3 (d3) and day 7 (d7), there were significant differences in cell growth rate between 
HUVECs and C3As (Figure 2-5A), resulting in significant population doubling between d3 
and d7 in HUVECs (p=0.03) and C3As (p=0.01). HUVECs had proliferated significantly 
more slowly than C3As by d3 (188.9 ± 9.19 % in HUVECs vs 260 ± 11.55 % in C3As, 
(p=0.0002) and by d7, 257.3 ± 27.60 % in HUVECs vs 417.6 ± 53.04 % in C3As, (p= 0.016) 
(Figure 2-5A and Table 2-1). 
Table 2-1 Percentage of cell growth rate from initial day (D0) to final day (D3 or D7) 
Table shows the percentage of cell growth rate on day d3 and d7, obtained following the 
evacuation: Growth rate (100%) = Number of cells harvested on final day (Df)/ Number of 
cells seeded on initial day (D0). Data is expressed as the mean ± SEM of three different 
experiments in triplicate (n=3). *P<0.05, ***P<0.0005, HUVEC d3 vs C3A d3, HUVEC d7 
vs C3A d7. 
Cell growth rate % HUVEC d3 HUVEC d7 C3A d3 C3A d7 
Mean 188.9 257.3   260.0*** 417.6* 
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Population doubling and population doubling time 
Population doubling of C3As showed 1.51 fold increase compared to HUVECs by d3 (from 
0.90 ± 0.07 in HUVECs to 1.37 ± 0.06 in C3As; (p=0.0002) and by d7, from 1.28 ± 0.18 in 
HUVECs to 1.94 ± 0.23 in C3As; (p=0.039) (Figure 2-5B and Table 2-2). This suggests that 
the population time by d3 was 47.93 ± 6.13 hr in C3As and 76.59 ± 11.53hr in HUVECs and 
by d7 92.38 ± 17.38hr in C3As and 166.4 ± 49.08hr in HUVECs (Figure 2-5C and Table 2-
2). 
Table 2-2 Population doubling and population doubling time from initial day (d0) to 
final day (d3 or d7) expressed in hours 
Table shows the Population doubling and Population double time on day d3 and d7, 
obtained following the evacuation: Population doubling (PD) = log [Df/ D0] / log2. 
Population doubling time (PDT) = culture time /PD (time was expressed in hours). Data is 
expressed as the mean ± SEM of three different experiments in triplicate (n=3). *P<0.05, 
***P<0.0001, HUVEC d3 vs C3A d3, HUVEC d7 vs C3A d7. 
Population doubling HUVEC d3 HUVEC d7 C3A d3 C3A d7 
Mean 0.90 1.28 1.37*** 1.94* 
SEM 0.07 0.18 0.07 0.23 
Population doubling time (hours)     
Mean 76.59 166.4 47.93* 92.38 
SEM 11.53 49.08 6.13 17.68 
 
Co-culture phenotype: Flow cytometry 
The proportions of each cell line present in co-cultures after 3 and 7 days of culture were 
compared for three different starting ratios of 3:1 (HUVEC:C3A), 1:1 (HUVEC:C3A) and 
1:3 (HUVEC:C3A). Initially, when setting up co-culture experiments, HUVECs and C3As 
were seeded into wells at the same time. However, this resulted in poor attachment of 
HUVECs because C3As seems to overtake faster the cell culture surface. This was overcome 
by seeding HUVECs four hours before the addition of C3As. This allowed adhesion of 
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HUVECs to the culture surface and resulted in successful co-culture between HUVECs and 
C3As. 
To distinguish the sub-populations of HUVECs from C3As, the proportions of HUVECs and 
C3As following 3 and 7 days of culture were assessed by flow cytometry of samples stained 
using endothelial (CD31+) and hepatic (EpCAM+) antibodies. In each case, the initial ratio 
seeded was more or less maintained at day 3 (Figure 2-5A), whereas by day 7 in all ratios 
tested, C3As were in the majority (Figure 2-6B). At a HUVEC:C3A starting ratio of 1:1, by 
day 3, co-cultures showed 37.34 ± 5.36 % of CD31+ and 56.59 ± 4.46 % of EpCAM+ 
whereas by day 7, co-cultures showed 13.63 ± 6.71 % of CD31+ and 80.77 ± 8.72 % of 
EpCAM+. At a HUVEC:C3A starting ratio of 1:3, by day 3, co-cultures showed 13.61 ± 2.81 
% of CD31+ and 82.98 ± 3.58 % of EpCAM+, whereas at day 7, co-cultures showed 4.84 ± 
1.47 % of CD31+ and 92.86 ± 2.90 % of EpCAM+. Finally at a HUVEC:C3A starting ratio of 
3:1 (HUVEC:C3A), by day 3, co-cultures showed 55.22 ± 11.24 % of CD31+ and 38.16 ± 
10.91 % of EpCAM+ whereas at day 7, co-cultures showed 30.90 ± 9.15 % of CD31+ and 
58.47 ± 14.84 % of EpCAM+ (Figure 2-6A-C). 
These observations revealed that 7 days of co-cultures, at any of the ratios tested, did not 
maintain the initially seeded ratio. However, when the assessment was performed on d3, 
ratio 1:1 and ratio 1:3 (HUVEC:C3A) were able to maintain closer to the starting ratio. This 
data were subsequently confirmed morphologically with fluorescent staining and phase 
contrast imaging of HUVECs and C3As in co-cultures. Morphological analyses showed that 
HUVECs and C3As maintained characteristic epithelial and cobblestone appearance, 
respectively, when cultured together in EGM-2 culture media for 3 days, at ratio 1:1 (Figure 
2-7). These conditions resulted in the least change in relative proportions of cells in co-
culture over time. Importantly, this allowed results from functional analyses, to be 
normalised to initial C3A cell numbers.   




Figure 2-5 HUVECs and C3As proliferation day 3 and by day 7 
Day 3 and day 7 growth kinetics of HUVEC and C3A mono-cultures on polystyrene in 
endothelial media (EGM-2 media). Numbers of HUVECs and C3As at the end of each period 
(d3 and d7) was compared to the initial number of cells on day (d0) calculated as indicated 
in Materials and Methods in Section 2.2.7. A) Growth rate, B) doubling population, and C) 
doubling population times. Data is expressed as the mean ± SEM of three different 
experiments in triplicate (n=3). Statistical significant was considered * p < 0.05, ** p < 
0.001. 




Figure 2-6 HUVEC:C3A co-culture proliferation by day 3 and by day 7 
HUVECs and C3As were co-cultured for 3 and 7 days in EGM-2 at three different ratios 3:1 
(HUVEC:C3A), 1:1 (HUVEC:C3A) and 1:3 (HUVEC:C3A) and stained with CD31 and 
EpCAM to be analysed by flow cytometry analyses as described in Material and Methods in 
Section 2.2.6. The percentage of CD31+ and EpCAM+ cells was compared to the initial 
number of cells on day 0. A) Percentages of EpCAM+ (C3As) and CD31+ (HUVECs) by day 
3 (A) and by day 7 (B). C) Flow cytometry analysis of CD31+ and EpCAM+ in co-culture at 
ratio 1:1 (HUVEC:C3A) on day 3. Data is expressed as the mean ± SEM of at least three 










Figure 2-7 Morphology and specific-endothelial and hepatic surface expression in 
HUVECs and C3As co-cultured at ratio 1:1 in EGM-2 on day 3 
HUVECs and C3As were co-cultured in EGM-2 medium for 3 days. On day 3 of culture, 
HUVECs and C3As were fixed and labelled with EpCAM and CD31 antibodies and DAPI 
(nuclei). Immunofluorescence images of DAPI (nuclei) (A), EpCAM (red) (B) and CD31 
(green) (C) and phase contrast (D) were taken using an inverted microscope (Zeiss Axio-
Observer A1, Germany) at magnification of 20x and respectively images of DAPI and 
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2.4.4 Hepatic Functionality in HUVEC:C3A heterotypic co-cultures 
 
Synthetic, detoxification and biotransformation capacity of C3A cells in HUVEC:C3A 
heterotypic co-cultures were assessed by measuring, respectively, albumin production, urea 
synthesis and CYP3A4 activity. 
2.4.4.1 Albumin synthesis of C3As in mono-culture and HUVEC:C3A heterotypic  
 
Albumin, the most abundant serum protein found in blood, is synthesised by hepatocytes. 
Hepatic-specific functionality of C3A mono-cultures and HUVEC:C3A co-cultures at three 
different ratios (3:1 HUVEC:C3A, 1:1 HUVEC:C3A and 1:3 HUVEC:C3A) was therefore 
assessed by measuring albumin concentration in serum-free endothelial cell growth medium 
2 (EGM-2) over 24hr. EGM-2 medium is normally supplemented with 2% FBS, containing 
albumin, but to assess C3A albumin synthesis, it was necessary to use serum-free EGM-2 
cell culture medium. However, while C3As are normally cultured in serum free medium for 
albumin measurement, the effect of removing serum on endothelial cells is unknown. It was 
therefore necessary to assess the effect of 24hr in serum-free culture conditions on HUVECs 
to ensure that differences in albumin secretion between experimental groups would not 
simply be a result of serum withdrawal. 
HUVECs were cultured in 3 different endothelial cell medium: i) endothelial growth 
medium-2 (EGM-2) (containing growth factors and 2% (V/V) serum), ii) endothelial cell 
basal medium (EBM-2) (without growth factors or serum) and iii) endothelial cell growth 
medium (EGM-2-GF) (supplemented with growth factors but no serum). After 24hr, CD31 
expression was analysed by flow cytometry to evaluate the effect of EGM-2-GF and EBM-2 
on HUVECs.  
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Flow cytometry dot plot representation data confirmed that CD31 expression was maintained 
in EGM-2-GF better than in EBM-2 compared with control (EGM-2) (Figure 2-8). 
 
Figure 2-8 Phenotypic characterization of HUVECs cultured in modified endothelial 
cell growth medium  
HUVECs were cultured in three different conditions of endothelial cell growth medium 
EGM-2; EGM-2 (control, containing growth factors and serum), EBM-2 (without growth 
factors or serum) and EGM-2-GF (supplemented with growth factors but no serum). After 
24hr, CD31 expression was analysed by flow cytometry to evaluate the effect of EGM-2-GF 
and EBM-2 on HUVECs as described in Material and Methods in Section 2.2.6. The flow 
cytometry dot plots representation and histogram shows unstained HUVECs, CD31 stained 
HUVECs in three different media conditions: EGM-2, EGM-2-GF and EBM-2. 
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Therefore, medium EGM-2-GF (serum-free EGM-2 with growth factors) was selected to 
measure albumin concentration in mono and co-cultures at ratios 1:3 (HUVEC:C3A), 1:1 
(HUVEC:C3A) and 3:1 (HUVEC:C3A) from day 2 to day 3 (i.e. the final 24hr of cell 
culture). To quantitate albumin concentration in the cell culture supernatants a standard 
curve was prepared using known concentrations (0-200 µg/ml) of human serum albumin in 
phosphate buffer (Figure 2-9).  
Then, albumin concentration was obtained from the slope and applying the following 
equation:  
y= mx + c  
x = y – c /m  
where x is unknown albumin concentration, y is the relative emission value (arbitrary units), 
c is the x-intercept and m corresponds to the slope of the curve (Figure 2-9) and albumin 
concentration obtained was normalised by the number of hepatocytes seeded on the initial 
day. 
We found significant differences in albumin concentration in mono-cultures vs co-cultures. 
Not surprisingly, HUVECs mono-cultures did not synthesize albumin, whereas C3A mono-
cultures did, while C3As showed elevated albumin synthesis when co-cultured with 
HUVECs, compared to C3A mono-cultures. Although, levels of albumin synthesis increased 
in all HUVEC:C3A ratios tested, the increase only reached statistical significance between 
C3A mono-cultures and HUVEC:C3A co-cultured at ratio 1:1 (20.50 ±  3.46 µg/ml/106 in 
C3As vs 34.17 ± 3.59 µg/ml/106 in ratio 1:1 (HUVEC:C3A); 1.7-fold; (p = 0.011). 
Conversely, the 3:1 (HUVEC:C3A) ratio showed lowest albumin levels with 25.04 ± 5.00 
µg/ml/106 in comparison with HUVEC:C3A ratio 1:1 (34.17 ± 3.59 µg/ml/106) or ratio 1:3 
(31.51 ± 5.25 µg/ml/106). Since HUVEC:C3A ratio 3:1 gave the lowest increase in albumin 
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secretion, and this ratio probably lacks physiological relevance to that seen in vivo, it was 
decided there was no benefit in testing it further in vitro (Figure 2-10). 
 
Figure 2-9 Representative standard curve of albumin concentration from 0-200µg/ml. 
Human albumin was diluted in phosphate buffer to obtain a serial of albumin concentrations 
from 0-200 µg/ml. The relative emission and the different points of human albumin provide a 
linear regression curve which is used to determine the albumin concentration from unknown 
samples using the equation x = y – c /m; where x is unknown albumin concentration (ug/ml), 
y is the relative emission value (arbitrary units), c is the x-intercept and m corresponds to 
the slope of the curve. Data is expressed as the mean ± SEM of three different standard 










Figure 2-10 Hepatic albumin synthesis of C3As in mono-culture and co-cultures with 
HUVECs at three different ratios at 3:1, 1:1, 1:3 (HUVEC:C3A) 
Using the same number of C3As in each condition, C3As (white bar), HUVECs (black bar) 
and co-cultures (patterned bars) were cultured in EGM-2 and albumin synthesis was 
measured from day 2 to day 3 of culture (24hr) when cells were cultured in EGM-2 serum 
free using Albumin Blue 580 Fluorescence Assay, as described in Materials and Methods in 
Section 2.2.7.1. Results are expressed as µg/ml/106 of initial viable C3A cells seeded. Data is 
expressed as the mean ± SEM of three independent experiments in triplicate (n=3). C3As 
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2.4.4.2 Urea synthesis rate (USR) of C3As in mono-culture and HUVEC:C3A 
heterotypic co-culture  
 
Urea synthesis rate (USR) was determined for both HUVECs and C3As in mono- and co-
culture at ratios of 1:1 (HUVEC:C3A) and 1:3 (HUVEC:C3A) on 3 day of culture in EGM-
2. Figure 2-11 shows that HUVECs in mono-cultures synthesised extremely low levels of 
urea, 1.36 ± 0.93 nmol/hr/106. Comparison of urea synthesis in C3As in mono- and co-
cultures, demonstrated no significant increase in the presence of HUVECs, compared with 
C3As alone: 26.21 ± 2.00 nmol/hr/106 mono-culture vs 1:1 (HUVEC:C3A) 25.16 ± 4.40 
nmol/hr/106 at co-culture ratio 1:1 (HUVEC:C3A); and 18.11 ± 4.42 nmol/hr/106 at co-








Figure 2-11 Comparison of hepatic urea synthesis in C3As mono- and co-cultures with 
HUVECs at HUVEC:C3A ratios at 1:1, 1:3 on day 3 in EGM-2 media 
Using the same number of C3As in each condition, HUVECs and C3As in mono- (white 
bars) and co-cultures (patterned bars) at HUVEC:C3A ratios 1:1 and 1:3, were incubated 
with 2 mM NH4Cl for 2 hr on day 3 of culture. Urea synthesis rate was determined from time 
0 to time 2 hours using a quantitative colorimetric Urea Assay Kit, as described in Materials 
and Methods in Section 2.2.7.2. Results are expressed as nmol/hr/106 of initial C3As. Values 
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2.4.5 Cytochrome P450 3A4 (CYP3A4) enzyme activity in C3As in mono-culture and 
HUVEC:C3A heterotypic co-cultures 
 
Basal levels of CYP3A4 enzyme activity in C3As mono-cultures were measured and 
compared to the levels seen in C3As in HUVEC:C3A co-cultures, at ratios of 1:1 and 1:3 
(HUVEC:C3A) using luminescent biochemical assay, as well as immunofluorescence 
staining.  
In C3A mono-cultures, basal levels of CYP450 activity are known to be very low. Notably 
therefore, the effect of HUVECs on C3A cellular CYP450 activity, would be an extremely 
important factor in determining the usefulness of in vitro co-culture models for improving 
drug testing - using human hepatic C3A cells.  
CYP3A4 enzyme activity: A) Luminescence raw data values show that HUVECs did not 
show any CYP3A4 activity; however, comparing C3As with HUVEC:C3A co-cultures, data 
showed highly significant increases at both ratio 1:1 (HUVEC:C3A) (p = 0.009), and ratio 
1:3 (HUVEC:C3A) (p = 0.005) (Figure 2-12-A); B) Fold change: Raw luminescence data 
were used to calculate the fold increase between C3As as a control to HUVEC:C3A co-
cultures at ratio 1:1 and 1:3. Results showed that C3As in co-cultures had 2.27 ± 0.56 fold 
increase in CYP3A4 expression at ratio 1:1 and 2.14 ± 0.50 at ratio 1:3 (HUVEC:C3A) 
(Figure 2-12-B).  
Phenotypic staining for CYP3A4 in mono- and co-cultures:  
Immunostaining of C3As, HUVECs in mono- and co-cultures for CYP3A4 expression in 
situ, revealed higher fluorescence intensity in co-cultures compared to that seen in C3A 
mono-cultures (Figure 2-13). Furthermore, F-actin staining demonstrated characteristic cell 
structure and phenotypic differentiation in mono-cultures. (Figure 2-13). 
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The functional assays showed a trend for enhanced hepatic functional activity (CYP3A4 
biotransformation) in C3A cells, in the presence of HUVECs.   
 
Figure 2-12 CYP3A4 activity in C3As mono- and co-cultures at two different ratios at 
1:1, 1:3 (HUVEC:C3A) 
HUVECs and C3As in mono and co-culture were cultured for 3 days and basal CYP3A4 
activity measurement was performed directly on the cells using P450-Glo CYP3A4 activity 
assays with Luciferin-IPA (Promega). A) Luminescence raw data values of CYP3A4 activity 
detected by day 3 of culture in C3As (white bars) or HUVECs (striped pattern) mono-
cultures and HUVEC:C3A co-cultures, at ratio 1:1 and 1:3 (HUVEC:C3A) activity and the 
CYP3A4 activity is expressed in relative luminescence units (RLU). B) Fold increase 
obtained from the luminescence raw data were used to calculate the fold increase between 
C3As as a control to co-cultures at ratio 1:1 and 1:3 (HUVEC:C3A). Values represent the 
mean ± SEM of three different experiments each containing technical triplicates, (n=3). 
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Figure 2-13 CYP3A4 immunofluorescent staining in C3A cells in mono-culture and in 
co-culture with HUVECs 
Representative immunofluorescence photomicrographs showing morphological phenotype of 
mono- and co-cultures: (A) C3As, (B) HUVECs and mono- and (C) co-cultures at day 3, 
fluorescently-labelled with F-actin (red), CYP3A4 (green) or DAPI (blue). 
Photomicrographs of DAPI, F-actin and CYP3A4 were merged using imageJ 1.46r. These 
images were taken using an inverted microscope (Zeiss Axio-Observer A1, Germany) at 
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2.4.6 Regulation of cellular surface marker expression in HUVECs and C3As 
 
Endothelial and hepatic phenotype was evaluated in HUVECs and C3As mono- and co-
cultures on day 3 of culture. Adhesion molecules such as CD31 and EpCAM were selected 
respectively as specific endothelial and hepatic specific markers. Furthermore, modulation of 
expression of vascular endothelial growth factor receptor 2 (VEGFR-2) and C-met were also 
evaluated (Figure 2-14). In mono-culture, both cell types showed high expression of the 
respective phenotypic marker CD31+ (HUVECs) and EpCAM+ (C3As). When HUVECs and 
C3As were cultured together, HUVECs showed a 1.98 ± 0.16 fold increase in CD31 
expression compared to HUVECs mono-cultures, when in contact with C3As. The 
interaction between HUVECs and C3As also modulated expression of both VEGFR-2 and 
C-met receptors, involved in paracrine signalling. Analysis revealed that VEGFR-2 was 
significantly down-regulated in HUVECs when in co-culture with C3As, the fold change 
being 0.60 ± 0.06 in co-culture (p=0.0334) as compared to HUVECs in mono-cultures. C-
met receptor expression by HUVEC was not modulated in co-cultures. However, C3A 








Figure 2-14 CD31+ for HUVECs and EpCAM+ for C3As gating prior to VEGFR-2 
analysis by flow cytometry 
HUVECs and C3As in co-cultures, following a staining with: VEGFR-2, EpCAM, CD31 and 
C-met for analysis by flow cytometry as described in Material and Methods in Section 2.2.6. 
Flow cytometry analysis show CD31+ for HUVECs and EpCAM+ for C3As gating prior 
VEGFR-2 analysis to show an example of the assessment of Mean Fluorescense Intensity 









Figure 2-15 Comparison of HUVECs and C3A phenotypes in mono- and co-cultures 
HUVECs and C3As as either mono or co-cultures were cultured for 3 days in EGM-2, 
following a staining with: VEGFR-2, EpCAM, CD31 and C-met for analysis by flow 
cytometry as described in Material and Methods in Section 2.2.6. Flow cytometry histograms 
show VEGFR-2,  C-met, CD31 and EpCAM expression in HUVECs and C3As in mono- and 
co-culture and percentage obtained from the Mean Fluorescence Intensity in co-culture 
compared with positive HUVECs and C3As controls. Unstained cells as control (grey) and 
stained cells (coloured). HUVECs and C3As mono-cultures were considered 100% 
expression and compared to co-cultures. Data is expressed as Mean ± SEM of three different 
experiments with significant difference at *p < 0.05, against controls (n=3). Abbreviations: 
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2.5 Conclusions  
 
The data here presents proof-of-principle development of an in vitro hepatic environment in 
which hepatocytes (C3As) and endothelial cells (HUVECs) can be co-cultured, and in which 
they maintain morphology, phenotype, viability and functional properties. In the presence of 
HUVECs at a ratio 1:1, the function of C3A cells was significantly improved in terms of 
albumin synthesis and CYP3A4 activity whereas ureagenesis did not show improvements. 
Endothelial cells and hepatocytes can interact in vitro. CYP3A4 activity (the most important 
Phase I drug metabolizing enzyme) was increased in C3A cells in co-cultures, this being 
especially important as the aim is to develop an improved in vitro human hepatic model for 
drug testing which is representative of liver function in vivo. 
The results from the evaluation of morphology, phenotype, hepatic-specific function and 
cell- signalling presented in this chapter lead to the following conclusions: 
1. Cell phenotypic profile: CD31 is expressed only in HUVECs, while EpCAM is 
expressed only in C3As. 
2. Biocompatibility: Endothelial cell culture growth medium (EGM-2); EGM-2 
maintained for at least 3 days, in culture the characteristic epithelial morphology of 
C3As cobblestone morphology in HUVECs and optimal expression of EpCAM in 
C3As and CD31 HUVECs. Hepatic medium, MEME, was not able to maintain 
HUVECs morphology or viability after only 3 days in culture. 
3. Cell co-culture growth kinetics C3As proliferate faster than HUVECs and co-
cultures at ratio 1:1, and 1:3 (HUVEC:C3A) better maintained the initial seeding 
ratio at day 3 as compared to day 7. Co-culture seems not to affect cell growth.  
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4. Co-culture Functionality: Co-culture with endothelial cells significantly enhanced 
C3A albumin synthesis and CYP3A4 activity in the organotypic hepatic model at 
ratio 1:1 on day 3.      
5. Co-culture phenotype: HUVEC:C3A co-culture up-regulated CD31 and down-



























In vitro human hepatic models represent a promising technology for predicting 
hepatotoxicity in pre-clinical drug discovery. During this complex process, compounds are 
tested in vitro and in vivo. However, as mentioned in the introduction, animal models used 
for drug testing often do not predict human drug toxicity due to interspecies-differences, and 
in vitro human hepatic models using only hepatocytes, for prediction of human toxicity 
(Gomez-Lechon et al., 2014).  
PHH cultured alone have previously been shown to rapidly lose functionality, polarity and 
drug enzyme activity (Gomez-Lechon et al., 2010, Nelson et al., 2010). Recently, a new 
hepatic cell line, HepaRG, derived from a female with hepatocellular carcinoma has been 
compared to PHH. HepaRG cells have been shown to express the major drug metabolizing 
CYP450 enzymes including phase II enzymes and hepatic membrane transport proteins 
(MTP). It comprises cells of two different phenotypes in a bipotential culture: hepatocyte-
like and cholangiocytes-like. However, the supply of HepaRG is limited, and they are 
expensive to purchase and expand in vitro (Gerets et al., 2012, Hart et al., 2010) and, on cost 
grounds alone, should probably only be used when these additional phenotypic 
characteristics are essential for the investigation being undertaken.  
Despite some progress in the pharmaceutical sector, many in vitro hepatic models still use 
either primary hepatocytes or animal-derived cell lines, which limit the interpretation of 
testing outcomes in respect of human metabolism. In developing an in vitro hepatic co-
culture model for drug metabolism studies, it is important to consider incorporation of non-
parenchymal cells, since cytokines and growth factors secreted by stromal cells, are almost 
certainly involved in detoxification and when hepatic cell are damage in hepatotoxicity 
(DeLeve et al., 2004, DeLeve, 2013). To recreate liver-like tissue in vitro it is important to 
allow cell-cell interaction of hepatocytes with non-parenchymal cells for preserving hepatic 
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function (Bhatia et al., 1999, Kim et al., 2012). Indeed, given the importance of cell-cell 
interactions this is not surprising, as in the embryo hepatocytes interact with endothelial cells 
to fully differentiate and form a vascularised liver parenchyma (Matsumoto et al., 2001). 
Developing an in vitro human vascularised hepatic model, that more closely mimics that 
seen in the liver in vivo, could help clarify direct/indirect cell-cell interaction and paracrine 
signalling involved in drug metabolism. Such models could in fact, improve prediction, 
screening and detection of hepatic drug activity. 
This investigation aimed to develop an in vitro hepatic model using HUVECs and human 
hepatic C3A cells, to examine the hypothesis that co-culture of HUVECs and C3As could 
provide an improved in vitro hepatic model for drug metabolism studies by enhancing 
cellular interactions. Further, understanding the role of endothelial cells in such a hepatic 
model may be highly beneficial, to understanding in vivo hepatotoxicity. 
The use of C3As as an alternative to PHH have a number of advantages: C3A cells is an 
affordable cell line, easy to proliferate, unlimited cell source and provide reproducible 
experiments for an in vitro hepatic model for metabolic and drug metabolism studies 
(Lockman et al., 2012, Filippi et al., 2004, Tsiaoussis et al., 2001, Choucha Snouber et al., 
2013). 
In this study, chemically-defined endothelial growth medium (EGM-2) resulted in a 
biocompatible medium culture for combining HUVEC and C3A in co-cultures, achieving a 
human heterotypic in vitro hepatic model. EGM-2 was selected to culture mono- and co-
cultures as it maintained the morphology and hepatic phenotype of C3As, whereas HUVECs 
only supported characteristic endothelial in vitro ‘cobblestone’ morphology in EGM-2 
endothelial medium (Figure 2-1). HUVECs can be significantly damaged by using a cell 
culture medium which does not contain essential specific growth factors (Bala et al., 2011). 
Finally, optimization of this in vitro co-culture model required identification of specific 
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phenotypic markers of hepatic (EpCAM) and endothelial (CD31) cells to distinguish these 
two cell population in co-culture by flow cytometry. Crucially, this allowed for optimization 
and assessment of the required proportion of each cell type at the start and end of co-culture 
(Figure 2-5). Although measurement of lactate dehydrogenase has previously been 
considered to decide between ratios (Soto-Gutierrez et al., 2010), flow cytometry analysis is 
likely a more robust methodology to select the optimal ratio for HUVEC:C3A. Flow 
cytometry permits precise electronic gating, allowing analysis of the relative percentage of 
CD31+ and EpCAM+, important given different cell types often both proliferate and die at 
different rates. 
In this study, HUVECs and C3As in mono- and co-cultures were evaluated on two different 
days of culture (d3 and d7). Using these two time points demonstrated that the initial ratio 
can be lost in the short-term. It was very important to maintain the initial ratio as closely as 
possible, in order to allow consistency of cell-cell interaction to interpret functional assays 
and to confirm the maintained presence of HUVECs. Amongst ratios and days, only co-
cultures seeded at ratio 1:1 for 3 days were able to maintain the initial ratio. Day 7 cultures 
showed that the higher proliferation rate of C3As would result in HUVECs being 
‘overgrown’, resulting in C3As being the predominant cell line, at the end of the culture 
period, which would skew interpretation of results (Figure 2-5). We have shown that 
endothelial cells can improve C3As function using the optimal in vitro ratio of 1:1 of 
HUVEC:C3A for 3 days. Despite not being physiological, ratio 1:1 (HUVEC:C3A) provides 
significant benefits in controlling cell growth and maintaining the ratio. Published studies 
have also shown better approaches with similar but not identical physiological ratios. For 
examples, co-culture of rat or human primary hepatocytes with endothelial cells improves 
hepatic function when they are co-cultured at proportion of 60% and 40% respectively (Kim 
et al., 2012, Kostadinova et al., 2013). 
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The presence of HUVECs significantly enhanced hepatic functionality including albumin 
synthesis and CYP3A4 activity (Figures 2-10 and 2-12), supporting the idea that C3As are in 
a more physiological environment in the presence of endothelial cells, increasing cell-cell 
interaction and cell-extracellular matrix interaction (Soto-Gutierrez et al., 2010, Nahmias et 
al., 2006). The maintenance of the 1:1 ratio (HUVEC:C3A) correlated with a significant 
increase in albumin production. In this study, hepatic function was normalised by the number 
of C3As on day 0, as C3As were seeded at the same density at each ratio to compare the 
albumin synthesis using the same number of C3As hepatocytes in combination with 
HUVECs. An alternate strategy may have been to quantify the extent of albumin synthesis 
by analysing the percentage of C3As hepatocytes in the co-cultures via FACS, and compare 
the albumin synthesis in each ratio using this technique. However, measuring albumin 
synthesis in a 96 well plate using flow cytometry was not the best approach in this study, 
especially for high throughput screening when you require a large number of samples to be 
assessed rapidly in different conditions.  
Only low levels of urea synthesis were detected as a detoxification activity, and this was not 
improved in co-cultures (Figure 2-11). Although the ammonia detoxification pathway can be 
induced in HepG2 (Tang et al., 2008), in C3As it is not clear whether this pathway is 
functional, or if C3As use alternative pathways (Mavri-Damelin et al., 2008). In this study, 
CYP3A4 activity, involved in the metabolism of the majority of drugs in the market, was 
improved approximately two fold in C3As in the presence of HUVECs (Figure 2-12). 
Additionally, morphological and phenotype assessment using immunofluorescent staining in 
co-cultures, demonstrated enhanced CYP3A4 expression in C3As when in co-culture (Figure 
2-13). Improved CYP3A4 activity has also been seen in primary rat hepatocytes in the 
presence of HUVECs where the presence of HUVECs maintain CYP3A4 activity in 
hepatocytes (Leong et al., 2013). The evidence of improvement in C3As hepatic function 
observed in this in vitro model was therefore possible without using specific, liver-derived 
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endothelial cells. There are studies using mouse LSECs co-cultured with hepatocytes to 
investigate acetaminophen (APAP) hepatotoxicity (DeLeve et al., 1997) but to date there are 
few published studies using human LSECs for characterization of phenotype (Fomin et al., 
2013), because of difficulty of obtaining sufficient cells for experimentation, meaning that it 
will be difficult to use human LSECs in drug metabolism.  
Previous studies have also demonstrated enhanced albumin synthesis and some CYP450 
activity (CYP1A2) in rat hepatocytes, when in contact with HUVECs or human micro vessel 
endothelial cells (Nahmias et al., 2006) or HepG2 co-cultured with bovine endothelial cells 
(Ohno et al., 2009). However, whereas many of these in vitro hepatic models combine 
animal and human cell lines to demonstrate a potential advantage, such improvements have 
not previously been shown using both human hepatic (C3As) and endothelial (HUVECs) 
heterotypic cells in combination. This study demonstrates the importance of interactions 
between HUVECs and C3As, and suggests that such interaction may be required for 
improvement of in vitro drug metabolism studies.  
In the liver, cells regulate molecular mechanisms through the activation of specific receptors. 
Paracrine signalling from endothelial cells and hepatocytes are stimulated in regeneration 
and liver injury, but the precise mechanisms remain unknown. Transcription factors such as 
DNA binding 1 targets proteins like VEGF and HGF have been shown to stimulate liver 
regeneration (DeLeve, 2013, Ding et al., 2010). VEGF and HGF can be activated in liver 
injury and activate mechanism of liver regeneration (Kato et al., 2011, Li et al., 2014). It was 
important to assess whether cross-talk between co-cultured cells resulted in modulation of 
phenotypic markers. Here, when HUVECs and C3As were co-cultured at ratio 1:1, flow 
cytometry analysis revealed that there is a modulation of expression of specific markers. 
Endothelial cells up-regulated expression of CD31, when in direct contact with C3As (Figure 
2-14). CD31 expression has been shown to be down-regulated in rat LSECs when co-culture 
with hepatocytes (DeLeve et al., 2004) and HGF promotes rat hepatocyte migration to 
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HUVECs (Nahmias et al., 2006). HUVECs express and can regulate C-met expression in 
stress conditions (Tomizawa et al., 2014). In this study, C-met which is HGF receptor was 
identified in both HUVECs and C3As, maintaining strong expression in co-cultures, whereas 
VEGFR-2 expression was down-regulated, with CD31 maintained (Figure 2-12). These 
findings show that HUVECs do not show any degradation of phenotype in the presence of 
C3As.  
In this study, the in vitro human hepatic model, incorporating hepatocytes and endothelial 
cells to improve pharmaceutical drug testing, should in future also offer the opportunity to 
investigate the role of endothelial cells in hepatotoxicity. This is of interest as drugs cause 
liver injury not only by damaging hepatocytes, but though also LSECs affects (Badmann et 
al., 2012, DeLeve et al., 1997). Thus, co-cultures of a hepatic cell line and endothelial cells 
in an in vitro model could provide a more physiologically-relevant platform for evaluating 
drug detoxification. The next stage to more fully characterize the in vitro human hepatic co-
culture model would be to assess endothelial cell and hepatocyte functional response to 
detoxification, using a hepatotoxicity drug such as acetaminophen (APAP), including 
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3 Chapter 3: Human organotypic co-culture enhances hepatic drug metabolic 




As discussed in the main introduction to this thesis (Section 1.5), drugs are screened 
extensively in in vitro models, animal and human clinical trials during drug development, but 
hepatotoxicity is not always predicted accurately. As a consequence, drugs can be classified 
with a warning label or be withdrawn from the market (Kaplowitz, 2005, Arrowsmith and 
Miller, 2013, Shah et al., 2013). Indeed, drug dose-dependent hepatotoxicity is often not 
detected in these pre-clinical studies because in vitro hepatic model do not accurately 
represent in vivo and drug doses tested in vivo do not always achieve toxic levels.  
One example of such a drug is APAP which displays dose-dependent hepatotoxicity and is 
the foremost cause of acute liver failure (ALF) in the UK and the US (Blachier et al., 2013). 
In a small number of people, even at therapeutic doses, medicines can cause drug 
hepatotoxicity as an idiosyncratic event which is unpredictable in nature and can lead to 
severe ALF, with the only life-saving treatment being liver transplantation (Gulmez et al., 
2013, Chalasani and Bjornsson, 2010). The available effective antidote for APAP overdose 
is n-acetylcysteine (NAC). NAC needs to be administered in the first few hours following 
overdose, before hepatic necrosis occurs. Similar efficacy is also observed using in vitro 
PHH models where NAC is significantly more effective after 6hr of APAP exposure 
compared to 24hr (Xie et al., 2014b).   
The ability to model toxic effects of APAP in vitro could enhance drug safety for 
individuals. In the classic detox pathway APAP metabolized by liver cells (hepatocytes) via 
the CYP450 system, mainly through the isoform CYP2E1, produces a highly toxic by-
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product NAPQI and can also disrupt metabolic processes, resulting in the production of more 
lactate than pyruvate in early stages of liver failure (Shah et al., 2011). At therapeutic doses, 
NAPQI is detoxified by GSH conjugation. However, at toxic levels, GSH stores become 
depleted and cannot neutralise excess of NAPQI; cells then get damaged because NAPQI 
binds macromolecules (proteins and DNA) causing an increase in the levels of ROS and a 
toxic reaction, affecting also the glycolysis mechanism (Rashid et al., 2013, Moyer et al., 
2011, Shah et al., 2011). This disruption in glycolysis metabolism can reduce ATP 
formation, the major source of energy produced in the mitochondria, accompanied by 
activation of oxidants and enhanced drug toxicity (Han et al., 2013, Kon et al., 2004). 
Further investigation is still required about the APAP mechanism of toxicity. However, 
APAP may also damage endothelial cells by additional mechanisms. High levels of lactate 
have been associated with mitochondrial dysfunction in human aortic endothelial cells. 
APAP can also damage the endothelial fenestrae affecting drug clearance, mitochondria 
function and accumulation of toxins in the liver (Ito et al., 2003, Badmann et al., 2012, Shah 
et al., 2011, Deavall et al., 2012).   
Necrosis in hepatocytes is associated to the accumulation of the toxic NAPQI. NAPQI reacts 
with GSH to be neutralised but at high doses APAP toxicity can cause changes in endothelial 
permeability which can result in haemorrhage and accumulation of erythrocytes in the 
sinusoidal space (Ito et al., 2003). These findings suggest that APAP at toxic levels, can alter 
the permeability of LSECs and damage the fenestrae (Kim et al., 2001, Jaeschke et al., 2002, 
Badmann et al., 2012). Identifying endothelial cells as an early target of drug toxicity would 
have an important impact in evaluating response to injury caused by drug activation and may 
lead to improved understanding of the contribution of endothelial cell metabolism in DILI. 
Therefore, use of an in vitro vascularized hepatic model in drug testing, could make clearer 
the role of endothelial and hepatic intercellular signalling in drug-induced hepatotoxicity. In 
Chapter 2, the feasibility of developing a physiologically-relevant in vitro human hepatic co-
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culture model using HUVECs and C3As, which performed better than an in vitro mono-
culture model using C3As alone was demonstrated. Improved hepatic function (albumin 
synthesis and CYP3A4 activity) by day 3 of co-cultured is potentially the result of enhanced 
cell-cell interaction.  Indeed, liver tissue modelling using co-cultures combining hepatocytes 
and fibroblasts, have had improvements in maintaining hepatic functionality in vitro for 
hepatotoxicity studies (Ukairo et al., 2013). However, an in vitro human vascularised hepatic 
co-culture model using HUVECs as a source of endothelial cells may reveal heterotypic 
interactions which regulate drug toxicity and improve drug discovery. To investigate this 
possibility, the in vitro co-culture model was utilised to evaluate the cellular responses of 
HUVECs and C3As to the dose-dependent hepatotoxic drug, acetaminophen (APAP).  
We therefore hypothesize that an in vitro human liver ‘co-culture’ model comprising 
different types of cells, may allow closer representation of in-vivo liver-like function, 
especially closer representation of drug metabolism for predicting toxicity at an earlier stage 
of drug development. To test the hypothesis that the use of HUVECs with C3As is more 
relevant for prediction of drug toxicity than using C3As alone, the in vitro co-culture model 
described in Chapter 2 was exposed to a dose-dependent hepatotoxic drug, APAP. APAP 
hepatotoxicity was chosen as a model of drug-induced liver injury, with the aim of 
evaluating both cellular and metabolic mechanisms involved in hepatotoxicity. 
The following experiments were undertaken: 
I. Evaluation of the effect of APAP toxicity on intracellular ATP levels and 
mitochondrial activity as markers of cell viability and metabolic competence: 
HUVECs and C3As in mono- and co-cultures were exposed to low (5mM), 
intermediate (10mM) and high (20mM) APAP doses for 6hr and 24hr.  
II. Investigation of a known toxic APAP dose on the morphology and viability in mono 
and co-cultures. 
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III. Measurement of lactate and pyruvate levels as an indicators of disturbances on the 
glycolytic metabolic pathway in APAP toxicity. 
3.2 Materials and methods 
3.2.1 Experimental design  
APAP toxicity experiments 
HUVECs and C3As were first seeded at density of 21,000 cells/cm2 in monolayers, or co-
cultured together, unless otherwise indicated, at a ratio of 1:1 (HUVEC:C3A) in EGM-2 
medium. Subsequently, cells in mono- and co-culture were incubated with: 0 mM, 5 mM, 10 
mM and 20 mM APAP for 6hr and 24hr (0 mM APAP represents untreated control). When 
cells were incubated with n-acetylcysteine (NAC), cells were washed twice in PBS to 
remove APAP, and then exposed for a further 24hr of 5 mM NAC. Doses have already been 
used previously with HepG2 cells (Manov et al., 2004) to assess the recovery of cells from 
APAP exposure. 
3.2.2 Cell viability assay: Live/Dead fluorescent staining  
 
The viability of HUVECs and C3A in mono and co-cultures was determined using a 
LIVE/DEAD® Viability/Cytotoxicity Kit (Life Technologies). Live and dead cells are 
distinguished enzymatically and by nucleic acid binding using two-colour calcein and 
ethidium homodimer fluorescent dyes. In brief, Calcein AM detects intracellular esterase 
activity in cells with intact membranes, producing green fluorescence and ethidium 
homodimer binds to nucleic acids in damaged cells producing bright red fluorescence. 
 
Calcein and ethidium homodimer dyes were added to control and APAP-treated cells 
following the manufacturer’s instructions. After 45 min incubation at room temperature, in 
the dark, phase contrast and fluorescence images of controls and treated cells were acquired 
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using filters for green fluorescence (Calcein = 494/517 nm) and red fluorescence (Ethidium 
homodimer-1 in the presence of DNA = 528/617 nm) using an inverted microscope (Zeiss 
Axio-Observer A1, Germany). Images were captured with a mounted camera (Zeiss 
AxioCam MRm) and processed and merged using ImageJ 1.46r (National Institute of Health, 
USA, http://imagej.nih.gov/ij/docs/guide/146-2.html). 
3.2.3 Total intracellular ATP levels 
 
Total intracellular ATP levels were measured in HUVEC and C3A mono- and co-cultures as 
an invasive endpoint for hepatotoxicity using the CellTiter-Glo Luminescent Cell Viability 
assay (Promega). In brief, HUVECs and C3As in mono- and co-cultures were seeded at a 
density 0.12 x 104 cells per well in EGM-2 medium and cultured for 2 days. Subsequently, 
cells were washed twice with PBS and incubated at 37ºC and 5% (v/v) CO2 with a serial 
concentration of 0 mM, 5 mM, 10 mM and 20 mM APAP in EGM-2 medium (0 mM APAP 
represents untreated control) for 6hr or 24hr. After APAP incubation, cells were lysed using 
CellTiter-Glo reagent and supernatants transferred to a white-walled 96 well plate to be read 
on the GloMax plate-reader (Promega). Total intracellular ATP levels in untreated controls 
were considered as reference control values with nominal 100% ATP content for C3As, 
HUVECs or co-cultures. ATP levels in treated cells were normalised to appropriate controls 
values to determine cell viability. 
3.2.4 Mitochondrial function and membrane integrity assay 
 
Mitochondrial function can be measured using viability biomarkers of cell membrane 
integrity and by quantification of the ATP generated during brief incubation with galactose 
during 90 min at 37ºC and 5% (v/v) CO2. In this study, mitochondria function was measured 
using Mitochondria ToxGlo Assay (Promega) following the manufacturer’s instructions. 
This assay measures protease activity associated to necrosis using a fluorogenic peptide 
   
83 
 
substrate and the capacity of the mitochondria to generate ATP after incubation with D-(+)-
galactose.  
 The capacity of mitochondria to generate ATP was evaluated in HUVEC and C3A mono- 
and co-cultures following 24hr exposure to 0 mM, 5 mM, 10 mM or 20 mM APAP (0 mM 
APAP represents untreated control). Following APAP exposure, cells were washed twice 
with PBS and incubated at 37ºC and 5% (v/v) CO2 with 5 mM D-(+)-galactose in EGM-2 
medium for 90 min to measure membrane integrity using Mitochondria ToxGlo Assay 
(Promega).  
Untreated control cells (0 mM) were considered 100% viable (with no alteration in the 
integrity of the membrane) for C3As, HUVECs and co-cultures. Values for treated cells were 
normalised to untreated controls. 
The reason D-(+)-galactose was chosen as substrate, instead of glucose, is that metabolism of 
galactose generates only limited amounts of ATP from glycolysis, forcing the cells to use 
oxidative phosphorylation to produce additional ATP, a process depending on intact 
mitochondrial function. For that reason, the use of galactose allows the detection of 
mitochondrial perturbations in the membrane with greater sensitivity than when using 
glucose (Dott et al., 2014, Aguer et al., 2011, Marroquin et al., 2007). 
 
 




Figure 3-1 Galactose metabolism in glycolysis 
The addition of galactose is taken into the cells to produce glucose for ATP production. The 
use of galactose is more responsive to reflect mitochondria function as cells use 
mitochondrial oxidative phosphorylation to generate ATP. Image modified from Ostergaard 
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3.2.5 Pyruvate and lactate measurement 
 
The production of lactate and pyruvate from HUVECs and C3As in mono and co-culture are 
catalysed in a reversible reaction by lactic dehydrogenase (LDH), in the presence of the co-
factors adenine dinucleotide reduced (NADH) and dinucleotide oxidized (NAD+) 
respectively. The measurement of these co-factors in culture supernatants using two different 
buffers by spectrophotometry can be used to determine lactate/pyruvate concentrations 
independently. Lactate/NADH can be determined by absorption measurement at 340nm and 
pyruvate/NAD values can be determined measuring the reduction in absorbance due to the 
conversion of NADH to NAD with specific buffers pushing the reaction one way or the 
other.  
                LDH  
                                          Pyruvate + NADH                     Lactate + NAD+ 
 
For the experiment, cells were exposed to 10 mM APAP on the second day of HUVECs and 
C3As in mono and co-cultures for 24hr. Then, cells were washed with PBS to remove 
APAP; 5 mM n-acetylcysteine (NAC) was additional added for another 24hr. After APAP, 
NAC or EGM-2 (controls) incubations, cell supernatants were removed for measurement and 
cells were collected and sonicated for total protein measurements (BCA assay, Pierce). 
Samples were read in cuvettes (Cuvettes Semi micro ps 100/pk, Fisherbrand) using Unicam 
UV1 Spectrophotometer (Equionet) and values were normalised by total protein (BCA 
assay, Pierce). 
3.2.5.1.1 Lactate measurement 
 
For lactate measurement, 10µl of each cell supernatant sample or water control was added to 
cuvettes (Cuvettes Semi micro ps 100/pk, Fisherbrand, UK) containing 1 ml lactate buffer 
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(freshly prepared by mixing with 50mg NAD+, 3g of glycine, 2ml hydrate hydrazine, 100ml 
of water and 100µl of LDH). Samples were mixed gently by inverting cuvette and incubated 
for 1.5hr at RT Following incubation, the NADH concentration was determined by 
absorbance at 340nm.  
The lactate concentration was calculated as following: 
Lactate (mM) =         ΔA 340mM x RV (ml) 
                            6.22 x VS (ml) x lightpath (cm) 
ΔA340: Final absorbance at 340nm  
6.22: mM-1 .cm-1 extinction coefficient of NADH at 340mM 
RV: Reaction volume = 1 mL 
VS: Volume of sample in cuvette = 10µl (0.01 ml) 
Lightpath = 1 cm 
3.2.5.1.2  Pyruvate measurement 
 
For pyruvate measurement, 50µl of each cell supernatant sample or water control was were 
added to cuvettes (Cuvettes Semi micro ps 100/pk, Fisherbrand, UK) containing 1 ml 
pyruvate buffer, prepared fresh every time by mixing 12mg NADH for 100ml PBS. Then 
samples were mixed and NADH was detected by absorbance at 340nm. Subsequently, 10 µl 
of a solution of LDH diluted at 1/11 in water was added into each cuvette, alongside a water 
sample as control and incubated 15 min at room temperature. After incubation, second 
reading was recorded, thus: 
ΔA340 = Initial A340 – final A340 
 Pyruvate (mM) =                ΔA 340mM x RV (ml) 
                                          6.22 x VS (ml) x lightpath (cm) 
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ΔA340: Final absorbance at 340nm  
6.22: mM-1 .cm-1 extinction coefficient of NADH at 340mM 
RV: Reaction volume = 1 mL 
VS: Volume of sample in cuvette = 10µl (0.01 ml) 
Lightpath = 1 cm 
3.3 Determination of total protein  
 
Cells were scraped from cell culture wells in ice-cold PBS and sonicated to quantify total 
protein content. Total protein was measured using a bicinchoninic acid assay (BCA assay, 
Pierce) according to the manufacturer’s instructions, and read using Sunrise™ microplate 
reader (Tecan, Switzerland) and absorbance was measured at 550 nm. Total protein 
concentration was obtained from a standard curve using Albumin Standard Ampoules, 
2mg/mL.   
3.4 Statistical Analysis  
 
Experiments were performed in triplicate on at least three biological replicates. GraphPad 
software Prism®5 was used for statistical analysis. Results were reported as mean ± standard 
error (SEM). Student’s unpaired t-test was used to compare all co-cultures to their 
appropriate HUVECs and C3As controls (statistical significance *p<0.05).  
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3.5 Results  
3.5.1 Intracellular ATP levels as a measure of cell viability following 6hr and 24hr 
APAP exposure 
 
APAP can be used as a hepatotoxic drug to test dose-dependent effects in hepatocytes in 
vitro. In this study, HUVECs and C3As were cultured for 3 days in both mono- and co-
culture. Cells were exposed to APAP at low (5 mM), intermediate (10 mM) and high APAP 
(20 mM) doses for 6hr and 24hr after which intracellular ATP content was measured to 
determine cell viability following each time of APAP incubation.  
In summary, percentages of ATP depletion following 6hr APAP at all concentrations were 
not significant between untreated and APAP treated HUVEC and C3A mono- and co-
cultures (Figure 3-1A). When HUVECs mono-cultures were exposed to 5 mM APAP, ATP 
levels rose to 117.01 ± 11.74 % as compared to controls (untreated). At 10 mM and 20 mM 
APAP, the percentage of ATP was respectively 117.16 ± 11.20 % and 110.21 ± 12.03 % of 
HUVECs controls (untreated). In C3As mono-cultures, percentage of ATP levels went from 
100% in controls (untreated) to 97.95 ± 5.28 % when C3As were exposed to 5 mM APAP. 
At 10 mM APAP, 93.93 ± 1.41 % of ATP values were observed and 82.52 ± 2.78 % at 20 
mM APAP. In co-cultures, percentage of ATP values were 112.32 ± 3.4 % when co-cultures 
were exposed to 5 mM APAP, 104.07 ± 3.01 % at 10 mM and 97.81 ± 10.36 % at 20 mM 
APAP.  
By contrast, significant changes in the percentage of ATP levels were detected in HUVECs 
and C3As in mono and co-cultures after 24hr of incubation with APAP. Results revealed that 
APAP incubation in HUVEC and C3A mono-cultures showed a relative decrease in ATP 
values at all doses, whereas in co-culture ATP levels were not significantly affected by 
intermediate (10 mM) doses of APAP.  
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After 5 mM APAP exposure, the percentage of ATP levels in HUVECs mono-culture 
declined to 50.46 ± 12.71 % of control ATP levels, which was also significantly different to 
the percentage of ATP levels observed in C3A mono-cultures (87.19 ± 4.92 % ;p=0.012) and 
also in HUVEC:C3A co-culture (103.71 ± 9.34 % ; p=0.009). Comparison of C3A mono- 
and co-cultures showed that there were no significant differences in ATP levels at 5 mM 
APAP (Figure 3-1B).  
After 10 mM APAP exposure, ATP levels were reduced respectively to 44.73 ± 19.23 % and 
62.41 ± 7.53 % in HUVEC and C3A mono-cultures. By comparison, after 10 mM APAP 
exposure ATP levels in co-cultures (106.49 ± 10.45 %) were maintained, and were 
significantly higher than HUVECs (p=0.007) and C3As (p=0.007) mono-cultures (Figure 3-
1B). 
After 20 mM APAP exposure, ATP levels were respectively 35.60 ± 20.72 % in HUVECs 
and 51.33 ± 12.16 % in C3As, whereas co-cultures showed the highest percentage with 
81.29 ± 13.15 % of control ATP levels, though this value was not significantly different to 
ATP levels in HUVEC or C3A mono-cultures (Figure 3-2B). 




Figure 3-2 Effects of APAP treatment on intracellular ATP levels as a cell viability 
marker in C3As, HUVECs and co-cultures at time 6hr and 24hr 
Intracellular ATP levels were measured as a marker of cell viability using CellTiter-Glo 
Luminescent Cell Viability assay (Promega) in HUVECs and C3As mono- and co-cultures 
(at a ratio of 1:1) following exposure to serial concentrations of 0 mM, 5 mM, 10 mM and 20 
mM APAP (0 mM APAP represents control) for either (A) 6hr and (B) 24hr. The Percentage 
of total intracellular ATP levels was obtained dividing relative luminescence units (RLU) in 
each group by their corresponding untreated RLU controls values and multiplying by 100. 
Data is expressed by the mean ± SEM of three different experiments with significant different 
at *P<0.05, **P<0.001. (n=3) 
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3.5.2 Mitochondrial function and membrane integrity in APAP toxicity 
 
Here, after 24hr exposure to low, intermediate and high doses (5 mM, 10 mM and 20 mM) 
of APAP, cells in mono- and co-cultures were incubated with galactose for 90 min to 
determine ATP generation, as described in Section 3.2.4, as a measure of the susceptibility 
of mitochondria to damage by APAP cytotoxicity. Injury caused by APAP affecting cell 
membrane and mitochondrial function was detected in both endothelial and hepatic cells. 
Data showed that although significant cytotoxic damage was observed to membrane integrity 
especially in HUVEC mono-cultures, cells were still able to take up galactose to produce 
ATP by oxidative phosphorylation (Figure 3-3). 
When APAP-treated HUVEC and C3A mono- and co-cultures were incubated with D-
galactose for 90 min, the evaluation of cytotoxicity in HUVEC mono-cultures revealed that 
exposure to 5 mM APAP can disrupt membrane integrity (Figure 3-3). 5 mM APAP caused 
cytotoxic effect in 38.16 ± 0.99 % on HUVECs, which is significantly greater than that on 
C3As (23.67 ± 4.18 %; p=0.03) and also significantly greater than that on co-cultures (14.11 
± 6.89 %; p = 0.03). Similarly, at 10 mM, while 27.71 ± 7.95% of C3As had damage to their 
membranes, 60.33 ± 7.68 % of HUVECs where affected, a significantly higher compared to 
C3As (p=0.04) and also co-cultures where only 27.94 ± 4.76 % of cells showed disruption 
(p=0.02) (Figure 3-3). No significant difference was observed between C3As alone and co-
cultures.  
At high dose (20 mM APAP), 89.59 ± 4.16 % of HUVECs showed damage, while only 
53.68 ± 6.03% of C3As (significantly lower than HUVECs, p=0.0081), and 33.42 ± 15.56 % 
of co-cultures (significantly lower than HUVECs, p=0.025), showed damage due to APAP 
toxicity after 24hr) (Figure 3-3).  
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Taken together, the data shows that in all cell types, the capacity to generate mitochondrial 
ATP dropped proportionally as the dose of APAP increased (Figure 3-3). The percentage of 
ATP generated in C3As after APAP exposure compared to untreated was 88.32 ± 4.74 % of 
ATP produced after 5 mM APAP exposure, 61.42 ± 9.06 % of ATP produced after 10 mM 
APAP and 22.64 ± 11.32 % of ATP after 20 mM APAP. The percentage of ATP generated 
in HUVECs after 5 mM APAP exposure was 91.03 ± 21.89 %, 73.73 ± 20.62 % after 10 mM 
APAP exposure and 12.01 ± 6.05 % after 20 mM APAP exposure. In co-cultures exposed to 
APAP, HUVECs and C3As were still able to produce high levels of ATP, resulting in 96.72 
± 5.85 % of control after 5mM APAP exposure and 74.19 ± 19.14 % of control after 10 mM 
APAP exposure. A lower percentage of ATP was detected at doses of 20 mM APAP with 
only 40.95 ± 21.14 % of ATP being produced by HUVECs and C3As in co-cultures 









Figure 3-3 Mitochondrial ATP production and damage to the integrity of the 
membrane in HUVECs, C3As and co-cultures after APAP exposure 
HUVECs, C3As and co-cultures (at a ratio of 1:1) were incubated with low, intermediate 
and high doses (5 mM, 10 mM and 20 mM) of APAP for 24hr followed by an incubation with 
D-(+)-galactose for 90 min at 37ºC to evaluate mitochondria function using Mitochondria 
ToxGlo Assay (Promega). Percentages of total intracellular ATP levels and cytotoxicity 
were obtained by dividing relative luminescence units (RLU) in each group of controls by 
their corresponding untreated RLU values and multiplying by 100. Data is expressed by the 
mean ± SEM of three different experiments of three different replicates with significant 
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3.5.3 Morphology in HUVECs and C3As after 24hr 10 mM APAP exposure 
 
Previous results in Section 3.5.1 and 3.5.2 showed that co-cultures were significantly more 
resistant to an intermediate (10 mM) dose of APAP than in mono-cultures. Therefore mono 
and co-cultures were treated with 10 mM APAP for 24hr and analysed for signs of 
morphological changes as an indicator of APAP toxicity, by phase contrast microscopy using 
a cell viability fluorescent staining.  
Cell viability and cell death were confirmed using phase contrast and immunofluorescence 
using live (bright green) and dead (bright red) staining following exposure to 10 mM APAP. 
Phase contrast images in Figure 3-4 show that HUVECs in mono-culture after 24hr treatment 
with APAP, compared to controls (Figure 3-4A) failed to maintain their characteristic 
endothelial cobblestone morphology (Figure 3-4B) and show poor viability (bright red) and 
increased cell death (bright red); while C3As or HUVEC:C3A co-cultures were relatively 
unaffected by APAP exposure (Figure 3-4C & D), suggesting that HUVECs are more 








Figure 3-4 Cellular morphology and live and dead staining of HUVECs or C3A in 
mono and in co-cultures after 10 mM APAP exposure 
HUVECs and C3As in mono- or co-culture (at a ratio of 1:1) were incubated with EGM-2 
alone (controls) or containing 10 mM APAP for 24hr. Subsequently, live and dead staining 
reagents (LIVE/DEAD® Viability/Cytotoxicity Kit; Life technologies) was added to the 
culture wells and after 45 min of incubation at RT in the dark, phase contrast and 
fluorescence images of HUVECs (A), C3A (C) and co-culture (E) controls and HUVECs (B), 
C3A (D) and co-culture (F) APAP-treated cells were acquired to detect bright green 
fluorescence for live cells and bright red for death cells at magnification x10.  Images were 
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3.5.4 Number of HUVEC and C3A in co-cultures following APAP for 24hr 
 
Previously, Figure 3-4 showed that HUVECs in mono-culture showed considerably more 
cell death (bright red fluorescence) than C3As alone and in co-cultures exposed to APAP. 
Mitochondrial function (Figure 3-3) and cell morphology were maintained after APAP 
exposure in co-cultures (Figure 3-4). However, it is important to investigate whether the 
viability of HUVECs and/or C3As are maintained in co-culture. To demonstrate the presence 
of both cell lines together, cells were evaluated by flow cytometry to quantify the percentage 
of each cells affected in APAP toxicity by evaluating cell-specific markers.  
 
As described previously, CD31 and EpCAM can be used respectively to identify HUVECs 
and C3As in co-cultures (Figure 2-7). Flow cytometry analysis confirmed that in HUVEC 
and C3A co-cultures, CD31+ and EpCAM+ expression were essentially maintained after 24hr 
APAP exposure. There was a slight reduction in CD31+ of 0.87 ± 0.04 fold, whereas C3As 
showed a minor increase of 1.07 ± 0.04 fold increase observed, confirming that APAP had a 








Figure 3-5 Fold increase of platelet endothelial cell adhesion molecule (CD31), and 
hepatic epithelial cell adhesion molecule (EpCAM) in co-cultures after 24hr of APAP 
exposure 
HUVEC:C3A co-cultures at a ratio of 1:1, were exposed to 10 mM APAP for 24hr. 
Subsequently, cells were stained with CD31 and EpCAM and analysed by flow cytometry to 
obtain the percentage of CD31+ and EpCAM+ in co-cultures in untreated (controls) and 
APAP treated cells. Fold increase was obtained comparing to untreated CD31+/EpCAM+. 
Data is expressed as Mean ± SEM of three different experiments (n=3). Percentages of total 
intracellular ATP levels and cytotoxicity were obtained by dividing relative luminescence 
units (RLU) in each group of controls by their corresponding untreated RLU values and 
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3.5.5 Glycolysis and redox state in HUVECs and C3As after 24hr of APAP exposure 
followed by 24hr of NAC treatment  
 
Pyruvate and lactate levels (end-products of glycolysis released into the supernatant) were 
measured in untreated (control) and treated (10 mM APAP) HUVEC and C3A mono- and 
co-cultures after 24hr. Furthermore, the addition of NAC for 24hr after APAP exposure was 
also evaluated.  
Results showed several alterations in energy metabolism, especially in lactate 
concentrations. Pyruvate/lactate ratio of mono-cultures of HUVECs and C3As showed 
comparable changes when cells were exposed to 10 mM APAP; and when followed by 5 
mM NAC treatment. The increase in P/L ratio of APAP-treated cells was not significantly 
different from untreated cells in mono-cultures; however, the P/L ratio rose significantly 
following NAC treatment of mono-cultures. In co-cultures no significant changes were 
observed (Figure 3-6A). 
Pyruvate to lactate ratio (P/L) is proportional to the NAD/NADH ratio, i.e. the redox 
potential, itself depending on both the rate of NADH production (through glycolysis) and the 
function of mitochondria (Williamson et al., 1967).  
Glycolysis metabolism  
In C3A cells, treatment with 10mM APAP for 3 days had no effect the cytosolic redox 
potential (Figure 3-6A) or on glycolytic fluxes (Figure 3-6 B), as measured by the ratio of 
pyruvate to lactate. In the light of the previous results on ATP and cell integrity, this is quite 
surprising, as a decrease in ATP usually result in stimulation of glycolysis (Figure 3-2 B). 
The addition of NAC for another 24hr significantly increased the pyruvate to lactate ratio, a 
sign that the cells were in a much more oxidised state. The lack of effect on glycolysis is 
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surprising here as there is usually a correlation between cell integrity, glycolytic fluxes and 
redox potential. 
HUVECs in mono-cultures were much more sensitive to the addition of APAP, showing a 
strong and significant increase in glycolysis (mention the real values here 195.60 ± 59.09 vs 
29.65 ± 5.13, p<0.05). The P/L ratio was not significantly different with our number of 
replicates, though it seemed to indicate a more oxidised state in HUVECs after APAP 
treatment (Figure 3-6B). Taken together with the ATP and cytotoxicity measurements, it 
seems like APAP resulted in oxidative stress in HUVECs resulting in mitochondrial damage 
and hence lower ATP production forcing the cells to increase glycolysis to compensate the 
lack of ATP.  
The addition of NAC in HUVECs resulted in a much lower increase in the glycolytic flux, 
potentially a reflection of a lower damage to mitochondria. However, the P/L ratio indicated 
an even higher oxidation level in HUVECs, similar to the one found in C3As, a measurement 
of ATP and cell integrity in this case would have helped us determine the exact mechanism 
happening in these cells.  
The fact that HUVECs were much more sensitive to APAP than C3As could be due to the 
higher levels of anti-oxidant constitutively present in hepatocytes. 
Interestingly, the co-culture of HUVEC and C3A totally buffered the effects of APAP and 
the further addition of NAC, which is perfectly in line with the results found on ATP and 
cytotoxicity in the previous section (see Figure 3-2B). 




Figure 3-6 Lactate and pyruvate levels in C3A and HUVEC mono and co-cultures after 
24hr of APAP exposure and 24hr of NAC treatment 
Cells were cultured with EGM-2 (control), or 10 mM APAP in EGM-2 and post-treatment 
with NAC for 24hr period. Supernatants were collected to measure the ratio of 
pyruvate/lactate (A) and glycolysis metabolism (B) C3A (black bars) and HUVEC (white 
bars) mono- and co-culture (patterned bars). Values were compared statistically between 
untreated cells (controls) and cells treated with 10 mM APAP on day 3, as well as after 
additional treatment with 5 mM NAC for another 24hr. Data is displayed as the mean ± SEM 
from at least three separate experiments in triplicate, * p < 0.05/ ** p < 0.01/ *** p < 
0.001. 
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3.5.6 Relative total protein in HUVECs and C3As after 24hr APAP exposure 
followed by 24hr NAC treatment 
 
Here, the measurement of the percentages of total protein in untreated (control) HUVEC, and 
C3A mono- and co-cultures or treated with 10 mM APAP for 24hr and then NAC for 
another 24hr were measured to reveal the number of cells attached in the cultured plate after 
each treatment. 
Data revealed that the percentage of total protein in HUVEC mono-cultures dropped from 
100 % in controls to 26.96 ± 10.26 % after APAP treatment and to 13.22 ± 8.8 % after NAC 
treatment. C3A mono-cultures were slightly different in that the percentage of total protein 
measured was 70.09 ± 28.24 % after 24hr APAP exposure and 48.66 ± 26.66 % after NAC 
treatment. In co-culture, the respective percentages were 80.75 ± 23.04 % 24hr APAP 









Figure 3-7 Relative total protein in HUVECs and C3As after 24hr APAP exposure 
followed by 24hr NAC treatment 
Cells were cultured with EGM-2 (control), 10 mM APAP and post-treatment with NAC for 
24hr period. Cells were collected to measure the total protein as indicated in Materials and 
Methods in Section 3.3. Percentage of total protein was obtained dividing the total protein 
concentration (mg/ml) in each group of controls by their corresponding untreated values 
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3.6 Conclusions  
 
Previously in Chapter 2, the in vitro human HUVEC:C3A co-culture model (at a ratio of 1:1) 
was shown to enhance hepatic functionality; albumin synthesis and CYP3A4 activity, while 
maintaining both endothelial and hepatic phenotypes on day 3 of co-culture. To demonstrate 
if the improved function seen in co-cultures might also extend to responses to hepatotoxic 
drugs, co-cultures were exposed to a well-known hepatotoxic drug, APAP (Han et al., 2013).  
 
Data presented in this study has shown hepatotoxicity at doses of 10 mM APAP exposure for 
24hr in HUVEC and C3A mono-cultures, whereas the human HUVEC:C3A co-cultures 
showed increased resistance to the induced hepatotoxicity caused by APAP, reflecting a 
potential cell-cell interaction between HUVECs and C3As.  
 
The data obtained from the use of this heterotypic in vitro human hepatic model in 
hepatotoxicity studies revealed the following points:  
(i) Hepatotoxicity was achieved in HUVEC and C3A mono-cultures with doses of 10 
mM APAP 24hr. The effect of intermediate (10 mM) concentrations of APAP on 
intracellular ATP levels in HUVEC and C3A mono-cultures was only significant 
after 24hr, whereas no APAP toxicity was observed after 6hr of APAP incubation. 
The in vitro human HUVEC:C3A co-culture model maintained significantly greater 
intracellular ATP levels following 10 mM APAP exposure for 24hr, compared to 
mono-cultures. 
(ii) APAP toxicity damaged the cell membranes and mitochondrial ATP generation in 
mono-cultures whereas the in vitro human HUVEC:C3A co-culture model was able 
to resist to APAP toxicity, showing ATP generation after incubation with galactose 
for 90 min. 
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(iii)  APAP exposure altered morphology in HUVECs whereas morphology of C3A and 
co-cultures was not affected by APAP.  
(iv) APAP did not affect the percentage of HUVECs or C3A in co-cultures, as relative 
CD31+/EpCAM+ proportions were maintained after APAP treatment. 
(v) APAP toxicity strongly increase glycolytic metabolism in HUVECs mono-cultures 
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3.7 Discussion  
 
Improved in vitro human hepatic models for hepatotoxicity studies that reproduce aspects of 
the liver in vivo could improve pre-clinical pharmaceutical drug testing strategies. 
Investigation into hepatotoxicity has shown altered drug metabolism and regulation in C3As 
in the presence of endothelial cells, and provided evidence of cellular cross-talk.  
By confirming evidence that APAP can cause hepatotoxicity (Han et al., 2013), this study 
has shown that APAP cytotoxicity is time and dose-dependent. APAP can be highly toxic 
(>1 g per dose or 4 g total per day in adults (Schafer et al., 2013). In this, study, 10 mM and 
20 mM APAP were respectively the equivalent of 1.5g and 3g of APAP, but both of these 
doses did not appear to have a detrimental effect on in vitro cell cultures after 6hr (Figure 3-
2A). In contrast, 24hr exposure to 10 mM APAP demonstrated toxicity in mono-cultures, 
while 20 mM was required to demonstrate APAP toxicity in co-cultures (Figure 3-2B). 
Although ATP levels can be stimulated even before activation of cell death receptors during 
early cell death mechanisms (Zamaraeva et al., 2005, Klingenberg, 2008), this resistance to 
ATP-depletion may also be due the inhibition in apoptosis pathways or reactive oxygen 
species.  
Representative in vitro hepatic models using mouse hepatocytes have demonstrated that 
doses of 10 mM APAP can inhibit mitochondrial ATP generation after 6hr, and that 
administration of fructose and glycine before APAP exposure, can protect the mitochondria 
(Kon et al., 2004). In vivo, mouse models seem to be more sensitive to APAP than rat 
models, where 5 mM APAP can result in mitochondrial dysfunction (Burcham and Harman, 
1991). Recent studies have shown that HepG2 mono-cultures treated with high-dose 20 mM 
APAP for 24hr showed no evidence of mitochondrial dysfunction, or cell injury; suggesting 
very low levels of drug-metabolizing enzymes, which would radically reduce formation of 
the APAP intermediate NAPQI so preventing any toxicity in HepG2 cells (McGill et al., 
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2011). Given that C3As are a clonal derivative of HepG2 cells, the data suggests that 
improved hepatocyte function in co-cultures results in greater suitability of the heterotypic 
HUVEC:C3A co-culture model for drug testing, as compared with standard hepatic cell line 
mono-cultures. By contrast, a recent study demonstrated increased sensitivity to APAP in co-
cultures comprising mouse primary hepatocytes and HUVECs on Matrigel™ (Toyoda et al., 
2012). Thus animal-based co-culture models do not necessarily result in consistency of 
outcome for in vitro drug toxicity studies. Whether this is due to the potential confounding 
variables introduced by rodent hepatocytes, and/or the composition and growth factor 
concentrations in Matrigel™ is not yet known. In this study, 10 mM APAP caused toxicity 
in C3As mono-cultures, which however showed higher resistance to toxicity at 24hr when in 
co-cultures. Intracellular ATP content in co-cultures was significantly higher than in either 
C3As or HUVECs in mono-cultures challenged with APAP and was maintained even after 
24hr with 20 mM APAP (Figure 3-2B). Typically, ATP content is depleted following APAP 
challenge [≥ 10 mM], though cells have been shown to increase ATP content preceding 
apoptosis (Atlante et al., 2005). This could account for the effect of APAP on HUVECs 
intracellular ATP levels, having first increased by 6hr of APAP exposure and then being 
dramatically depleted at 24hr (Figure 3-2).  
When indices of mitochondrial toxicity and necrosis following APAP challenge in 
HUVEC:C3A mono- and co-cultures were measured, they were associated with (short-
exposure) changes in cellular ATP levels and cell membrane integrity, respectively, with the 
Mitochondrial ToxGlo™ Assay (Figure 3-3); and a cell viability assay as a measure of 
intracellular ATP content (ATP depletion) following 24hr exposure to different doses of 
APAP (Figure 3-2B). The latter clearly shows resistance to APAP toxicity in co-culture. The 
reduction in ATP with commensurate changes in membrane integrity (cytotoxicity) using the 
ToxGlo™ Assay, indicates that APAP is a mitochondrial toxin at an intermediate threshold 
dose of 10 mM APAP; with apparent (significant) primary necrosis also taking place (at the 
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lower dose of 5 mM APAP; Figure 3-2A). In co-cultures, the trend was greater resistance to 
mitochondrial toxicity and increased sensitivity to necrosis at all doses tested, compared with 
HUVEC and C3A mono-culture controls. Given this assay is designed to predict potential 
mitochondrial dysfunction as a result of xenobiotic exposure, initial cytotoxicity screening 
with organotypic co-cultures may inform subsequent screening strategies for complex 
adverse outcomes, and provide valuable information on whether to perform more stringent 
assays of mitochondrial dysfunction or mode of cell death, such as; Cytochrome c release 
(apoptosis marker), ROS production, mitochondrial APAP-protein-adduct formation; or the 
M65 necrosis marker. 
The observed ATP depletion was supported with morphological observations on HUVECs 
and C3As using a LIVE/DEAD® Viability/Cytotoxicity Kit (Life technologies), which 
distinguished damaged cells from viable cells. Live/dead staining revealed than HUVECs 
suffered APAP toxicity causing death (bright red) when they were mono-cultured, but 
retained more viability in co-cultures (bright green). Figure 3-4, revealing that APAP 
exposure had an effect on the cellular integrity especially in HUVECs mono-cultures while 
having little effect in co-cultures.  
It is important to highlight that HUVECs were more susceptible to damage, raising the 
question of whether this also occurs in vivo with the drug directly affecting the vascular 
system (Figure 3-4). This damage could activate receptors in hepatocytes and quiescent liver 
cells to contribute to endothelial cell recovery. This suggests the notion that hepatocytes 
effectively ‘endure’ the initial APAP toxicity event, and then accelerate metabolic function 
leading to initiation of cellular mechanisms involved in liver regeneration, provided that 
APAP levels are not so high as to deplete cellular glutathione levels and initiate a second 
round of hepatic cell death by oxidative stress.  
It is also possible that increased levels of ATP in hepatic co-culture could reduce metabolic 
activation of APAP, resulting in increased resistance to toxicity compared to that seen in 
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mono-cultures. Hypoxia can also cause ATP-depletion in endothelial cells or hepatocytes 
(Linden, 2006, Amaral et al., 2013). This resistance to injury observed in co-cultures may 
also be related to reduction in lactate levels in co-culture supernatants, as compared with 
HUVEC mono-cultures (Figure 3-7), suggestive of reduced oxidative stress (Limonciel et 
al., 2011). Interestingly, lactate levels have previously been shown to increase in wound 
healing and high levels of lactate have been related to the capacity of HUVECs to up-
regulate endothelial receptors such as VEGFR-2 (Ruan and Kazlauskas, 2013).  
Investigation of the pyruvate and lactate ratio showed evidence of alterations in glycolysis 
metabolism, especially in HUVEC mono-cultures (Figure 3-7).    
In vivo, lactate levels are related to liver dysfunction in early APAP overdose, indicative of 
damage in the endothelial sinusoid (Kim et al., 2001, Jaeschke et al., 2002, Ito et al., 2003, 
Badmann et al., 2012, Shah et al., 2011). In this study, lactate levels were lower in co-
cultures suggesting that the mitochondria were not affected as significantly by APAP as they 
were in mono-cultures. 
We observed an increase in P/L ratio most probably because an increase in oxidative stress 
in the presence of NAC following exposure to APAP in HUVECs mono-cultures. In C3As, 
there is no increase in glycolysis, though the cell viability seem to decrease. The 
consideration to measure mitochondrial function through cell respiration analysis would be 
an additional information to give an insight in the mechanism. Given 'normal' C3As 
metabolism is anaerobic (Patent No. WO 1991018087 A1; 1991), NAC may enhance the 
pool of cysteine which is then degraded and ends up as an energy substrate in the Krebs 
cycle to support oxidative phosphorylation resulting in enhanced mitochondrial energy 
(ATP) as well as pyruvate production (Figure 3-5).  
DeLeve et al. investigated the APAP effect on LSECs in co-cultures with rat hepatocytes and 
they suggested that hepatocytes might kill endothelial cells when in co-cultures (DeLeve et 
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al., 1997). Here, CD31+ expression was investigated in HUVECs co-cultured with C3As and 
the data showed that HUVECs were present in the co-cultures after APAP treatment and 
were able to maintain levels CD31+ comparable with untreated cells (Figure 3-7). This 
suggests that C3As did not affect HUVECs in co-cultures, whereas the exposure of APAP to 
HUVECs mono-cultures caused mitochondria dysfunction (Figure 3-3), loss of morphology 
(Figure 3-4) and cell death (Figure 3-5). 
We used APAP as a model hepatotoxin, which, as with other hepatotoxins, follows the 3-
step model of drug-induced liver injury (Willett et al., 2014). The first step, as an example, 
might include direct cell stress (cytotoxicity) or direct mitochondrial inhibition (Figure 3-3); 
the second step may involve mitochondrial dysfunction, such as by disruption of the 
permeability transition pore (PTP), which determines the extent of ATP depletion (Figure 3-
2); the third step essentially determines the type of cell death: necrosis (greater depletion of 
ATP) or apoptosis (a lesser depletion of ATP). 
Evidence of activation of other cellular mechanisms via endothelial cells in hepatic co-
culture in response to hepatotoxicity require further investigation, especially regulation of 
the endothelial phenotype and VEGFR-2 expression in co-cultures after APAP exposure in 
vitro. Understanding the role of endothelial cells in APAP toxicity compared with standard 
hepatocyte homotypic mono-cultures model may demonstrate the importance of using 
heterotypic hepatic models to more accurately represent liver-like function for pre-clinical in 
vitro testing of drug safety and efficacy studies. The complex interplay observed in 
heterotypic co-culture may better reflect the situation found in vivo, and provide an insight 
into the mechanisms of drug toxicity. 
Although further studies are required to elucidate the cellular mechanism involved in 
hepatoprotection, it is tempting to speculate that the modulation of APAP toxicity in the 
HUVEC:C3A organotypic model may be in part due to the interaction between epithelial 
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hepatocytes and endothelial cells. As mentioned by Schafer et al pre-clinical studies have 
demonstrated that human and rodents can become resistant to APAP toxicity (Schafer et al., 
2013) and in vitro co-culture models combining hepatocytes and fibroblasts can also show 
less toxicity and provide a protective effect probably due to the hepatic metabolism (Cole et 
al., 2014). One of these studies suggests that multidrug resistance-associated proteins (Mrp4) 
can be induced, resulting in potential resistance to a second dose of APAP (Aleksunes et al., 
2008) but in this study, it seemed to be cell-cell communication between the cells which was 
crucial improvement in the in vitro human models suitable for drug testing in response to 
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4 Chapter 4: Characterization of hepatic phenotypic, antioxidant and oxidant 




Given the highly complex nature of APAP toxicity, more extensive investigations are 
required to fully understand the underlying mechanisms; including, for example, the effect of 
APAP on the endothelium and interaction with non-parenchymal cells (Badmann et al., 
2012, Toyoda et al., 2012). To date, most studies of APAP hepatotoxicity have been 
performed in rodents (DeLeve et al., 1997, Ito et al., 2003, Jaeschke et al., 2012a). In vitro 
pharmacology studies using rat hepatocytes in mono-culture and more recently rodent co-
culture models using endothelial cells, have shown the importance of the toxic effect of 
APAP on the endothelial cell mitochondrial apoptotic pathway during drug metabolism 
(Badmann et al., 2012, Toyoda et al., 2012). However, there is still a need to understand the 
role of human endothelial cells in a human hepatic model (Aritomi et al., 2014). In Chapter 
3, we have seen that the outcome of APAP-induced liver injury in a human in vitro cell 
culture models was significantly improved in the presence of endothelial cells. We then 
focused on the generation of reactive nitrogen species (RNS) and reactive oxygen species 
(ROS) formation were not investigated. 
At therapeutic doses, glucuronidation and sulfation (Phase II) reactions metabolise ~90% of 
APAP, and do not normally produce hepatotoxic effects. As discussed in detail in Section 
1.4.1, published studies using rodents have shown that ~5-15% of APAP is catabolised in 
Phase I mainly by CYP450 (CYP2E1, CYP3A4, CYP1A2), which can result in production 
of reactive and hepatotoxic molecule such as N-acetyl-p-benzoquinone imine (NAPQI). 
NAPQI can be detoxified by glutathione S-transferase enzymes in the cytosol, microsomes, 
and mitochondria, using reduced glutathione (GSH) as substrate, but in APAP overdose, the 
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need to metabolise high concentrations of NAPQI can deplete intracellular GSH to the point 
where NAPQI begins to react with other cellular proteins, to form toxic nitric compounds – 
leading to an increase in ROS and RNS formation. The altered balance between antioxidant 
and oxidant levels leads eventually to mitochondrial dysfunction and cell death by necrosis 
(Agarwal et al., 2012, McGill and Jaeschke, 2013, Getachew et al., 2010). 
The formation of peroxynitrite from the combination between superoxide and nitric oxide 
has also been associated in dropping antioxidants such as manganese superoxide dismutase, 
damaging the mitochondria permeability (Agarwal et al., 2012). Endothelial-derived nitric 
oxide (NO) regulates vascularization and also interacts with cysteine to form S-nitrosothiol 
which activates the erythroid 2-related factor 2 (Nrf-2) antioxidant pathway and is also 
associated with VEGFR-2 activation (Cox et al., 2014). Xenobiotic toxicity can therefore 
induce angiogenesis, ROS formation and regulation of inflammatory cytokines such as TNF-
alpha or interleukins (Pires et al., 2014, Yang et al., 2013a, Xie et al., 2014a, Nagendra et al., 
1997).  
Previous studies in our laboratory have shown that β1-integrin receptor expression in 
hepatocytes can be altered following toxic APAP challenge affecting cell adhesion 
(Newsome et al., 2004). Vascular endothelial growth factor (VEGF) and receptors are also 
important in hepatic differentiation and are related to the capacity to enhance both 
angiogenesis and wound healing in liver macro-vascular injury. In APAP-induced 
hepatotoxicity, injury of LSECs, and collapse of the space of Disse, results in the 
accumulation of blood cells in the space leading to centrilobular necrosis (Donahower et al., 
2010, Kato et al., 2011, Ito et al., 2003).   
Drug toxicity can also cause the activation and regulation of vascular endothelial receptors 
(Badmann et al., 2012, Ito et al., 2003), suggesting that endothelial cells may be associated 
with the early events in hepatotoxicity. Other hepatotoxic drugs such as amidarone can also 
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regulate the expression of CD54 (Intercellular Adhesion Molecule 1 (ICAM-1)) receptor in 
association with metabolic activation by interleukin-1 or TNF-α (Endo et al., 2012).  
In the present study, i) in vitro human mono and co-culture models were exposed to APAP to 
test the hypothesis that the presence of HUVECs could modulate APAP toxicity on C3A 
cells, for example, in conserving total intracellular glutathione levels (tGSH) and NO and ii) 
whether receptors whose expressions are known to be affected by drugs show any 
modification in HUVECs or C3As in response to hepatotoxic challenge. Oxidant and 
antioxidant levels and expression of cellular receptors by hepatocytes and HUVECs were 
evaluated, as outlined below: 
(i) Cytochrome P450 enzyme activity mediation in APAP metabolism, through 
characterization of CYP2E1, CYP3A4, and CYP1A2 expression in mono and co-
cultures;  
(ii) Oxidative stress in APAP metabolism. Superoxide formation during mitochondrial 
respiration; 
(iii)  Endothelial and hepatic antioxidant and intracellular signalling in APAP toxicity; 
NO and tGSH levels as an antioxidant defence in APAP toxicity 
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4.2 Material and Methods 
4.2.1 Experiment design 
 
HUVECs and C3As were cultured at density of 21,000 cells/cm2 in mono- or co-cultures, at 
ratio of 1:1 (HUVEC:C3A) in EGM-2 for a 3 day period. Subsequently, cells were incubated 
with: 0 mM, 5 mM, 10 mM and 20 mM APAP for 24 hr (0 mM APAP represents untreated 
control).  
4.2.2 Real-time reverse-transcription polymerase chain reaction (RT-PCR) 
 
CYP1A2 gene expression was measured in C3As and HUVECs after 3 days of culture and 
treatment with APAP for 24 hr. Cells were then washed twice with PBS and suspended in 
0.5ml Trizol (Invitrogen) at -80ºC for later analysis. 
Total RNA was isolated using Trizol (Life Technologies) from untreated and APAP-treated 
HUVEC and C3A mono- and co-cultures (1:1), and RNA concentration and purity measured 
using the Nanodrop ND100 spectrophotometer (Labtech International). 1µg of total RNA 
from each sample was reverse transcribed into cDNA using the High Capacity cDNA reverse 
transcription kit from Applied Biosystems. 
Primers for human CYP2E1 was obtained from Biopredic International and oligonucleotide 
primer was designed for human GAPDH genes using Primer 3 Output program for control 
(Table 4.1). GADPH was used as a housekeeping control. In Chapter 3, we showed that 
glycolysis was strongly affected by APAP treatment so selection of GAPDH as a 
housekeeping was probably a bad choice as GAPDH is an enzyme of the glycolysis and in 
this experiment, we might expect changes in glycolysis enzymes expression. 
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Standard and Real Time quantitative PCR (RT-PCR) amplification of control liver cDNA 
was performed to optimise CYP2E1 and GAPDH primers. PCR products from standard PCR 
reactions were first tested on 2% gel electrophoresis to confirm the presence of a specific 
band corresponding to the anticipated length of the amplified product.  Primer specificity in 
RT-PCR reactions was then tested by performing a melt curve analysis of RT-PCR data to 
confirm that only a single PCR product was amplified. 
A SYBR green PCR assay using SYBR Green PCR master mix (Life Technologies) was 
employed for RT-PCR analysis (LightCycler® 96 System, Roche). Three biological 
replicates were used from each study group; and each biological replicate was tested three 
times i.e. three technical replicates/sample were run to test for any technical errors. The 
cDNA concentration was equal in all study groups (100ng/µl). The RT-PCR reactions were 
carried out using pre-incubation at 95ºC for 10 minutes, 3 step amplification for 35 cycles 
(95ºC for 20 seconds, 60 ºC for 15 seconds and 72 ºC for 15 seconds), cooling at 37 ºC for 
30 second, melt curve analyses were carried out with cycling at 95 ºC for 10 seconds, 65 ºC 
for 1 minute and 97 ºC for 15 seconds.  
Control cDNA was used to set up a standard curve for each of the studied genes and to test 
primers efficiency. The study conformed to the MIQE guidelines (Minimum Information for 
Publication of Quantitative Real-Time PCR Experiments).  
Data were reported as the fold change with GAPDH normalisation.   
Table 4-1 Primers designed for gene expression analysis 
Gene  Forward primer  (5′…..3′)  Reverse primer (5′…..3′) Product 
size (bp) 
GAPDH  CTGACTTCAACAGCGACACC GTGGTCCAGGGGTCTTACTC 172 
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CYP1A2 and CYP3A4 activity 
CYP activity for CYP1A2 and CYP3A4 reactions were performed in HUVECs or C3As as 
mono-cultures, and in co-cultures at ratio of 1:1, using P450-Glo Luminometry Assays. 
CYP3A4 was measured directly in the cells using luminescence P450-Glo™ CYP3A4 Assay 
with Luciferin-IPA (Promega) (See Section 2.2.8.3) and CYP1A2 activity using a 
luminescence CYP1A2 Induction/Inhibition Assay, (Promega). For CYP1A2, Lucifering-
1A2 was diluted in PBS containing 3 mM salicylamide in DMSO and added into the plate 
for 60 min incubation at 37ºC and 5% CO2. Then, the same volume of supernatant was 
mixed with Luciferin detection reagent supplemented with D-cysteine. Samples were 
incubated at RT for 20 min before reading on a luminometer GloMax Multi+ plate reader 
(Promega). Wells with medium alone were also incubated with luciferin-IPA as a 
background control. Values were obtained in relative luminescence units (RLU) of activity.  
4.2.3 Mitochondrial superoxide indicator  
 
In oxidative phosphorylation electrons can react with molecular oxygen forming 
mitochondrial superoxide anion (O2·-) the main reactive oxygen species (ROS). Formation 
of O2·- was measured in untreated (control) and 10 mM APAP-treated HUVEC and C3A 
mono- and co-cultures using MitoSOX™ Red for live-cell Imaging (Molecular probes, Life 
Technologies, M36008) for 24hr, following manufacturer's instructions. O2·- formation 
causes oxidization of MitoSOX™ generating bright fluorescence at Ex/Em: 510/580 nm (red 
fluorescence).  
For the experiment, HUVEC or C3A in mono- or co-cultures, were cultured for 2 days. Cells 
were then washed twice with PBS and control cells (untreated) were incubated with EGM-2 
containing 4µM MitoSOX™; treated cells were incubated with EMG-2 containing 10mM 
APAP and 4µM MitoSOX™. After 24hr of incubation at 37˚C, phase contrast and 
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fluorescence images of controls and treated cells were acquired to detect the formation of 
mitochondrial superoxide under phase contrast microscopy inverted microscope (Zeiss Axio-
Observer A1, Germany) and images were captured with a mounted camera (Zeiss AxioCam 
MRm). Then, images were processed and merged using ImageJ 1.46r (National Institute of 
Health, USA). 
4.2.4 Total Nitric oxide and Nitrate/Nitrite assay 
 
Total nitric oxide (NO) released by endothelial cells and hepatocytes into cell culture 
supernatant is synthesised from L-arginine. It is measured using an assay based on the Griess 
assay.               
                    nNOS/eNOS 
 L-arginine                                L-citrulline + NO (nitrite (NO2−) + nitrate (NO3−)) 
 
In this study, the same total number of HUVECs and C3As in mono- or co-cultures at ratio 
1:1 (HUVEC:C3A) were cultured for two days before exposure to APAP (0 mM, 5 mM, 10 
mM, and 20 mM) for 24hr. Supernatants were then collected and analysed to determinate 
total Nitric Oxide using the Total Nitric oxide and Nitrate/Nitrite Parameter assay kit (R&D 
systems) following the manufacturer’s instructions. This assay measures concentration of 
nitrate/NO3- and nitrite/NO2- in two different procedures. The concentration of nitrite present 
is measured and then total NO is measured by converting nitrate to nitrite. Results were read 
in a 96 well plate using a Sunrise™ micro plate reader (Tecan, Switzerland).  
4.2.5 Enzymatic method for quantitative determination of total intracellular 
glutathione levels (tGSH) 
 
Total intracellular glutathione levels (tGSH) were measured in the cells following a modified 
protocol of Rahman et al (Rahman et al., 2006).  
   
118 
 
HUVECs and C3As in mono- and co-cultures at ratio 1:1 (HUVEC:C3A) were cultured for 
two days on 6 well plates. Cells were then washed twice with PBS-, and cell culture media 
was replaced with media-containing 10 mM APAP in EGM-2, or just EGM-2 for controls. 
After 24hr of APAP incubation, cells were washed twice with cold PBS- and collected from 
wells by scraping into 1 ml of ice-cold PBS. The cell suspensions were transferred into 1.5 
ml safe lock tubes (Eppendorf, Germany) and centrifuged at 1000g for 5 minutes at 4ºC. 
Supernatants were discarded, and cell pellets re-suspended in 0.5 ml of ice-cold PBS-. 
Samples were centrifuged again and the cell pellets treated with 0.5 ml of ice-cold extraction 
KPE buffer (KPE buffer was made by mixing 8 ml of solution: A (6.8 g KH2PO4 to 500 ml) 
with 42 ml of solution: B (11.4 g K2HPO4.3H2O to 500 ml) and with 0.1.86 g EDTA.: 0.1% 
(v/v) Triton X-100 and 0.6% sulfosalicylic acid in 0.1M potassium phosphate buffer with 5 
mM EDTA disodium salt; pH 7.5). The buffer was made up fresh each time. Cell pellets in 
0.5ml of the extraction buffer were homogenised on ice using a PowerGen 125 Homogenizer 
(Fisher Scientific) for 30 s and then frozen at -80ºC for at least 24hr. The cell homogenates 
were then centrifuged at 3000g for 4 min at 4ºC, and two reagents added: 5,5′-dithio-bis (2-
nitrobenzoic acid) (DTNB) (reagent 1; final concentration of 0.5 mM) and glutathione 
reductase (reagent 2; final concentration of 1µ/ml) for measurement of total intracellular 
glutathione levels (tGSH) (GSH + GSSG).  
These measurements were performed on a Cobas Fara Centrifugal Analyser (Roche) with the 
collaboration of Dr Forbes Howie at The Queen’s Medical Research Institute, The 
University of Edinburgh. 
4.2.6 Flow cytometry 
See Section 2.2.6 
4.2.7 Determination of total protein  
See Section 3.3 
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4.2.8 Statistical analysis   
 
Experiments were performed in triplicate on at least three biological replicates. GraphPad 
Prism®5 software was used for statistical analysis. Results were reported as mean ± standard 
error (SEM). Student’s unpaired t-test was used to compare all co-cultures to their 

















4.3.1 Cytochrome P450 (CYP2E1, CYP3A4 and CYP1A2) activity and expression 
analyses 
 
Cytochrome P450 activity such as: CYP2E1, CYP3A4 and CYP1A2 were measured and 
compared in HUVEC:C3A mono- and co-cultures; either untreated for controls or following 
treatment for 24hr with a toxic dose of 10 mM APAP.  
CYP2E1 was selected for RT-PCR expression analysis because of its involvement in the 
formation of the reactive metabolite NAPQI and ROS formation in response to APAP 
activation. CYP3A4 and CYP1A2 isoforms are associated with drug clearance and 
detoxification mechanisms and were evaluated by luminescence assays.  
CYP2E1 gene expression 
Untreated (EGM-2) C3As co-cultures compared to C3As alone had not significant 1.46 ± 
0.28 fold increase in CYP2E1 gene expression (p = 0.064). When C3As mono- and co-
cultures were treated with APAP, CYP2E1 levels were 0.76 ± 0.44 fold reduced in co-
cultures compared to C3As mono-cultures (Figure 4-1). GADPH was used as a 
housekeeping control in this experiment where we might expect changes in glycolysis 
enzymes expression. Looking at the raw data, GADPH expression was 2,5 cycle difference 
between untreated and treated cells, so GAPDH was not an ideal housekeeping (Table 4-1). 
CYP1A2 Activity 
CYP1A2 activity showed a non-significant reduction in C3As treated with 10 mM APAP 
compared to untreated controls, levels dropping from 159.30 ± 39.58 RLU in untreated 
C3As to 101.50 ± 37.06 RLU in treated C3As. CYP1A2 activity in co-cultures also showed 
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a non-significant reduction from 142.60 ± 23.31 RLU in untreated co-cultures to 120.10  ± 
16.24 RLU in APAP treated co-cultures (Figure 4-2 –A). 
CYP3A4 Activity 
As presented in Chapter 2 (Figure 2-12), untreated C3As showed significantly greater 
CYP3A4 activity when co-cultured with endothelial cells at 490.20 ± 62.95 RLU, compared 
with C3As in mono-cultures at 270.60 ± 38.73 RLU (p=0.0090).  
APAP treatment of C3A mono-cultures resulted in a non-significant reduction in CYP3A4 
activity compared with untreated mono-cultures at 160.60 ± 42.67 in 10mM APAP treated 
mono-culture vs 270.60 ± 38.73 RLU (untreated) vs (Figure 4-2-B). 
However, CYP3A4 activity was significantly reduced from 490.2 ± 62.95 RLU in untreated 
HUVEC:C3A co-cultures to 288.40 ± 49.68 RLU in 10 mM APAP-treated co-cultures 











Figure 4-1 Cytochrome P450 CYP2E1 gene expression in C3As in mono- and co-
cultures with HUVECs at ratio 1:1 (HUVEC:C3A) in EGM-2 and exposed to 10 mM 
APAP at time 24hr 
C3As in mono- and co-cultures were cultured for 3 days. On the second day, cells were 
exposed to 10mM APAP and just EGM-2 for controls for 24hr. After 24hr, basal CYP2E1 
gene expression was measured by RT-PCR as indicated in Material and Methods in Section 
4.2.3. A) Fold increase of relative expression level of CYP2E1 detected by day 3 of culture in 
C3As in mono and HUVEC:C3A co-cultures at ratio 1:1 and APAP-treated cells compared 
to respectively controls. Values represent the mean ± SEM of three different experiment, 
(n=3). 
 
Table 4-1 GAPDH and CYP2E1 Ct values 




GAPDH Mean 18.44 18.89 20.78 19.15 
SEM 0.12 0.05 0.68 0.1 
CYP2E1 Mean 33.66 33.70 36.42 35.43 




1.83 1.78 1.75 1.85 




Figure 4-2 Cytochrome P450 CYP1A2 and CYP3A4 activity in C3As in mono and co-
culture with HUVECs at ratio 1:1 (HUVEC:C3A)  in EGM-2 and in 10 mM APAP at 
time 24hr 
HUVECs, C3As in mono- and HUVEC:C3A co-cultures were treated with 0 mM, 5 mM, 10 
mM and 20 mM APAP (0 mM APAP untreated control) for 24 hr, after which CYP3A4 and 
CYP1A2 reactions performed directly on  the cells using P450-Glo CYP3A4 and CYP1A2 
Activity Assays with Luciferin-IPA (Promega), as described in Materials and Methods in 
Section 4.2.2. A) CYP3A4 and B) CYP1A2 activity in the cells is expressed in relative 
luminescence units (RLU) activity. Values represent the mean ± SEM of three different 
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4.3.2  Superoxide formation in the mitochondria 
 
Superoxide formation in HUVECs and C3As mono- and co-cultures were examined after 
24hr of APAP incubation, by fluorescence imaging using the MitoSOX™ assay. Figure 4.3 
shows representative phase contrast and fluorescence images of untreated control and 10 
mM APAP-treated HUVEC:C3A mono- and co-cultures. The bright red fluorescence 
observed in these images demonstrated that peroxide formation occurred mainly in C3As in 
both mono- and co-cultures. These images revealed that HUVEC mono-cultures treated with 
APAP for 24hr significantly lost their cellular morphology whereas HUVECs in co-cultured 
appeared to maintain morphology (Figure 4-3) consistent with previously-reported 








Figure 4-3 Phase contrast and fluorescence images of mitochondrial superoxide 
formation (bright red) measured by MitoSOX™ red staining in HUVECs and C3As in 
mono- and co-cultures treated with 10mM APAP 
HUVEC:C3A mono- and co-cultures were incubated with EGM-2 containing MitoSOX™ for 
untreated controls in EGM-2 or treated with 10mM APAP containing MitoSOX™. After 
24hr of incubation, cellular morphology and superoxide formation was evaluated by phase 
contrast and fluorescence imaging, respectively, in controls (A, C, E) and APAP treated cells 
(B, D, F) to detect the formation of mitochondrial superoxide formation (bright red); 
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4.3.3 Measurement of parameters of oxidative stress: Total nitric oxide (NO)  
 
The effect of 10 mM APAP on the levels of total nitric oxide (NO) levels was investigated in 
HUVECs and C3As in mono- and co-cultures at 24hr.  
Figure 4.4 shows that 24hr exposure to 10 mM APAP significantly dropped NO 
concentration in C3A mono-cultures from 6.08 ± 0.98 µmol/L to 3.56 ± 0.49 µmol/L 
(p=0.04) whereas, there was no significant difference in NO output between untreated and 
treated HUVEC mono-cultures at respectively 6.04 ± 1.14 µmol/L and 5.35 ± 1.11 µmol/L. 
NO concentrations in HUVEC:C3A co-cultures were from 6.57 ± 0.75 µmol/L in untreated 
cells to 16.77 ± 5.47 µmol/L after APAP treatment. However, NO levels in APAP-exposed 
HUVEC:C3A co-cultures were significantly higher than levels in APAP-exposed C3A 
mono-cultures (p=0.03). When total nitric oxide was broken down into nitrite and nitrate 
formation, there were no significant differences between control and treated C3A and 
HUVEC mono-cultures, though there was a non-significant trend (p=0.21) towards higher 
nitrite levels in APAP-treated co-cultures (Figure 4.4).    




Figure 4-4 Effect of APAP on NO release into HUVEC and C3A cell supernatants in in 
untreated control mono and co-cultures or after treatment with 10 mM APAP 
Graphs A-C show the total levels of NO output in the cell supernatants of control (untreated) 
or HUVEC:C3A mono-or co-cultures treated with 10 mM APAP for 24 hr. C3As (black), 
HUVECs (white) mono- and co-cultures (stippled pattern). Total NO was measured as 
nitrate and nitrite in independent measurements based on Griess assay (Total Nitric oxide 
and Nitrate/Nitrite Parameter assay, R&D systems) as described in Material and Methods in 
Section 4.2.5: A) Total nitric oxide B) Nitrite; and C) Nitrate values represent the mean ± 
SEM of three independent experiments in triplicate; with significant difference at * p < 0.05. 
(n=3) 
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4.3.4 Measurement of oxidative stress: Total intracellular glutathione levels (tGSH) 
 
Total intracellular glutathione levels (tGSH) (GSH+GSSG) were assessed as a measure of 
oxidative stress. Effects of APAP on antioxidant defence were evaluated in endothelial and 
hepatocytes in untreated and 10mM APAP treated HUVEC:C3A mono- and co-cultures. 
Figure 4-5 shows tGSH levels found in HUVEC, and C3A mono- and co-culture untreated 
controls and after treatment with 10 mM APAP for 24hr on day 2 of cell culture. C3A mono-
cultures treated with APAP had significantly increased tGSH levels (47.4 ± 2.78 µmol/g, 
p=0.02) compared with controls (33.87 ± 4.39 µmol/g). tGSH levels decreased significantly 
in treated HUVECs from 32.73 ± 4.27 µmol/g to 9.26 ± 6.28 µmol/g (p=0.007). Treated-co-
cultures showed a non-significant increase in GSH levels from 25.12 ± 6.53 µmol/g to 36.55 











Figure 4-5 Total intracellular GSH levels in HUVECs and C3As mono- and co-cultures 
Total intracellular GSH levels in C3A (black bars), HUVEC (white), and co-cultures 
(stippled pattern) following 10 mM APAP incubation for 24hr, were measured using an 
enzymatic assay (as described in Materials and Methods in Section 4.2.6). Data is expressed 
as Mean ± SEM of three different experiments in triplicate with significant difference at * p 
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4.3.5 Cross-talk between HUVECs and C3As in co-culture: growth factor receptor-2 
(VEGFR2) 
 
To investigate possible changes in paracrine signalling in APAP toxicity, mean fluorescence 
intensity (MFI) obtained from flow cytometry histograms (Figure 4.6-A), were analysed as a 
measure of relative changes in expression of fluorescence markers, showed that endothelial 
expression of VEGFR-2 by HUVECs was altered by exposure to 10mM APAP . 
VEGFR-2 was not difference in HUVEC mono-cultures (119.70 ± 17.56 RU), following 
24hr treatment with APAP as compared with untreated controls (103.00 ± 9.40 RU). In 
HUVEC:C3A co-cultures however, the relative increase in VEGFR-2 expression was 
significantly greater in APAP-treated co-cultures (135.20 ± 24.18 RU; p=0.046) versus 
untreated controls (61.68 ± 8.97 RU) (Figure 4.6-B).  Interestingly, basal VEGFR-2 levels in 
untreated HUVEC:C3A co-cultures (61.68 ± 8.97 RU) were significantly lower than in 
HUVEC mono-cultures (103.00 ± 9.40 RU, p=0.033), suggesting that from C3As might be 
exerting an inhibitory effect on VEGFR-2 expression in HUVECs and that APAP treatment 












Figure 4-6 Endothelial expression of vascular endothelial growth factor receptor-2 
(VEGFR2-KDR) in APAP toxicity 
HUVEC mono-cultures and HUVEC:C3A co-cultures in EGM-2 (untreated control) and 
treated with 10mM APAP in EGM-2 for 24hr were stained with VEGFR-2 and EpCAM and 
analysed by flow cytometry. Flow cytometry analysis of the Mean Fluorescence Intensity 
(MFI) of VEGFR-2 in HUVECs was performed with electronic gating of HUVECs, to 
exclude EpCAM+ for C3As as indicated in Figure 2-14: (A) Flow cytometry histograms of 
untreated control, and APAP-treated HUVEC mono-cultures and HUVEC:C3A co-cultures; 
B) MFI of untreated control and APAP-treated HUVEC mono- and HUVEC:C3A co-
cultures. Data is expressed as Mean ± SEM of three independent experiments with 
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4.3.6 Cross-talk between HUVECs and C3As in co-culture: CD54 receptor  
 
As shown in Figure 4-7 B, there was an increase in the expression of the inter-cellular 
adhesion molecule CD54 (ICAM-1) in HUVECs in both mono and co-culture when they 
were exposure to APAP. In HUVEC and C3A mono-cultures, there was an increase of 4.35 
± 2.54 fold and 1.62 ± 0.07 fold respectively. HUVECs and C3As in co-cultures also showed 
increased expression of CD54 after APAP exposure. HUVECs in co-culture had an increase 












Figure 4-7 Fold increase in MFI of CD54 expression between treated with APAP and 
untreated HUVECs, C3As and co-cultures 
HUVEC and C3As mono- and HUVEC:C3A co-culture untreated controls and treated with 
10mM APAP for 24hr period were stained with CD54/CD31/EpCAM and analysed by flow 
cytometry. The mean fluorescence intensity (MFI) (A) and fold increase in MFI of CD54 (B) 
was measured in HUVECs and C3A using CD31+ HUVECs to exclude EpCAM+ for C3As 
and CD54 in C3As were analysed in EpCAM+ C3As to exclude CD31+ for HUVECs. Data is 
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4.4 Conclusions  
 
The aim was to investigate the effects on total intracellular glutathione levels (tGSH) and 
NO and associated receptors in HUVECs and C3As in mono- and co-cultures in response to 
10 mM APAP hepatotoxicity and to evaluate whether the use of endothelial cells can 
modulate drug responses of hepatocytes. The use of an organotypic co-culture model 
compared with mono-cultures showed the reduced effects of acetaminophen toxicity in co-
cultures. This work has demonstrated a relationship between endothelial and hepatic cells in 
APAP toxicity, as demonstrated by the positive modulation of CYP450 activity, oxidative 
stress and adhesion markers in co-cultures- leading to the following conclusions:  
Specific effects in hepatotoxicity: 
 
(i) APAP can significantly inhibited CYP3A4 activity in HUVEC:C3A co-cultures; 
(ii) APAP seems not to increase superoxide formation in HUVECs.  
(iii) APAP significantly dropped total nitric oxide in C3As and raised levels in co-cultures. 
APAP did not affect the release of NO from HUVECs; 
(iv) APAP produced a significant tGSH depletion in HUVECs, whereas it induced GSH 
levels in C3As, while tGSH content remained constant in co-cultures; 
(v) APAP up-regulates VEGFR-2 expression in HUVEC mono- and HUVEC:C3A co-
cultures. In untreated cells, VEGFR-2 was down-regulated in co-cultures compared with 
mono-culture controls, whereas 10 mM APAP treatment significantly increased 
VEGFR-2 levels in co-cultures. 









Application of the current HUVEC:C3A in vitro human hepatic model to understanding 
responses to the hepatotoxic drug acetaminophen suggests that the heterotypic cell-cell 
interactions are crucial for better representation of drug toxicity in vitro.  
Phase I CYP450 enzymes such as CYP1A2, CYP3A4 and CYP2E1 catalyse the activation of 
APAP, producing reactive molecules such as NAPQI which can result in ROS and RNS 
formation and damage to the mitochondria (Ribeiro et al., 2014, Jaeschke et al., 2012b). 
Current animal models of hepatotoxicity still do not fully represent the complex 
physiological mechanisms and processes of the liver in vivo (O'Brien et al., 2006, Gomez-
Lechon et al., 2010). APAP can cause mitochondrial dysfunction, which is a late effect in 
cytotoxicity, while early mechanisms involved in APAP toxicity are still unknown. To date, 
CYP1A2 and CYP3A4 have not been investigated extensively in APAP metabolism, 
although both have been shown to enhance acetaminophen-induced toxicity (Cheng et al., 
2009). In this study, CYP3A4 and CYP1A2 activity were investigated in HUVEC and C3A 
mono- and co-cultures demonstrating significantly higher CYP3A4 activity in control 
untreated co-cultures compared with untreated mono-cultures (Figure 4-1)  
APAP toxicity can lead to oxidative stress and mitochondria dysfunction (Han et al., 2013). 
Superoxide formation in response to APAP treatment was observed in C3As and co-cultures, 
but not in HUVEC mono-cultures. Apparently, APAP-treated HUVECs in mono-cultures do 
not show lower NO concentration (Figure 4-4) or produce superoxide but HUVECs did lose 
cobblestone morphology (Figure 4-3) and tGSH content (Figure 4-5) after 10 mM APAP 
treatment, suggesting that APAP can be substantially toxic to HUVECs, via alternative 
toxicology pathways.  
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Therefore, it seems likely that superoxide formation in mitochondria of co-cultures 
exposed to 10 mM APAP was happening only in hepatocytes (Mukhopadhyay et al., 2007).  
The absence of superoxide formation in HUVECs did not prevent injury, as HUVECs lost 
normal morphology and ATP levels were lower than C3As or co-cultures (Figure 4-3). Some 
studies have demonstrated that MitoSOX™ can detect superoxide formation in endothelial 
cells (Li et al., 2009), but here APAP did not significantly enhance superoxide formation in 
HUVECs at 24hr, possibly the HUVECs were no longer viable by this time. A recent 
hepatotoxicity study of superoxide formation used the bi-potential HepaRG hepatic cell line 
(hepatocytes and biliary epithelial-like cell co-culture) exposed to lethal doses of 20 mM 
APAP (McGill et al., 2011). In this study, it was demonstrated that superoxide formation 
occurred exclusively within hepatocytes, not in the biliary epithelial-like cells. HepaRG cells 
express sinusoidal and canalicular hepatic membrane transport proteins (Le Vee et al., 2006). 
The combination of those hepatic membrane transport proteins may boost drug clearance, by 
releasing drug metabolites into the biliary system and into the blood (Le Vee et al., 2006).  
The formation of the reactive oxidant, peroxynitrite, is the result of the combination of 
superoxide and NO. The absence of superoxide formation in HUVECs, with maintenance of 
relatively high levels of NO, suggest than peroxynitrite may not be formed in HUVECs. 
These observations are very complex and may be in part due to the fact that the reactivity of 
nitric oxide may be greatly overestimated in vitro, due to an accumulation in cell cultures 
that would not occur normally in vivo in the intact liver. Peroxynitrite formation does 
however occur in APAP metabolism (superoxide + NO  peroxynitrite (ONOO−), and is a 
highly reactive, potent oxidant and nitrating species, which causes mitochondrial damage 
and oxidative cellular stress. The main sources of peroxynitrite has been suggested to be 
from both Kupffer cells and neutrophils, although hepatocytes can also produce peroxynitrite 
in liver damage under stress conditions (Knight et al., 2002, Lawson et al., 2000).  
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A more in-depth investigation of oxidative stress mechanisms in response to APAP in our 
organotypic model showed that the NO level was unchanged in HUVECs, whereas C3As 
mono-cultures showed a significant decrease. However, given that increased NO levels were 
seen in co-cultures (Figure 4-4), we may also speculate that NO could induce an elevation of 
total intracellular glutathione levels thereby improving drug detoxification (Figure 4-4) 
(Alva et al., 2013). However, in this study, measurement of the independence values of GSH 
and GSSG may result in a better approach to understand total intracellular glutathione levels. 
GSH may be hepatotoprotective against APAP toxicity as a scavenger of ROS and 
peroxynitrite (Saito et al., 2010, Jaeschke et al., 2012a).  
This has been observed in AML-12 hepatocytes where exposure to a NO donor was 
concomitant with activation of the antioxidant transcription factors Hypoxia-inducible factor 
1α (HIF1α) and erythroid 2-related factor 2 (Nrf-2); leading to increased antioxidant defence 
(Aharoni-Simon et al., 2012). Moreover NO synthesis was dramatically increased in APAP 
toxicity in mice (Hinson et al., 2010), suggesting our organotypic model may mimic certain 
in vivo parameters of drug toxicity. 
When endothelial cells are damaged, it has been shown that endothelial nitric oxide (eNO) 
production is reduced and the formation of peroxynitrites are increased (Li et al., 2013).  
Nitric oxide can protect the liver vascular system, while lower concentration of NO can 
cause endothelial dysfunction (Alva et al., 2013, Forstermann and Munzel, 2006, Nagi et al., 
2010, Nicotera and Melino, 2004). In mice, the administration of endothelial specific 
angiogenic growth factors protected hepatocytes from apoptosis in APAP overdose 
(Donahower et al., 2010).  
Maintenance of hepatic phenotype and functional activity was observed in co-culture 
(Figures 3.5 and Figure 4.2), which exhibited resistance to APAP toxicity, likely through 
   
138 
 
enhanced production of total intracellular glutathione levels (tGSH) and cellular ATP, 
compared with mono-cultures of hepatocytes or endothelial cells alone (Figures 3.1). 
The EGM-2 medium in providing biocompatible trophic support in HUVEC:C3A co-
cultures contains defined supplements, including VEGF (EGM-2, CC-3162 Lonza). 
VEGFR-1 and VEGFR-2 are located in endothelial cells and play an important role in 
angiogenesis and permeability (LeCouter et al., 2003) and in orchestrating interactions with 
hepatocytes in organogenesis (Matsumoto et al., 2001). Treatment of mice with VEGF-A 
and activation of VEGFR-1 in co-cultures between hepatocytes and LSECs induce cell 
proliferation, and reduce by 86% carbon tetrachloride toxicity (LeCouter et al., 2003); 
whereas APAP treatment increased VEGF levels in mice, conferring hepatotoprotective 
effects, with concomitant increase in VEGFR2 expression (Hinson et al., 2010). 
VEGF is induced in vivo in APAP toxicity (Donahower et al., 2010). Here, we demonstrated 
down-regulation of VEGF in co-cultures (Figure 4-6), which may mean that cross-talk 
between HUVECs and C3As confers the observed resistance to APAP toxicity at 10 mM 
APAP. Expression of the cell adhesion molecule CD54 (ICAM-1) was also investigated. 
CD54 has been associated with activation of the immune system, increasing the levels of 
cytokines such as IL-8 and TNF-α and causing mitochondrial dysfunction when exposued to 
a hepatotoxic amiodarone drug (Endo et al., 2012). In the current study, CD54 was 
moderately induced by APAP in HUVEC mono and co-cultures (Figure 5-8), suggesting that 
the cells were affected by APAP toxicity at 10 mM (Figure 4-8). TNF-α induced the 
activation of CD54 which facilitates trans-endothelial migration – inducing cellular damage 
and reducing angiogenesis (Kanzler et al., 2013, Kjaergaard et al., 2013, Knudsen and 
Kleinstreuer, 2011). Taken together, these data suggest improved functionality and drug 
detoxification as a result of cell-cell communication between endothelial and hepatic cells in 
response to APAP hepatotoxicity in heterotypic co-cultures. 
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5 Chapter 5: In vitro vascularised co-culture model using an extracellular 
matrix: migration and wound healing studies 
 
5.1 Introduction  
 
In Chapter 2, 3 and 4, HUVECs were co-cultured with C3As to develop a more 
physiological in vitro human hepatic model, where the main interest was to improve hepatic 
function in C3As for drug metabolism studies. However, the endothelial component of the 
liver also plays critical roles in drug clearance and nutrient transfer to the hepatocytes. In this 
Chapter, HUVECs and C3As were co-cultured in the presence of an extracellular matrix, 
with the aim of reconstructing an in vitro vascularised hepatic model to test the role of the 
vascular system in hepatocyte maintenance and in responding to drug toxicity. Endothelial 
cells form the thin inner lining of blood vessels throughout the vascular system, form a semi-
selective barrier between the vessel lumen and surrounding tissue and can migrate and take 
part in blood vessel healing and new blood vessel formation in tissue regeneration (Takebe et 
al., 2013, Nahmias et al., 2006). To evaluate endothelial capacity to promote vascularisation 
and support normal hepatocyte function, including CYP450 activity, it is important to obtain 
insights into the mechanisms promoting angiogenesis and the morphology and migration of 
the individual cell types involved in these processes (Kavitha et al., 2011, Rivron et al., 
2008, Soto-Gutierrez et al., 2010).  
The use of extracellular matrix (ECM) as a support for endothelial cells can promote 
vascular network in vitro which promote albumin synthesis and CYP450 activity in 
hepatocytes to recapitulate drug metabolism in vitro (Nahmias et al., 2006). The most 
relevant ECM used to support formation of organised endothelial networks in vitro, is the 
animal-derived Matrigel™ which, despite not being fully-defined, is known to contain high 
concentrations of laminin, collagen, entactin and growth factors (Rohringer et al., 2014, Hadi 
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et al., 2013, Toyoda et al., 2012). Matrigel™ is an animal-derived scaffold. An experimental 
animal free ECM (xeno-free ECM), has also been developed to promote migration of growth 
in a 3D culture (Maas-Szabowski et al., 2005). However, formal comparison between xeno-
free ECM and animal-derived ECM (Matrigel™) is still required.  
Endothelial cells and hepatocytes, cultured in conventional tissue culture polystyrene, do not 
migrate to achieve self-organisation into defined vascular network (Nelson et al., 2010, 
Tourovskaia et al., 2014) in response to indirect stimulation by soluble trophic factors in 
endothelial-hepatic cross-talk. Cross-talk could generate a potential tool to maintain 
hepatocytes function in vitro (Hoehme et al., 2010, Rivron et al., 2008). Culturing rat 
primary hepatic cells using extracellular matrices has been shown, to some degree, overcome 
the loss of CYP3A3 activity and albumin synthesis seen when hepatocytes are cultured on 
polystyrene (Genove et al., 2009). Indeed, an in vitro angiogenesis model using rat 
hepatocytes and endothelial cells grown on Matrigel™ has demonstrated that the exchange 
of VEGF promotes endothelial cell migration and vascular tubes, and improved hepatic 
function (Nahmias et al., 2006), while the use of collagen-I as an ECM support, promotes 
cell-cell attachment between HUVECs and rat hepatocytes (Inamori et al., 2009).  
Transmembrane adhesion glycoproteins expressed on parenchymal cells can be bound to 
components of the ECM, such as CD44, which binds hyaluronic acid. CD44 is associated 
with cell migration, cell adhesion (Deboux et al., 2013) and showed APAP susceptibility 
(Harrill et al., 2009). CD49f, which binds laminin, is associated with cell survival and 
migration (Yu et al., 2012).  
The principal aim of this study was to evaluate endothelial function using HUVEC:C3A co-
culture in the presence of ECM to promote vascular network, wound healing and facilitate 
growth factor transfer to facilitate the outgrowth of hepatocytes. The recapitulation of cell 
migration in an in vitro system would give insights in the endothelial capacity to adapt and 
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build a vascular system (e.g. liver sinusoid-like structures) which could be applied to drug 
discovery.   
To develop an in vitro vascularised hepatic model using HUVECs and C3As, the following 
points were pursued:  
i. Selection of a biocompatible ECM to promote vascular network by HUVECs in 
mono and co-culture with C3As, and to allow further investigation of cell migration. 
ii. Investigation of the effect of using an ECM on hepatic function in C3As and on the 
endothelial function in HUVECs. The maintenance of albumin synthesis and 
CYP3A4 activity in a vascular network, is essential to recapitulate drug metabolism 
in vitro.  
iii. Evaluation of the effect of APAP toxicity on hepatic function, on endothelial 
properties such as vascular formation, wound healing as well as investigation of 

















5.2.1 Matrigel™ coating of tissue culture plates 
 
Matrigel™ Matrix Phenol Red-free (BD) or Matrigel™ Growth Factor Reduced (MG-GFR) 
(BD) was thawed overnight on ice in the cold room and handled with pre-cooled tips. Tissue 
culture plate wells were coated with cold liquid Matrigel™ and incubated at 37ºC and 5% 
CO2 for 1hr to allow protein polymerisation and gel formation before addition of cell 
suspensions at density of 26.000 cells/cm2.  
5.2.2 MaxGel™-Human ECM coating of tissue culture plates 
 
MaxGel™ (Sigma-Aldrich) is a human basement membrane extract containing extracellular 
matrix components which can be used to form a 3D environment for cell culture. This was 
selected to compare its effects with those of animal-derived hydrogels such as Matrigel™. 
To coat tissue culture plastic, MaxGel™ was thawed on ice in the cold room, handled with 
pre-cooled tips, diluted in 1:2 with cold cell culture media (EGM-2) and incubated at 37ºC 
and 5% CO2 for 2 hours to allow to polymerisation before addition of cells at density of 
26.000 cells/cm2.  
5.2.3 In vitro co-culture experiments 
 
For in vitro co-culture experiments, HUVECs were seeded with C3A cells at ratio 1:1 
(HUVEC:C3A) in pre-coated wells with ECM in EGM-2 for 3 days before the assessment of 
hepatic function, except where indicated. Starting cell density was based on surface area at 
26.000 cells/cm2. 
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5.2.4 Vybrant staining  
 
HUVECs and C3As were labelled with two different lipophilic membrane stains Vybrant™ 
Cell-Labelling Solution (Molecular Probes). HUVECs and C3As at a density of 1x106 cells 
per ml were labelled individually with DiI (red-fluorescent dye) or DiO (green-fluorescence 
dye), by incubation for 15 min at 37ºC and 5% CO2 and washed 3 times with PBS before 
seeding the cells.  
5.2.5 Hepatic activity  
 
Albumin synthesis was measured in cell culture supernatants using Albumin Blue 580 
Fluorescence Assay as indicated in Section 2.2.7.1, while CYP3A4 activity was measured as 
described in Section 2.2.7.3. 
5.2.6 CYP3A4 and Filamentous action (F-actin) staining 
 
HUVECs and C3As were cultured either separately or in co-culture at a density 21.000 
cells/cm2 on polystyrene well plate for 3 days. On day 3, cells were fixed and treated with 
0.1% Triton X-100 in PBS for 1hr at RT and blocked with PBS containing 5% BSA for 30 
min. Subsequently, they were stained for CYP3A4 and Filamentous actin (F-actin) as 
described in Section 2.2.4.2.   
5.2.7 Time-lapse fluorescence microscopy 
 
HUVECs and C3As were labelled with DiI (bright red-fluorescent dye) and DiO (bright 
green-fluorescent dye) respectively as described in Section 5.2.4 and seeded at the same time 
in 24 well plate pre-coated with Matrigel™.  
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Time-lapse fluorescence imaging was then performed for 20hr using an automated wide field 
observer inverted microscope (Zeiss Axio-Observer A1, Germany). The microscope was 
focused before the start point of time-lapse and was able to autofocus throughout the run. A 
total of 58 pictures were taken every 20 min for 20hr.  
5.2.8 Vascular network formation assay  
 
Standard experiments 
HUVEC and C3A mono and co-cultures at ratio 1:1 were seeded in pre-coated with 
Matrigel™ with EGM-2 for one week and cell viability was determined using a 
LIVE/DEAD® Viability/Cytotoxicity Kit (Life technologies) at the end of the experiment as 
described in Section 3.2.2. Vascular structures were photographed at time 6hr, 72hr and one 
week using a confocal microscope and Nikon Digital camera DXM1200. Images were 
merged using ImageJ 1.46r (National Institute of Health, USA). The images were used to 
manually count the number of vascular tubes formed. 
 
Drug toxicity studies 
HUVEC and C3A mono and co-cultures at ratio 1:1 were seeded in pre-coated with 
Matrigel™ with EGM-2 (control) and with EGM-2 containing 10 mM APAP. Cultures were 
photographed at time 24hr using inverted microscope (Zeiss Axio-Observer A1, Germany) 
and images were captured with a mounted camera (Zeiss AxioCam MRm).  
5.2.9 Trans-well cell migration assay 
 
C3As migration to the interconnected vascular network made by HUVECs on Matrigel™ 
was investigated using an 8µm porous filter insert of a trans-well cell migration assay. 24 
well tissue culture plates were pre-coated with Matrigel™ or with Matrigel-GFR as 
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described in Section 5.2.2. Then, unlabelled HUVECs were seeded on the Matrigel™ while 
C3As labelled with PE-DiI (red- fluorescent dye) (see Section 5.2.1.1) were placed in 
transwell inserts of 8µm pore diameter translucent ThinCert™ 24 Well Cell Culture Inserts 
(Greiner Bio-one) on the top of each 24 well plate (Figure 5-1). Then, wells were incubated 
at 37ºC and 5% CO2 for 24hr with EGM-2 culture media. 
After 24hr, EGM-2 and inserts were carefully removed and cells were washed with PBS and 
fixed in 4% (w/v) paraformaldehyde for 10 min at RT. The bottoms of the wells were 
photographed under fluorescence microscopy using a confocal microscope and Nikon 
Digital camera DXM1200 and images were merged using ImageJ 1.46r (National Institute of 
Health, USA).  
 
 
Figure 5-1 Representation of trans-well plate assay  
HUVECs were seeded in wells of 24 well tissue culture plates were pre-coated with 
Matrigel™, Matrigel™ GFR or uncoated polystyrene for one hour in the incubator at 37ºC 
and 5% CO2. C3As were labelled with DiI (red fluorescent dye) and plated, at the same 
density as HUVECs, in transwell inserts of 8µm pore diameter translucent ThinCert™ 24 












5.2.9.1 Cell Imaging and Analysis Package 
 
The percentage of area coverage by stained-DiI (red fluorescent dye) C3As was calculated 
using a Cell Imaging and Analysis Package designed by Dr. Scott Inglis (Department of 
Medical Physics, RIE, NHS Lothian) using the Matlab 7.1 (R14) Graphical User Interface 
(GUI) builder. 
 
The Cell Imaging and Analysis Package functioned by loading the original image in JPEG or  
TIFF format with C3As tracker with DiI (red fluorescent dye) (see Section 5.2.1), and 
splitting the image into three different thresholding levels (red, green and blue). Red was 
used as the reference component and green and blue were subtracted from the reference. 
When channels from the image were subtracted, red staining was converted into a smoothed 
white mask image corresponding to stained C3As and the percentage of the mask image was 
calculated. The accuracy of the Cell Imaging and Analysis Package was validated by 
comparing actual values for objects of known area with experimentally determined values. 
To perform this comparison, calibration squares of predetermined area were designed using 
Microsoft PowerPoint and the real areas compared with areas obtained by converting the 
objects into JPEG or TIFF format and analysing them using the programme. The error 
observed between real and experimentally determined values was calculated, with the result 
that the Cell Imaging and Analysis Package can determine the area covered by an object with 









Figure 5-2 Cell Imaging and Analysis Package Calibration 
Cell Imaging and Analysis Package was designed using Matlab 7.1 (R14) Graphical User 
Interface (GUI) builder. To detect the systematic error of each measurement, different sizes 
of squares were measured and calculated in table 5-1 and compared to known values. To 
perform this comparison, squares were designed using power point and the area was 
calculated following the equation of the area of the rectangle: Area = length * width, giving 
real values. Then, the same squares were used to obtain the experimental values using the 
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Table 5-1 Data calibration of real values compared to experimental values 
Real values from known areas were compared to experimental values to calculate systematic 
error to validate the of Cell Imaging and Analysis Package programme. Different sizes of 
squares were measured and compared to real values. Data were compared between both 
groups and the error observed between real and experimental values was calculated and the 
result was that the programme can calculate the area covered with an error of 0.07%. 
 Real values Real % Experimental % Systematic error 
Control 19.07*25.04=477.5 100   
A 8.46*11.03=93.3 19.54 19.31 0.23 
B 4.73*7.54=35.7 7.48 7.38 0.1 
C 2.34*3.22=7.53 1.58 1.54 0.04 
Control 4.8*6.2=29.76 100   
D 0.48*0.62=0.30 1 1.03 0.03 
E 0.28*0.31=0.09 0.34 0.31 0.03 
F 0.14*0.15=0.021 0.07 0.085 0.015 
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5.2.10 Wound healing assay 
 
Wound healing was evaluated by the ability of cells in confluent HUVEC and C3A mono- 
and co-cultures to migrate in response to an external ‘scratch’ wound. 
HUVECs and C3As were propagated in mono and co-culture for 3 days. On day 2 of cell 
culture, culture medium was removed and cells were wounded by drawing a pipette tip at an 
angle of approximately 30 degrees across the cell monolayers which were then washed with 
PBS and supplemented with fresh EGM-2 (control) and with EGM-2 containing 10 mM 
APAP. Cultures were photographed using EVOS ® inverted microscope (Life Technologies) 
at time 0 of the initial scratch and at time 24hr.  
Calculation of the percentage of HUVECs migration was evaluated as follow: 
Percentage of HUVECs migration = (B*100%)/A 
B = Distance of the width of the wound the final scratch at 24hr 
A = Distance of the width of the wound at the initial scratch at 0hr 
5.2.11 Flow cytometry  
 
CD44 and CD49f expression was evaluated using flow cytometry as described previously in 
Material and Methods Section 2.2.6  
5.3  Statistical Analysis 
 
Experiments were performed in triplicate on at least three biological replicates. GraphPad 
software Prism®5 was used for statistical analysis. Results were reported as mean ± standard 
error (SEM). Student’s unpaired t-test was used to compare all co-cultures to their 
appropriate HUVECs and C3As controls (statistical significance *p<0.05).  
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5.4 Results  
5.4.1 Biocompatibility of an extracellular matrix (ECM) for HUVEC:C3A  
 
 
The in vitro hepatic co-culture model established previously using HUVECs and C3As was 
evaluated after 24hr culture in the presence of ECM using two different commercial 
basement membranes, namely MaxGel™ and Matrigel™. MaxGel™ is isolated and purified 
from human epithelial fibroblasts to produce a basement membrane rich in laminin, and 
reduced growth factors (Maas-Szabowski et al., 2005), while Matrigel™ is an animal-
derived hydrogel. Despite these differences, both of the hydrogels contain laminin and both 
were used here experimentally in assays to measure induction of angiogenesis using 
HUVECs. Because the MaxGel™ preparation contains only low levels of growth factors, 
VEGF was added to the gel to promote tube formation by HUVECs. 
 
Co-culture of HUVEC:C3A on Matrigel™ for 24hr induced a vascular tube formation 
response as evidenced by the formation of hexagonal networks of endothelial cell tubes 
(Figure 5.3A, B green stain). Further analysis showed that the distribution of C3A cells in 
the co-culture were not random, but that majority of C3As seemed to have migrated towards 
the endothelial network, while C3As between the network were sparse or absent (Figure 
5.3C red stain). Comparison of HUVEC:C3A co-cultures on Matrigel™-GFR with standard 
Matrigel™ preparations showed similar self-organisation of HUVECs and migration of 
C3As towards endothelial networks (data not shown). In contrast, co-culture of 
HUVEC:C3A on MaxGel™ failed to promote any such organisational response, with both 
HUVECS and C3As being randomly distributed, even with the addition of VEGF (Figure 5-
3D-F). Together this suggests that HUVECs self-organisation and C3As migratory 
behaviours are due to a component of the Matrigel™, rather than growth factor content. 
 
 




Figure 5-3 Biocompatibility of an ECM as a scaffold for HUVEC:C3A 
HUVECs and C3As plated at a ratio of 1:1 were grown for up to 24hr in plates pre-coated 
with thick Matrigel™ and MaxGel™ as described in Sections 5.2.2 & 5.2.3 . MaxGel™ was 
preloaded with 1µg/ml of VEGF. Then, HUVECs and C3As were labellerd with Vybrant™ 
Cell-Labelling Solution (Molecular Probes) as described in section 5.2.1. DiO (green-
fluorescence dye) was used for HUVECs and DiI (red-fluorescent dye) for C3As. Phase-
contrast imaging for co-cultures in Matrigel™ (A-C) and MaxGel™ (D-F), and fluorescence 
images for HUVEC (bright green) in Matrigel™ (B) and MaxGel™ (E) C3As (bright red) in 
Matrigel™ (C) and MaxGel™ (F). Images were taken using inverted microscope (Zeiss 
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5.4.2 Effect of Matrigel™ on hepatic function 
 
The effect of Matrigel™ on hepatic activity was evaluated by analysing both albumin 
synthesis and cytochrome P450 3A4 activity in C3A cells following 3 days of mono-culture 
or HUVEC:C3A co-culture at ratio 1:1 on Matrigel™ and compared to the data seen before 
when hepatocytes were cultured on polystyrene (Section 2.6.1 and 2.6.2). 
Results revealed that culture on Matrigel™ significantly enhanced albumin synthesis in C3A 
mono-cultures to 30.64 ± 2.13 µg/106 initial cells compared to C3As grown on polystyrene 
20.50 ± 3.46 µg/106 initial cells (p=0.046). In co-cultures, there was no significant difference 
in albumin synthesis between HUVEC:C3As co-cultures on polystyrene or Matrigel™, 
where synthesis was already enhanced at 34.17 ± 3.59 µg/106 initial cells and 31.89 ± 2.79 
µg/106 initial cells respectively (Figure 5-4-A). This suggest that both culture of C3As on 
Matrigel™ and co-cultures with HUVECs is able to provide factors that increases hepatic 
albumin synthesis compared to simple culture on polystyrene. 
Similarly, culture on Matrigel™ maintained CYP3A4 activity in C3As mono-cultures by day 
3 compared to polystyrene, from 270.6 ± 38.73 RLU on polystyrene to 363.4 ± 32.36 RLU 
on Matrigel™. Again, co-culturing of HUVEC:C3A cells on Matrigel™ did not result in 
significantly increased CYP3A4 activity as compared to co-cultures on polystyrene, (360.6 ± 








Figure 5-4 Hepatic-specific activity in C3A mono-cultures and HUVEC co-cultures on 
day 3 in EGM-2 medium 
C3As in mono-cultures and HUVEC:C3A co-cultures (ratio of 1:1) were cultured for 3 days 
on Matrigel™ or polystyrene. Albumin synthesis was measured in cell culture supernatants 
on day 3, and CYP3A4 activity was performed using P450-Glo CYP3A4 activity assays 
explained in Materials and Methods in Sections 2.2.7.1 and 2.2.7.3. Figure A) shows 
albumin synthesis; and B) CYP3A4 activity against Luciferin-IPA compared to previous data 
obtained from culturing cells in polystyrene. Data is expressed as the mean ± SEM of three 
different experiments in triplicate, * p < 0.05/ ** p < 0.01. (n=3).  
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5.4.3 Effect of APAP on CYP3A4 activity in C3As and HUVEC:C3A cultured on 
Matrigel™ 
 
In the presence of Matrigel™, treatment with 10 mM APAP for 24hr significantly induced 
CYP3A4 activity between untreated and APAP treated cell in mono-cultures and co-culture 
with HUVECs. Both untreated C3A mono-cultures and HUVEC:C3A co-cultures showed 
similar low levels of CYP3A4 activity. Following APAP treatment, CYP3A4 activity in 
untreated C3A mono-cultures increased from 375.40 ± 27.43 RLU to 2119.00 ± 349.90 RLU 
following treatment (p=0.0001). A similar pattern was observed in HUVEC:C3A co-cultures 
when untreated co-cultures showed 334.20 ± 49.28 RLU CYP3A4 activity compared to 2467 
± 474.10 RLU (p=0.0004) following treatment. In total, APAP treatment induced CYP3A4 












Figure 5-5 CYP3A4 activity APAP metabolism in C3A mono-cultures and 
HUVEC:C3A co-cultures on day 3 of culture on Matrigel™ in EGM-2 medium 
C3As in mono-cultures and HUVEC:C3A co-cultures (ratio of 1:1) were cultured on 
Matrigel™ for 3 days. On day 2, cells were treated for 24hr with 10 mM APAP or with just 
EGM-2 medium as a control. CYP3A4 activity assay was then measured using the P450-Glo 
CYP3A4 activity assay as described in Section 2.2.7.3. Data is expressed as the mean ± SEM 
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5.4.4 Endothelial and hepatic cell migration on Matrigel™  
 
At time 0hr, HUVECs and C3As were randomly distributed in a Matrigel™ coated well 
(Figure 5-6A). At time 10hr, HUVECs had formed an interconnected vascular network, with 
defined geometry and well organized endothelial vascular structures. Also HUVECs and 
C3As had moved toward each other and areas where HUVECs and C3As overlie one another 
can be seen as yellow points in Figure 5-6B. By time 20hr, more consolidated endothelial 
loops with closely associated C3As were apparent (Figure 5-6C). No differences were found 
between Matrigel™-GFR and standard Matrigel™ (data not shown). C3As seemed to 









Figure 5-6 Time lapse fluorescence microscopy of HUVEC:C3A on Matrigel™ at time 
0hr, 10hr and 20hr in EGM-2 media. 
HUVECs and C3As at ratio 1:1 were suspended in EGM-2 medium and seeded on wells pre-
coated with thick Matrigel™ to investigate interaction between the different cell types in 
more depth. To identify each cell line in co-cultures, HUVECs and C3As were labelled 
respectively with DiI (bright red) and DiO (bright green) fluorescent dyes (as described in 
Section 5.2.4). Then, cells were then observed using Time-lapse fluorescence imaging using 
automated wide field observer inverted microscope (Zeiss Axio-Observer A1, Germany). A 
total of 58 pictures were taken every 20 min for 20hr as described in Section 5.2.7. Sample 
pictures shown here at time 0hr (A), at time 10hr (B) and at time 20hr (C). Magnification of 
10X and scale bar of 100µm. 
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5.4.5 Vascular network formation on Matrigel™ 
 
To determine the effect of toxic APAP challenge to vascular network formation, HUVECs 
and C3As in mono-culture or co-cultures seeded on Matrigel™ were exposed to 10 mM 
APAP in EGM-2 for 24hr or with EGM-2 as control, to determine APAP toxicity. As 
expected untreated HUVEC mono-cultures formed well-defined tube structures on 
Matrigel™, resulting in an organised network (Figure 5-7A). However APAP-treated 
HUVECs showed no organisation into vascular tubes, but instead formed cell clumps 
indicative of cell death after 24hr (Figure 5-7B). Meanwhile, C3A mono-cultures maintained 
their morphology after APAP treatment as compared to untreated controls (Figure 5-7C&D). 
In APAP treated HUVEC:C3A co-cultures, HUVECs were again able to form an 
interconnected vascular network with which C3As were closely associated. This was 
essentially comparable to that seen in untreated co-cultures though the tubes formed by 
APAP-treated HUVECs were shorter (Figure 5-7E&F), suggesting that C3A cells provide a 
‘survival’ factor.  
 




Figure 5-7  Light fluorescence microscopy of HUVECs, C3As and co-cultures at time 
24hr in EGM-2 media (control) and 10 mM APAP (treated cells) 
HUVECs and C3As seeded in mono-culture and in co-culture at ratio of 1:1 on pre-coated 
wells with Matrigel™, were photographed following 24hr of cell culture. Pictures here show 
(A) HUVECs untreated control, (B), HUVECs 10mM APAP-treated, (C) C3As untreated 
control, (D, C3As 10mM APAP-treated, (E) co-cultures untreated control, and (F) co-
cultures 10mM APAP treated). Pictures were taken using an inverted microscope (Zeiss 
Axio-Observer A1, Germany) at magnification of 10X and scale bar of 100µm. 
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5.4.6 Endothelial functionality in the presence of C3As on Matrigel™ 
 
The effect of C3A cells on the vascular tube formation by HUVECs was assessed by 
monitoring the number of vascular tubes and loops formed in HUVECs mono-cultures and in 
the presence of C3As in co-cultures on Matrigel™ from 0hr to up to one week.  
HUVECs formed 36 ± 5 vascular tubes following 6hr culture on Matrigel™ whereas 38 ± 5 
vascular tubes were observed in HUVEC:C3A co-cultures after 6hr, the highest values 
observed over the period of study (Figure 5-8). 
Following 72hr of culture, HUVEC mono-cultures showed a significant reduction in the 
number of vascular tubes to 19 ± 2 compared to HUVEC mono-cultures at 6hr (p=0.0103), 
where 25 ± 3 vascular tubes were observed at 72hr in HUVEC:C3A co-cultures (p=0.1120). 
The differences between HUVEC in mono-culture and co-cultures were only significant at 
one week. By this time, HUVEC mono-cultures displayed 14 ± 2 tube tubes compared to 25 
± 3 in HUVEC:C3A co-cultures (p = 0.004) (Figure 5.8-K). The same pattern was observed 
when counting the number of loops formed, resulting in significant difference at one week 
(p= 0.006) (Figure 5-8L). 
Cell viability at the end of culture (one week) was confirmed using LIVE/DEAD® 
Viability/Cytotoxicity Kit (Life technologies) (Section 3.2.2). As can be seen from Figure 5-
8 (D-E), HUVECs in mono-culture remained viable in endothelial vascular tubes (bright 
green) after one week on Matrigel™. Similar levels of cell viability are observed for 
HUVECs in HUVEC:C3A co-cultures (Figure 5-9 I-J), with the addition that qualitatively 
the integrity of the network formed by HUVECs appeared to better maintained and stronger 
in the presence of C3As compared to HUVECs in mono-cultures (Figure 5-8 D, I).  
 




Figure 5-8 Endothelial vascular network in the presence of C3As on Matrigel™ 
HUVECs in mono-culture and HUVEC:C3A co-cultures in 24 well tissue culture plates pre-
coated with Matrigel™. HUVECs (A-C) and HUVEC:C3A (D-F) were grown and 
photographed  using a confocal microscope and Nikon Digital camera DXM1200 at time 6hr 
(A, D), 72hr (B, E) and one week (C, F). At time one week, cells were stained with live 
[bright green] and dead (bright red) (LIVE/DEAD® Viability/Cytotoxicity Kit (Life 
technologies)) as described in Section 3.2.2 for HUVECs (D-E) and HUVEC:C3A co-
cultures (I-J). Capillary tube and loop numbers were counted manually and results are 
presented as tubes and loop numbers present at specified time points. Images were merged 
using ImageJ 1.46r (National Institute of Health, USA). Data is expressed as the mean ± 
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5.4.7 Filamentous actin and cell-junctions in HUVECs and C3As  
 
The endothelial tube formation assays described above (Section 5.4.6) showed that vascular 
network formation in HUVEC:C3A co-cultures on Matrigel™ formed early on 6hr declined 
more slowly in co-culture as compared to HUVECs cultured on Matrigel™ alone. 
Previously, time lapse photography also demonstrated that C3As migrated to the vascular 
tube structures (Section 5.4.4). Actin microtubules are known to participate in cell migration 
and formation of cell-cell-junctions (Stroka et al., 2013). Here, the development of actin 
filaments was used as a measure of cell migration. HUVEC and C3A mono- and co-cultures 
were grown on polystyrene and stained on day 3 of cell culture with rhodamine phalloidin 
(bright red) which has a high-affinity probe for F-actin to detect the capacity of cells to 
migrate. Cultures were also co-stained for CYP3A4 expression to identify hepatic cell 
phenotype.  
As shown in Figure 5-9-A, specific cells in C3A mono-cultures that demonstrated a hepatic 
phenotype, as evidenced by CYP3A4 staining, also stained prominently for F-actin at the cell 
junctions, reminiscent of bile canaliculi and the apical side of polarized epithelial cells 
(Goler-Baron and Assaraf, 2011). As shown in Figure 5-9-B, HUVECs cultured alone did 
not show F-actin bright staining at cell-cell junctions but did show F-actin staining 
cytoplasmic. As anticipated, CYP3A4 staining was not observed in HUVECs. In 
HUVEC:C3A co-cultures, F-actin filaments were probably increased in relation to 
chemotaxis or haptoxis migration. Meanwhile, C3As in co-cultures, stained more strongly 
for CYP3A4 activity (bright green) and more predominant foci of actin expression (bright 
red) were seen at junctions between HUVECs and C3As (Figure 5-9-C)  




Figure 5-9 Actin filaments in C3As and HUVEC mono-cultures and HUVEC:C3A co-
cultures at ratio 1:1 on polystyrene after 3 days culture in EGM-2. 
HUVECs and C3A mono-cultures and HUVEC:C3A co-cultures grown for 3 days on 
polystyrene were fixed and stained with Rhodamine phalloidin (bright red) to detect F-actin, 
stained with CYP3A4 antibody (bright green) and DAPI nuclear stain (bright blue) as 
described in Section 2.2.5.2. Representative immunofluorescence images showing cell 
morphology and staining for F-actin, CYP3A4 and nuclei of (A) C3As, (B) HUVECs mono-
cultures and (C) HUVEC:C3A co-cultures at ratio of 1:1. White arrows indicate cell-
junctions, green arrows indicate C3As (CYP3A4 staining) and red arrows indicate HUVECs 
(cytoplasmic actin staining). These images were taken using an inverted microscope (Zeiss 
Axio-Observer A1, Germany) at magnification x10 and were merged using imageJ 1.46r. 
Scale bar 100µm.  
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5.4.8 Cell transmigration studies within HUVECs and C3As  
 
To investigate further the apparent interaction between HUVECs and C3As in co-cultures, 
transwell cell migration assays were used. Transwell inserts containing red fluorescent 
labelled- C3As were added to 4 different condition wells: i) HUVECs seeded on the top of 
Matrigel™, ii) wells without HUVECs coated with Matrigel™, iii) wells without HUVECs 
coated with Matrigel™GFR and iiii) wells without HUVECs uncoated polystyrene. After 
24hr, the transwell inserts were removed, wells were photographed and migration was 
quantified by calculating the area of the well covered by stained-C3As 
As shown in Figure 5-10-A, C3A cells migrated from the transwell insert through the 
membrane to the vascular network formed by HUVECs in the base of the tissue culture wells 
and became associated with the vascular network rather than being randomly distributed. 
3.30 ± 0.36 % of C3A cells migrated through the transwell membrane toward the vascular 
network formed by HUVECs plated on Matrigel™, as quantified by coverage of the well 
area and 1.67 ± 0.39 % of C3As migrated into wells containing Matrigel™ only (p=0.0081), 
while cells containing Matrigel™GFR or uncoated polystyrene attracted only 0.34 ± 0.066 % 
(p<0.0001) and 0.17 ± 0.04 % (p<0.0001) of C3As respectively (Figure 5.10). These 
findings are consistent with the previous data presented for C3A cells migration in 
HUVEC:C3A co-cultures obtained by time lapse photography (Section 5.4.4) and confirm 
that migration of C3As towards HUVECs is in part dependent on chemotactic factors 








          
B 
 
Figure 5-10 Percentage of area coverage by C3As (red dye) trans endothelial cell 
migration after 24hr. 
HUVECs were seeded in tissue culture wells pre-coated with Matrigel™. Uncoated wells 
(polystyrene) or wells pre-coated with Matrigel™, or growth factor reduced Matrigel™. 
C3As were labelled with DiI (red-fluorescent dye, Vybrant™ Cell-Labelling Solution 
(Molecular Probes) as described in Section 5.2.1 and placed in transwell inserts [8-µm pore 
size. After 24hr, bottoms of the well were photographed for graphical quantification of 
HUVECs on Matrigel™, Matrigel™, Matrigel™ GFR and polystyrene (A). Photographic 
images showing panel B: (A) C3As transmigration to HUVECs vascular network on 
Matrigel™, (B), C3As transmigration to Matrigel™ in the absence of HUVECs, (C) C3As 
transmigration to Matrigel™ GFR in the absence of HUVECs, (D) C3As transmigration to 
polystyrene in the absence of HUVECs and (E) an example transwell membrane showing 
retained C3A cells. Values are expressed as means ± SEM, **p<0.001 ***p<0.001. Images 
were takin using a confocal microscope and Nikon Digital camera DXM1200 and were 
merged using image J 1.46r. Magnification x10. (n=3).  
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5.4.9 Endothelial capacity of repair in wound healing 
 
HUVECs and C3As mono- and co-cultures were subjected to scratch injury on to assess 
wound healing capacity by measuring the percentage of cell migration across the scratch 
after 24hr. The effect of APAP on cell migration was also measured by scratch assay to 
evaluate the ability of HUVECs and C3As to metabolise drugs during injury. Data presented 
in Figure 5.11 shows that HUVECs migrated and achieved complete wound closure after 
24hr, migrating to fill the damaged area and C3As did not appear to migrate (Figures 5.11). 
When HUVECs were cultured and scratched in the presence of 10mM APAP, their normal 
cobblestone morphology was altered and no cell migration was observed either in HUVECs 
or C3As (Figures 5.12 & 5-13).   
In standard HUVEC:C3A co-cultures, HUVECs were able to migrate and achieve a 
significant level of wound closure after 24hr as expected (Figure 5-11), albeit apparently 
being impeded by having to move around non-migratory C3As. This migration is indicated 
by a white arrow in Figure 5-11. In HUVEC:C3A co-cultures, APAP did not affect 
morphology of either cell type, but the extent of endothelial healing was reduced in 10 mM-
APAP as compared to untreated controls (35.42 ± 7.51 % vs 70.31 ± 4.69 % (P = 0.007), an 
approximate 50% reduction in cell migration (Figure 5.13). Since APAP-treated HUVEC 
mono-cultures showed no cell migration and wound healing, the C3As in co-cultures must 
have acted in some way to support HUVEC migration in a toxic environment. 
 
 




Figure 5-11 HUVECs and C3As in wound healing assay  
HUVECs and C3As mono and co-cultured were wounded using a pipette tip under an angle 
of approximately of 30 degrees and washed with PBS. Then, cells were incubated with EGM-
2 (control) for 24hr to evaluate HUVECs migration and wound healing. To identify 
HUVECs and C3As in co-cultures, HUVECs and C3As were stained respectively using DiI 
(bright red) and DiO (bright green) (Vybrant™ Cell-Labelling Solutions), as described in 
Section 5.2.1. Phase contrast images of HUVECs, C3As and co-cultures and labelled red-
HUVEC and green-C3A of co-cultures at time 0hr and 24hr after scratching. Images were 
taken at 10x magnification Images were merged using imageJ 1.46r. 




Figure 5-12 HUVECs and C3As in wound healing in the presence of APAP 
HUVECs and C3As mono- and co-cultured were wounded using a pipette tip under an angle 
of approximately of 30 degrees and washed with PBS. Then, cells were incubated with 10 
mM APAP for 24hr to evaluate HUVECs migration and wound healing in the presence of 
APAP. To identify HUVECs and C3As in co-cultures, HUVECs and C3As were stained 
respectively using DiI (bright red) and DiO (bright green) (Vybrant™ Cell-Labelling 
Solutions), as described in Section 5.2.1. Phase contrast images of HUVECs, C3As and co-
cultures and labelled red-HUVEC and green-C3A of co-cultures at time 0hr and 24hr after 
scratching. Images were taken at 10x magnification Images were merged using imageJ 
1.46r. 




Figure 5-13 Percentage of HUVECs migration in wound healing assay 
Percentage of HUVECs migration into the scratch wound after 24hr observed in untreated 
and APAP-treated HUVEC mono-cultures and HUVEC:C3A co-cultures. Data is expressed 
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5.4.10 Regulation of CD49f and CD44 receptor expression in HUVECs and C3As by 
APAP-treatment 
 
Endothelial and hepatic cells phenotype was analysed following APAP treatment using flow 
cytometry by comparing MFI data obtained from flow cytometry histograms between 
untreated and APAP treated cells. This revealed that APAP up-regulated the expression of 
receptors related to hyaluronic acid CD44 but had no effect on the laminin receptor CD49f 
expression (Figure 5.14).  
CD49f receptor was expressed in HUVEC mono-cultures and in C3As controls and there 
was no significant difference between them, 164.70 ± 78.62 vs 90.26 ± 47.10 RU. After 
APAP exposure, CD49f receptor expression in HUVEC mono-cultures was slightly down-
regulated (143.30 ± 64.76) while C3As showed increased expression at 111.50 ± 55.35 RU. 
In co-cultures, CD49f expression was maintain in HUVECs when they were exposed to 
APAP, from 157.20 ± 71.00 RU in untreated controls compared to 129.50 ± 63.78 RU in 
APAP-treated HUVECs, and CD49f was also maintained in C3As from 120.90 ± 62.38 RU 
in untreated controls compared to 154.30 ± 78.42 RU in APAP-treated C3As. 
Similarly, in control (untreated) cells, the CD44 receptor was expressed in HUVEC mono-
cultures with an MFI values of 389.30 ± 115.50 RU which was higher when HUVECs were 
exposed to APAP, rising to 957.10 ± 283.90 RU. CD44 was expressed at only low levels in 
untreated C3A mono-cultures at 28.83 ± 13.75 RU and was essentially unchanged in APAP-
treated C3As, 39.23 ± 17.65 RU. 
Comparison of CD44 expression in cell sorted populations of CD31+ HUVECs and EpCAM+ 
C3As, showed that there was no change in CD44 expression between mono- and co-cultures. 
CD44 MFI values in APAP treated HUVECs when in co-cultured did not showed any 
difference as compared to untreated HUVECs (respectively 466.60 ± 182.70 RU vs 297.30 ± 
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42.50 RU). Meanwhile, CD44 expression in C3As showed little change in co-cultures with 
APAP-treated values from 32.82 ± 34.37 RU in untreated controls to 44.52 ± 42.75 RU 
APAP-treated C3As.  
 
Figure 5-14 MFI of CD44 and CD49f expression in HUVECs and C3As following 
APAP treatment 
HUVECs and C3As in mono and co-cultures were stained with CD49f or CD44 for flow 
cytometry analysis (See Section 2.2.6) after 24hr incubation with 10 mM APAP for treated 
cells (APAP) and EGM-2 for untreated controls (CTL). Flow cytometry analysis of the mean 
fluorescence intensity values (MFI) for (A) CD49f B) CD44 and fold increase in MFI of (C) 
CD49f and (D CD44 expression. Data is expressed as Mean ± SEM of three different 









This evidence presented in this study demonstrates that HUVECs and C3As in co-cultures 
can together promote self-organization when plated on an appropriate ECM. This suggests 
that development of an in vitro vascularised hepatic model can be modulated in vitro by 
optimising conditions promoting self-organization and cell migration using ECM.  
The success in developing an in vitro vascularised human hepatic model led to the following 
conclusions: 
i. Matrigel™ was more biocompatible extracellular matrix (ECM) than MaxGel™ for 
promoting endothelial vascular network formation in vitro. Also, Matrigel™ ECM 
as a system on which to culture HUVECs and C3As, induced self-assembly of an 
interconnecting vascular network.   
ii. HUVEC:C3A compared to C3As cultured alone maintained albumin synthesis on 
day 3 of culture in Matrigel™. However, albumin synthesis was not necessarily 
higher than when HUVEC:C3A co-cultures were cultured on polystyrene.  
iii. Visualising cell mobility by microscopy, Matrigel™ revealed that HUVECs and 
C3As migrate and self-assemble into to an interconnected vascular network from 
time 10hr, demonstrating the importance of cell migration for vascular network 
formation.   
iv. HUVECs function as assessed by endothelial vascular network formation, was 
inhibited by APAP toxicity when HUVECs were cultured alone but this effect was 
reduced in HUVEC:C3A co-cultures, which showed higher viability and resistance 
to APAP toxicity. 
v. HUVECs in co-cultures maintained wound healing properties in EGM-2 and in 
APAP toxicity only in the presence of C3As in co-cultures. Wound healing in 
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HUVEC mono-cultures was inhibited by APAP but was partly restored in co-
cultures in the presence of C3A cells. 
vi. CD44 expression was up-regulated both in HUVEC and C3As mono- and co-
cultures in response to APAP treatment.  
 
Table 5-2  Tabular summary when comparing co-cultures of HUVECS and C3A cells 
with the corresponding mono-cultures in each condition 
 Polystyrene  Matrigel 
Phenotype CD31+Cobblestone and 
EpCAM+Epithelial were maintained in 
co-cultures 
Self-assembling of an 
interconnected vascular 
network in co-cultures 
Albumin 
synthesis 
Improved in co-cultures Maintained in co-cultures 
CYP3A4 Improved in co-cultures Maintained in co-cultures 
Migration Observed effect in co-culture Observed effect in co-cultures 





















Pre-clinical studies using in vitro hepatic models for drug discovery would be improved by 
development of in vitro human hepatic models with physiological characteristics more 
comparable to those seen in vivo. Since in vivo hepatic physiology is not determined 
exclusively by hepatocytes, in vitro hepatocyte mono-culture models may not be fully 
representative of the in vivo situation and the development of heterotypic models that 
reproduce in vivo cell interactions would be a step towards this goal. The liver comprises 
about 15% vascular tissue through which materials are transported to the liver parenchyma 
for drug detoxification (Hammad et al., 2014). The development of vascular structures in 
vitro requires interaction between ECM and endothelial cells for their differentiation into 
vascular structures (Rohringer et al., 2014). The lack of heterotypic interactions between 
hepatocytes and endothelial cells in mono-cultures in vitro may limit structural and 
functional stability used to investigate drug metabolism (Nahmias et al., 2006).  
The use of Matrigel™ in liver tissue engineering has demonstrated improvements in rat 
hepatic morphology, function (Germano et al., 2014) and also in drug metabolism activity in 
hepatocytes derived from mice (Toyoda et al., 2012). 
The maturation of vascular network is induced when endothelial cells are co-cultured on  
Matrigel™ together with adipose stem cells (Rohringer et al., 2014), while culture on 
Matrigel™ can also prompt differentiation of human induced pluripotent stem cell into 
hepatocytes (Takebe et al., 2013), and endothelial cells to form endothelial vascular 
structures in combination with rat hepatocytes both in vitro and in vivo (Soto-Gutierrez et al., 
2010, Nahmias et al., 2006).  
It is clear from these reports that Matrigel™ has a significant capacity to promote endothelial 
properties but because of its undefined nature, the active components remain unknown. 
   
175 
 
Unfortunately, of the many new, synthetic ECM (e.g. puramatrix, hyaluronic acid, 
fibronectin or MaxGel) designed to provide defined animal- or blood-free replacement for 
Matrigel™, none have achieved the same formation of mature vessels by endothelial cells 
(Allen et al., 2011, Zeisberg et al., 2006). Matrigel™ has therefore become a standard 
component in advanced methods such as differentiation of stem cells into hepatocytes 
(Sullivan et al., 2010).  
The aim of this Chapter was to define conditions to promote angiogenesis and cell migration 
to create an in vitro human vascularised co-culture model in which to evaluate drug toxicity. 
Exploration of the hypothesis that the use of an extracellular matrix would promote vascular 
network as measured by endothelial vascular tube formation in a HUVEC:C3A co-cultures 
resulted in a system in which Matrigel™ promoted the development of an interconnected 
vascular network between HUVECs and C3As in co-cultures. 
In contrast to the results observed with Matrigel™, no angiogenesis was observed using 
MaxGel™ as ECM (Figure 5-3). Furthermore, the addition of VEGF did not enhance 
endothelial tube formation by HUVECs cultured on MaxGel, suggesting that vascular 
network formation in vitro is promoted by unknown components in Matrigel™ which are 
absent in MaxGel™.   
It has been clear for some time that HUVECs can form vascular tubes following 2-24hr 
culture on Matrigel™ (Kubota et al., 1988). However, in addition to forming an 
interconnected vascular network on Matrigel™, in the present study HUVECs were shown 
to induce the migration of C3As into the vascular network in HUVEC:C3A co-cultures 
(Figure 5-3). Under these circumstances, C3As maintained hepatic activity, including 
albumin synthesis and CYP3A4 activity (Figure 5-4). In addition, CYP3A4 activity in C3As 
mono-cultures and in HUVEC:C3A co-cultures on Matrigel™ was significantly induced 
after APAP exposure, suggesting that Matrigel™ contains components that maintain 
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CYP450 activity and might therefore lead to an improved metabolism of APAP in C3As. In 
this context, primary human hepatocytes have been also reported to maintain CYP450 
activity when grown on Matrigel™ (Skovseth et al., 2007, Kleinman and Martin, 2005, Silva 
et al., 1998). When these results are compared to those seen in Chapters 2, 3, 4, it can be 
seen that Matrigel™ did not provide higher hepatic activity but maintained the hepatic 
phenotype allowing the investigation of endothelial tube formation and C3As migration 
toward the vascular network. Time-lapse microscopy and the use of different fluorescent 
dyes with HUVECs (DiI bright red dye) and C3As (DiO bright green dye) showed the 
endothelial capacity to build an interconnected vascular network vascular structure and the 
close association of C3As with the vascular network in co-cultures, simulating sinusoid-like 
structures (Figure 5-6). This vascular network appeared to be viable for up to one week in 
the presence of C3As (Figure 5-8). Finally, staining with F-actin showed major foci of actin 
polymerization at hepatic and endothelial cell junctions in HUVEC:C3A co-cultures 
reminiscent of bile canaliculi and the apical side of polarized epithelial cells (Figure 5-9). 
Transwell cell migration assays were therefore used to further investigate cell-cell 
interactions between HUVEC and C3A in co-cultures. In this system, the migration of C3As 
into wells coated with growth factor reduced Matrigel™ or uncoated polystyrene was 
minimal, while some migration was observed using Matrigel™. However, the presence of 
HUVECs in cell culture wells provided the strongest attraction to C3As migration (Figure 5-
10). This data provides preliminary evidence that cell migration between HUVECs and 
C3As, in a static environment, can be stimulated by a combination of direct contact and the 
effect of cross-talk.   
The endothelial capacity to build a vascular system might be inhibited by the exposure to 
APAP, which affected HUVECs endothelial tube formation in mono-cultures in the absence 
of C3As (Figure 5-7A). This suggest that APAP can also affect the vascular formation 
without the formation of NAPQI, the metabolic product of CYP450 activity on APAP in 
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hepatocytes. However, inhibition of vascular network formation was not observed in 
HUVECs when in cultured with C3As in co-cultures (Figure 5-7C). 
Further confirmation of these findings was achieved using another non-invasive migration 
assay, the wound healing assay. The wound healing assay, confirmed the maintenance of 
HUVECs viability and migration activity in the presence of APAP when in co-culture with 
C3As (Figure 5-12).  
This data were consistent with the evidence presented in Chapter 3 (Section 3-3) and Chapter 
4 (Section 4-3) where HUVECs mono-cultures lose their characteristic cobblestone 
morphology in response to APAP exposure, while HUVECs survive APAP treatment in the 
presence of C3As. The comparison of both studies suggests that APAP resistance in co-
culture was not directly due to the use of an ECM, Matrigel™, but rather was promoted 
primarily by the combination of HUVECs and C3As in co-cultures.   
Rodent hepatocytes migrate towards HUVECs plated on Matrigel™ (Nahmias et al., 2006, 
Soto-Gutierrez et al., 2010). However, to our knowledge, the establishment of a stable 
interconnected vascular network in HUVEC:C3A co-cultures (Figure 5-8) which shows 
resistance to hepatotoxicity has not been reported before. Interestingly, evidence of improved 
hepatocyte function has also been presented when hepatocytes are combined with fibroblasts 
(Cole et al., 2014).  
Laminin is present surrounding blood vessels (Rauterberg et al., 1981, Stamati et al., 2014) 
and changes in laminin concentration and reduction in expression of integrin α6β1 in 
hepatocytes. Integrin α6β1 is a key regulator of cell surface receptor expression on 
hepatocytes and has been shown to be associated with fibrosis (Newsome et al., 2004), also 
to induce endothelial cells to form vascular structures in vitro (Kubota et al., 1988), cell 
migration, invasion and cell polarity in tissue organisation (Li et al., 2003, Ahmed et al., 
2005) 
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When HUVECs and C3As were analysed for CD49f expression (integrin subunit α6 and 
ligand laminin), there was no significant regulation either in HUVEC mono-cultures or in 
C3As after APAP exposure (Figure 5-14). CD49f regulates cell survival, migration and 
apoptosis through the 3-kinase (PI3K)/AKT signalling pathway (Yu et al., 2012), resulting in 
significant roles in determining cell stability.  
Expression of the CD44 receptor which binds hyaluronic acid, has also been reported on 
hepatocytes (Harrill et al., 2009, Kao et al., 2009). In previous published studies, CD44 
receptor expression was affected by APAP treatment, probably due its role in TGF-β 
activation in hepatocytes (Harrill et al., 2009, Kao et al., 2009). In endothelial cells, CD44 
has also been associated to caspase activation (Tsuneki and Madri, 2014).  
In this study, the evaluation of CD44 expression showed that APAP toxicity did not affect 
CD44 expression in hepatocytes but it was up-regulated in APAP treated HUVECs (Figure 
5-14), suggesting the activation of apoptosis mechanism.  
In conclusion, recapitulation of the complex vascularization of the hepatic tissue in vitro 
requires understanding of the roles of cell migration and laminin receptors.  In this context, 
HUVEC:C3A co cultured on Matrigel™ extracellular matrix components revealed events 
not seen in conventional polystyrene mono-cultures. The fact that the development of an in 
vitro human co-culture model has demonstrated migration activity between cells and the 
formation of vascular network, provides a rationale for why the co-culture of different cells 
lines may provide insights into establishing vascularised hepatic in vitro cell culture models 
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6 Chapter 6: General discussion 
 
The liver is a soft organ, comprised of hepatocytes (70-80%), LSECs (20%), Kupffer cells 
and hepatic stellate cells (10%) (Godoy et al., 2013) and is the principal organ involved in 
drug detoxification. As explored in detail in the thesis introduction (Section 1.7), during the 
multiple phases of drug discovery (Figure 7-1), drug candidates are tested through successive 
stages of high throughput screening (HTS) using in vitro and in vivo animal hepatic models, 
before in vivo testing in human trials to demonstrate their therapeutic effect and efficacy, and 
safety for use in humans (Cecchelli et al., 2007, Kraljevic et al., 2004). However, even after 
significant spending on the clinical trial phases of drug discovery, drug-induced liver injury 
(DILI) is still a major issue as pre-clinical in vitro animal and human cell culture models 
remain poor in accurately predicting toxicity. Indeed, a high percentage of drugs that 
successfully pass in vitro and in vivo drug trials subsequently do not meet safety criteria and 
fail human clinical trials (Arrowsmith and Miller, 2013, Kola and Landis, 2004), thus 
proving a costly failure for the drug product. Furthermore, other drugs, having passed all 
clinical trial stages and having successfully gained regulatory drug approval for 
commercialization, subsequently have to be withdrawn from the market or require a warning 
to be displayed due to unforeseen rare adverse reactions (Kaplowitz, 2005, Gomez-Lechon et 
al., 2014).  
Pharmaceutical companies are aware of the economic and safety benefits which would result 
from developing improved in vitro hepatic models and assays which could better mimic 
DILI in vitro, especially for high throughput screening (Kostadinova et al., 2013). The 
development of more physiological in vitro human hepatic model using human-derived cell 
lines would allow early detection of ineffective drugs, prediction of drug toxicity at low and 
high doses and would also reduce animal drug testing. Furthermore, the development of a 
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suitable in vitro hepatic model may provide greater insight into cellular mechanisms (e.g. 
crosstalk) involved in human hepatotoxicity (Tourovskaia et al., 2014, McGill et al., 2011). 
In vitro human hepatic models, using only primary human hepatocytes or immortalised 
hepatocytes limit the interpretation of in vivo drug metabolism pathways and in vivo liver 
functions (Gomez-Lechon et al., 2010, Ramaiahgari et al., 2014).They  also often fail to 
reproduce drug metabolism pathways seen in vivo due to the absence of homotypic and 
heterotypic cell-cell/cell-ECM interactions, occurring in human metabolism (Bhatia et al., 
1999, Palakkan et al., 2013).  
In the embryo and in adulthood, hepatic cellular communication and regulation is mediated 
by paracrine signalling. Signalling between hepatocytes and non-parenchymal cells enhances 
liver regeneration, restores the vascular system after hepatectomy (Stolz et al., 2007, Wang 
et al., 2012b) and improves hepatic function and vascular structures (Hwa et al., 2007, 
Nahmias et al., 2006).  
In the liver, the hepatic sinusoid transports nutrients and oxygen and its porosity and 
permeability allow the filtration of drugs to the hepatocytes in the space of Disse (DeLeve, 
2013) where specialised fenestrated, endocytic endothelial cells LSECs and hepatocytes are 
in contact. This in fact, suggests the possibility that LSECs could be the first target in drug 
toxicity (Ito et al., 2003) and also that the development of an in vitro hepatic model system 
based on culturing hepatocytes alone may be not relevant to correlate the data to in vivo 
responses.   
LSECs mainly participate in clearance of waste molecules and their capacity for endocytosis 
differentiates them from other endothelial cells in the body (Elvevold et al., 2008) though 
characterization and optimization of phenotype in vitro is on-going (DeLeve et al., 2004, 
Salerno et al., 2011).  
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Thus it is reasonable to consider that in vitro hepatic models combining different cell types 
are necessary to represent cell-cell interaction in drug metabolism and achieve 
physiologically significant responses. Vascularisation and cell migration are important in the 
fabrication of organotypic structures to mimic aspects of the complex structure of the liver 
and overcome tissue engineering challenges.  
Ideally this would include interaction of hepatocytes with non-parenchymal cells, which 
when affected by the drug toxicity would stimulate endothelial cells to release VEGF to 
boost early hepatic recovery and regeneration (Kato et al., 2011, Ito et al., 2003, Godoy et 
al., 2013). 
 
Figure 6-1 Phases of drug discovery 
The early phase of drug discovery, High Throughput Screening (HTS) is used to identify and 
optimize compounds to be tested using in vitro and in vivo models. When new compounds 
pass toxicity assays and demonstrates their therapeutic effect, then the compound is tested in 
human clinical trials following the regulatory approval (Cecchelli et al., 2007, Kraljevic et 
al., 2004). 
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6.1 Thesis aims findings and outcomes 
 
The main aim in this project was to explore the possibility that in vitro human hepatic 
models could be improved for drug testing, efficacy and safety by culturing hepatocytes and 
endothelial cells together. In this thesis, an improved in vitro human hepatic model using 
endothelial cells (HUVECs) and hepatocytes (C3As) was demonstrated to show better 
hepatic and endothelial function in drug metabolism. During the transitional development of 
a more physiological human hepatic organotypic model, four crucial aims were explored to 
verify the hypothesis:   
1. Selection of human hepatocyte and endothelial cell lines to develop a biocompatible, 
functional in vitro human co-culture model with a stable specific-tissue phenotype. 
The in vitro human hepatic model developed using HUVECs and C3As at ratio 1:1 
(HUVEC:C3A) cultured for 3 days in EGM-2 (endothelial media) resulted in a 
human hepatic model with higher hepatic function than using C3As alone. Crucially, 
both endothelial (CD31) and hepatic (EpCAM) cell phenotype were maintained on 
day 3. 
2. The use of a model hepatotoxic dose-dependent drug (APAP) for the investigation of 
the principal cellular mechanisms involved in hepatotoxicity (e.g. ATP depletion and 
mitochondria dysfunction) using C3As in mono-culture and co-cultures with 
HUVECs. This revealed that endothelial co-culture conferred a significant hepatic 
mitochondrial protection and survival to APAP hepatotoxicity. 
3. The investigation of the role of oxidative stress in the cellular mechanisms 
underpinning APAP drug toxicity on early events in the in vitro human co-culture 
model compared to mono-cultures, demonstrated that APAP can promote the 
regulation of vascular endothelial growth factor receptors.  
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4. Examination of the properties of endothelial cells in mono- and co-culture using cell 
migration assays showed that co-culture of HUVECs and C3As in Matrigel™ 
resulted in a long-term interconnected vascular network and enhanced survival in 




























The development of an improved in vitro human co-culture model for pre-clinical studies 
using HUVECs and C3As, provides a more physiological approach in investigating the role 
of the importance of endothelial-hepatic interactions in drug metabolism in order to improve 
the efficacy and safety of new drugs.  
 
In this study, the combination of both cells lines required investigation initially into the 
selection of appropriate cell culture media. Endothelial cells are sensitive to changes in the 
media and they require growth factors to maintain phenotype in vitro (Bala et al., 2011), 
whereas C3As are a robust cell line. The comparison between hepatic (MEME) and 
endothelial media (EGM-2) revealed that the use of endothelial media allowed the co-culture 
of both cell lines together without losing the endothelial and hepatic phenotype (Figure 2.4). 
The assessment of interaction between endothelial and hepatic cells, using cell lines with 
different growth rates in long-term cultures, can result in varied and often challenging 
information. However, flow cytometry analysis after short term co-culture using specific 
antibodies allowed the identification of each cell line independently and the investigation of 
their endothelial phenotype (CD31+) and hepatic phenotype (EpCAM+) (Figure 2-6). 
 
The characterization of different ratios, 3:1 (HUVEC:C3A), 1:1 (HUVEC:C3A) and 1:3 
(HUVEC:C3A), revealed that using HUVECs and C3As, which have different growth rates, 
did not necessarily provide higher hepatic activity at the more physiological ratio of 1:3 
(HUVEC:C3A) seen in the liver. The evaluation of these ratios showed that seeding at ratio 
1:1 (HUVEC:C3A) overcame the difficulties caused by the difference in growth rate, 
achieving an in vitro controllable hepatic model, with improved hepatic function such as 
albumin synthesis and CYP3A4 activity as compared to C3A mono-cultures (Figure 2-10 & 
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Figure 2-12). Other in vitro hepatic co-culture models using endothelial:hepatocytes seeded 
at similar ratios (60%:40%) also showed improvement in hepatic function in short-term 
culture (Kim et al., 2012, Kostadinova et al., 2013). 
The activity of the main drug metabolism enzymes in C3As such as CYP3A4 activity were 
improved in basal drug metabolism conditions in the presence of HUVECs when cultured on 
polystyrene (Figure 2-12). The selection of technique for measuring CYP450 activity and 
gene expression was controversial. I agreed with the view of Jaeschke et al, in his 
description that the best way to evaluate CYP450 activity is using P450 enzyme activity 
assays because it should reflect the metabolic activity of live cells under any given 
circumstance (Jaeschke et al., 2013).  High-throughput, RT-PCR analysis of CYP450 gene 
expression offers the alternative of monitoring gene-expression changes to toxic drug 
challenge, but reports on upstream events that may not directly represent the metabolic status 
of the cell at that point, especially if the drug under examination directly inhibits CYP450 
enzyme activity. Furthermore, CYP450 activity can be induced artificially using a cocktail of 
inducers (e.g. rifampicin for induction of CYP3A4 activity) but these compounds are not 
usually used for hepatotoxicity studies (Jaeschke et al., 2013). Here, endothelial cells 
improved CYP3A4 activity in C3As without the use of any inducer.  
APAP is a well-characterised dose-dependent model hepatotoxic drug. In this study, APAP 
was used at both low and high does to determine which dose caused hepatotoxicity in vitro. 
Prediction of APAP toxicity in vitro required assessment of the main cellular properties 
known to be affected in APAP toxicity, namely cell viability, mitochondrial function and 
oxidative stress.  Assessment of these criteria revealed that APAP toxicity can be achieved in 
mono-cultures at low doses (<10 mM) of APAP after 24hr of culture, showing reduced ATP 
content and causing damage in the mitochondria function, whereas higher doses (>20 mM) 
were required to achieve toxicity in HUVEC:C3A co-cultures with more complete 
detoxification of APAP under these circumstances.  
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At 5 mM APAP dose, APAP was observed only to affect the viability of HUVECs, whereas 
no effects were observed on C3A mono-cultures or HUVEC:C3A co-cultures. However, 10 
mM APAP resulted in hepatic mitochondria dysfunction and reduction in ATP content in 
C3A mono-cultures, whereas a greater resistance was observed in HUVEC:C3A co-cultures 
(Figure 3-1 & Figure 3-2).  
 
The exposure of HUVECs to >10 mM APAP for 24hr in the absence of C3As resulted in 
toxicity, affecting ATP production (Figure 3-1), and cell viability (Figure 3-3), suggesting 
that there is an alternative pathways (e.g. oxidative stress) in APAP toxicity as endothelial 
cells were affected without any toxic metabolism (formation of NAPQI) or detoxification of 
APAP by hepatocytes (DeLeve et al., 1997). HUVECs in combination with C3As, showed a 
different response to 10 mM APAP toxicity compared to when HUVECs were mono-
cultured on their own, resulting in maintenance of mitochondria, ATP levels and cell 
viability (Figure 3-1 to 3-3). That observation suggests that there is protective effect and/or 
more complete APAP detoxification resulting from cross-talk between two different cells 
lines cultured together. Interestingly, this resistance to APAP toxicity is the opposite to that 
seen when rat hepatocytes and HUVECs were co-cultured in Matrigel™ (Toyoda et al., 
2012).  
Mitochondrial dysfunction is one of the main effects seen in APAP toxicity and it can result 
in alterations in lactate levels (Shah et al., 2011). Lactate is one of the parameters that 
healthcare professionals consider before liver transplantation in APAP overdose to evaluate 
the degree of liver damage and the necessity for transplant (Shah et al., 2011). In this study, 
APAP caused high levels of lactate in HUVECs in mono-cultures but did not affect lactate 
levels in co-cultures, where there was also an absence of response to NAC, suggesting that 
oxidant levels were unaffected (Figure 3.5). This suggests that in co-cultures, there might be 
a raised threshold of protection against lactate production in response to APAP at the doses 
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tested, as a result of cell-cell interactions, thus preserving HUVECs and also avoiding a 
reduction in cellular antioxidant levels (Reliene et al., 2004). 
In APAP toxicity, the APAP metabolite NAPQI reacts with proteins to form APAP-protein 
adducts which cause oxidative stress in the mitochondria. Reduction in NO is a signal of 
endothelial dysfunction and its combination with superoxide formation can form 
peroxynitrite (Zhang et al., 2014, Agarwal et al., 2012).  
In this study, mitochondria in both HUVECs and C3As were affected by APAP toxicity; 
however oxidative stress was not associated with mitochondrial dysfunction in HUVEC 
mono-cultures which did not form superoxide (Figure 4.3), and maintained NO and GSH 
levels, whereas C3A mono-cultures showed reduced NO levels and increased GSH after 
APAP exposure. By contrast, C3As in co-cultures did not show significant changes in NO 
and GSH levels (Figure 4-4 and Figure 4-5). This finding suggests that oxidative stress does 
not occur in HUVEC mono-cultures, possibly as there is no NAPQI formation in the absence 
of hepatocytes (DeLeve et al., 1997). APAP is associated with necrosis (Ito et al., 2003) and 
here APAP caused HUVEC death, without causing oxidative stress, although reducing ATP 
levels. This finding suggests that HUVECs may die via other mechanisms e.g. apoptosis due 
to unknown mechanisms in response to drug toxicity that is repressed in co-cultures.   
The in vitro hepatic model described in this study improved drug metabolism activity using 
C3As co-cultured with HUVECs as compared to using C3As cultured alone. That finding 
suggested that the resistance to toxicity observed in co-cultures might be due to more 
complete APAP detoxification in C3As and for that reason, the co-culture system requires 
higher doses to mimic drug toxicity seen in vivo.  
The optimisation of endothelial and hepatic co-culture protocols allowed the investigation of 
endothelial signalling and regulation of cellular mechanisms. Exposure of HUVECs to toxic 
challenge enabled the identification of the up-regulation of endothelial cellular receptors 
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such as VEGFR-2 in our co-culture system (Figure 4-6). VEGFR-2 has previously been 
reported to be up-regulated in drug hepatotoxicity and regeneration (Ito et al., 2003, 
Matsumoto et al., 2001, Ding et al., 2010).  
Endothelial cell function is characterised by the capacity to migrate in response to scratch 
injury and promote angiogenesis as assessed by tube formation in vitro. The creation of a 
vascularized hepatic micro-environment in the in vitro co-cultured model albeit in 2D 
culture, maintained hepatic functionality and showed haptotactic interaction between 
HUVECs and C3As. Here, Matrigel™ induced CYP3A4 activity in C3As, while albumin 
synthesis was maintained (Figure 5-4). Tissue modelling of liver buds is very complex but 
the characterization of a vascular hepatic model shows that this requires appropriate 
hepatocyte and endothelial cell culture in an optimal extracellular matrix to simulate the 
human physiological environment (Takebe et al., 2013).  
Use of time-lapse video and migration assay techniques, revealed evidence of migration 
between cells in co-cultures, as C3As migrated towards HUVECs cultured on Matrigel™ 
(Figure 5-6), resulting in a more numerous vascular network that was stable for at least one 
week (Figure 5-8). 
These processes of micro-vascular formation and cell migration were apparently the result of 
the interaction of HUVECs and C3As both via paracrine signalling and direct contact 
between cells. The culture of HUVECs and C3As on Matrigel™ showed that using a more in 
vitro-liver like environment  in the presence of growth factors and ECM elements such as 
laminin, can provide a technology which has the potential to develop an in vitro vascularised 
hepatic model. In particular, the use of ECM, as opposed to simple culture on plastic, 
revealed that endothelial cells are able to function and induce a vascular network connected 
with C3As. 
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The development of this in vitro co-culture model using hepatocytes with endothelial cells 
provides a clear justification for using endothelial cells in a hepatic co-culture models of 
hepatotoxicity studies.  
It was also interesting to observe that in APAP-treated mono-cultures, HUVECs failed to 
make a network in Matrigel™, whereas in the presence of C3As, HUVECs formed and 
maintained the vascular network in the presence of 10 mM APAP (Figure 5-7). This suggests 
that C3As were able to detoxify APAP before it caused significant damage to HUVECs, 
which is reinforced by observed increase in C3A CYP3A4 activity.  
 
The results of this study provide significant insights into the requirements for the creation of 
an in vitro human liver model which would be accurate and effective in mimicking drug 
metabolism and detoxification mechanisms in order to predict drug toxicity robustly. This 
would in turn greatly enhance the discovery of safer drugs. Crucially, it was discovered that 
APAP had a direct effect on HUVECs in mono-cultures, demonstrating that drugs can also 
have toxic effects on endothelial cells, and that improved in vitro hepatic models of 
hepatotoxicity should reproduce liver cell-cell interactions during drug metabolism. We 
determined that endothelial cells have an important role in response to injury caused by drug 
activation and liver failure. Furthermore, I suggest from the data presented in this thesis that 
the interaction of endothelial cells and hepatocytes could be a key factor in drug 
detoxification and in maintenance of hepatic function. The absence of endothelial cells in 
previous hepatic models results in difficulty with accurately simulating drug absorption, 
distribution, metabolism and detoxification and elimination as it occurs in the human liver.  
 
This study has demonstrated a 2D in vitro hepatic culture system combining endothelial and 
hepatocytes in a more physiologically-relevant environment for hepatotoxicity studies, 
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which cover essential characteristics including preserving hepatic and endothelial functions, 
phenotype and improved responses to drug toxicity.  
It is important to understand the role of cellular mechanisms involved in drug-induced liver 
injury such as hepatic and endothelial mitochondrial function and oxidative stress, as cell-
cell communication is a crucial factor in permitting more efficient drug metabolism function 
and clearance to external agents.  
The development of an in vitro hepatic model in a 3D environment could provide greater 
advantages in simulating human physiology than conventional 2D culture but this needs 
more consideration and research. As discussed previously, the characterization of a vascular 
hepatic model requires culture of functional hepatocytes and endothelial cells in an optimal 
extracellular matrix to simulate the human physiological environment (Takebe et al., 2013), 
with the advantage that in the 3D context, ECM could also be used to provide structure.  3D 
versus 2D culture systems need to be considered in relation to the proposed application. The 
3D model would be advantageous for research purposes e.g. liver organogenesis for 
transplantation, whereas the 2D co-culture model, possibly incorporating ECM, would be 
more economic, reproducible and readily applicable in investigating the toxicity of 
compounds identified as drug candidates by HTS. 
This study has demonstrated that 2D co-culture of a hepatocyte cell line with endothelial 
cells improves the function of hepatocytes even in the presence of a hepatotoxic compound. 
It also shows that hepatocytes have a protective effect on endothelial cells from toxic effects 
of drugs. The ideal approach to confirm these findings would be to demonstrate that 
improved drug modulation also occurs when using a combination of primary human 
hepatocytes and LSECs. The approach to improving prediction of drug toxicity described in 
this study also provides a platform that could be applied to HTS used in the pharmaceutical 
industry for drug discovery.  
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The use of co-cultures with hepatocytes and endothelial cells aimed to produce an accurate 
integrated model which could be used as a potential human hepatic model, for the purpose of 
predicting drug toxicity, reducing animal drug testing and improving the accuracy of 
identifying ineffective or hepatotoxic drugs (Bale et al., 2014b), before they reach human 
trial stages. The data presented in this study demonstrates the potential of 2D co-culture of 
hepatocyte cell lines with endothelial cells for improving drug testing, which could be 
incorporated into a HTS system, does not require extended periods of culture to generate 
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6.3 Future work 
 
Development of the hepatic/endothelial co-culture model presented in this study 
demonstrated that C3As co-cultured with HUVECs are more representative of functional 
hepatic metabolism than culture of C3As alone. Co-cultures showed the requirement for 
endothelial paracrine signalling in the development of a potentially more reproducible, 
functional and more stable in vitro human co-culture model.  
This notion raises the question of whether this improvement in hepatic and endothelial 
function would also be seen using cells isolated from other lineages or differentiated from 
other sources. For example, embryonic and induced pluripotent stem cells have been shown 
to differentiate in vitro to hepatic and endothelial lineages and have been proposed as a 
reliable source of material for development of cell banks for use in cell-based therapies. 
Indeed, retinal tissue differentiated from human induced pluripotent stem cells (hiPSCs) 
derived originally from patient-specific skin cells is already being tested in early clinical 
trials and could pave the way for therapy of multiple tissue types in future (Reardon and 
Cyranoski, 2014). It is also possible that directed differentiation of induced pluripotent cells 
stem cells from individuals could be used to produce sustainable hepatocyte and endothelial 
cell lines as models for studies of drug toxicity and metabolism, liver infection, personalised 
medicine and cell therapeutics (Sullivan et al., 2010). However, problems still to be 
overcome include poor in vitro hepatic function and differentiation into the adult phenotype, 
while ES and hiPS-derived cell lines currently in use for drug testing are also limited by their 
derivation from a single individual which therefore does not take account of human 
polymorphism and its influence on patient-specific drug metabolism.  
If it were possible to use human hiPSC -derived to hepatocytes (hiPSC-HE) co-cultured with 
endothelial cells, this would offer the possibility of selecting a defined panel of hiPSC lines 
for drug testing and the opportunity to investigate liver disease and treatment in vitro. 
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Generating multiple independent hiPSC-HE cell lines would offer the possibility of 
examining drug toxicity in vitro using a panel of individuals rather than a just a single 
individual as is the case today when using an established cell line. Therefore, using hiPSC-
HE could reduce withdrawal rate, improve drug safety, reduce development of ineffective 
treatments and detect idiosyncratic side effects. However, achieving mature hepatocyte 
phenotype currently remains problematic, possibly due to a lack of paracrine signalling from 
non-parenchymal cells e.g. endothelial cells in hepatocytes differentiation (Matsumoto et al., 
2001, Nahmias et al., 2006). The introduction of a proper vascularized microenvironment 
could improve hepatic function in hepatocyte cell lines currently used in drug testing and 
may overcome the limitations found in hiESC-HE, resulting in improved drug evaluation 
(Berger et al., 2014). 
A short pilot study performed at the University of Oslo, during a short-stay sponsored by 
The Company of Biologists' journals – (Development, Journal of Cell Science, The Journal 
of Experimental Biology, and Disease Models & Mechanisms (DMM)), showed that human 
embryonic stem cell-derived hepatocytes could provide a physiologically relevant in vitro 
hepatic model. Considering the current requirement for expensive growth factors and the 
long differentiation protocol, this would currently be an unattractive option for application in 
pharmaceutical testing, but is likely to be amenable to further investigation and optimization. 
The rationale for using scaffolds in the construction of a 3D environment for in vitro co-
culture of hepatocytes with endothelial cells, is that it would allow for the formation of 
vascular structures, so that cell migration and cross-layer invasion, features of early steps of 
liver organogenesisis, could be reproduced and studied in vitro. 3D in vitro hepatic co-
culture would also allow investigation of the role of hepatic membrane transport proteins 
(MTP) in the absorption of drugs, drug-drug interactions, and canalicular excretion of drugs 
into the biliary and sinusoidal system (Ulvestad et al., 2013, Aleksunes et al., 2008, Kunze et 
al., 2012, Shukla et al., 2014, Le Vee et al., 2013), especially using the HepaRG hepatocyte-
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cholangiocyte bipotential cell line (Rebelo et al., 2014, Mueller et al., 2014). However, 3D in 
vitro hepatic co-culture, and employing approaches such as scaffolding and cell 
encapsulation, currently has disadvantages in cell viability, and the choice of hydrogel 
subtype supplemented with growth factors to mimic the stiffness and viability of the in vivo 
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7 Reagents and materials 
 
Table 7-1 Cell lines used in this study 
 
Table 7-2 Chemical and reagents 
Chemical and reagents Company 
Acetaminophen Sigma-Aldrich 
Ammonium Chloride Sigma-Aldrich 




VECTASHIELD® Mounting with DAPI Vector Labs 
Dipotassium hydrogen orthophosphate 3-hydrate 
(K2HPO4.3H2O) 
BDH 
D-(+) Galactose Sigma-Aldrich 
DMSO  
DTNB Sigma-Aldrich 
Dye albumin Blue 580 fluorescence assay  Molecular Probes (Eugene, OR) 
Dulbecco’s Phosphate Buffered Saline With 
MgCl2 and CaCl2 
Sigma-Aldrich 
Dulbecco’s PBS—Ca2+/Mg2+ free Sigma-Aldrich 
Ethylenediaminetetraacetic acid (EDTA)  Sigma-Aldrich 
Ethanol absolute, prolabo VWR Chemicals 
Flow cytometry Permeabilization/Wash Buffer I R&D Systems 
Human 
cell lines 







10% fetal calf serum 
























· FBS (Fetal Bovine 




· Ascorbic Acid 
· Heparin 
1-7 Lonza, UK 
(C2519A) 
(CC-3162) 




Flow cytometry Fixation Buffer (1X) R&D Systems 
Fetal bovine serum Sigma-Aldrich 
Formalin solution, neutral buffered, 10% Sigma-Aldrich 
β-Galactose Dehydrogenase S. Roche Diagnostics 
Glutathione reductase (250 units ml–1) Sigma-Aldrich 
Glutathione (reduced form), GSH, Sigma-Aldrich 
Glutathione (disulfide form), GSSG, Sigma-Aldrich 
Hank’s balanced salt solution (HBSS) Sigma 
Hexokinase, 1500U 11426362001 Roche 
Matrigel - Basement Membrane Matrix, Phenol 
Red-free, 10 ml – 356237 
BD eBioscience 
MitoSOX™ Molecular Probes  (Life 
Technogies) 
MOPS free acid  Sigma-Aldrich 
MOPS sodium salt Sigma-Aldrich 
L-Lactate Dehydrogenase L-LDH 10254754103 Roche 
NADH, appprox.98 1012802300 Roche 
Salicylamide 99% Sigma-Aldrich 
Tetramethylrhodamine Isothiocyanate 
Rhodamine phalloidin  
Molecular Probes (Life 
Technologies) 
Testosterone soluble Sigma-Aldrich 
Triton X-100 Sigma-Aldrich 
Triazol Invitrogen 
Trypan Blue  Invitrogen 
Pig gamma globulin Sigma-Aldrich 
Potassium phosphate monobasic (KH2PO4) Sigma-Aldrich 
Potassium phosphate dibasic (K2HPO4) Sigma-Aldrich 
2-Vinylpyridine Sigma-Aldrich 
 
Table 7-3 Buffers 
 Composition 
MOPS Buffer 0.6g MOPS free acid 
1.8g MOPS sodium salt 
2.4g NaCl 
0.2g EDTA disodium 
20ml isopropanol 
H2O qsp 200 ml 
pH=7.4 with NaOH 
Phosphate buffer of 100 ml 0.54g KH2PO4 
0.18g K2HPO4 
0.9g NaCl 
0.1g EDTA disodium 
10mg pig gamma globulin  
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Table 7-4 Materials for cell culture 
Materials Company  
6,12,24 and 96 well cell culture cluster  Corning 
96 well plate, polystyrene, non-treated, white flat 
bottom wells, non-sterile, white 
Corning 
24 well Thincert, 8µm pore diameter translucent Greiner Bio-one 
Polystyrene tube specifically designed for flow 
cytometry (5ml) 
Bioscience Technology 
Cryogenic tube Thermo Scientific-Nunc 
Cell scrapers Fisher Scientific 
Chamber slides  Nunc Lab Tek 
Cuvettes Semi micro ps 100/pk Fisherbrand, UK 
Safe-lock tubes (1.5ml) AG, Germany  
Improved Neubauer Hawksley, UK 
Microscope Cover glass 22 x 22 mm Menzel-Glaser, Braunschweig 
 
Table 7-5 Equipment 
Equipment Company 
Camera  Carl Zeiss, Germany 
Cobas Fara Centrifugal Analyser Roche 
Countess® Automated Cell Counter Life technologies 
CytoFluor® series 4000 Fluorescence Multi-Well 
Plate Reader 
Applied Biosystems 
Heraeus Biofuge Fresco  DJB labcare 
Galaxy S+ CO2Incubator RS Biotech 
GLS Aqua Plus Series Linear Shaking Water Bath Grant  
EVOS ® inverted microscope  Life Technologies 
FACS Calibur flow cytometer Becton Dickinson, UK 
GloMax®-Multi-Microplate Multimode Reader Promega 
LabTech-Nanodrop ND100 spectrophotometer Labtech International 
LightCycler® 96 System Roche Life Science 
Microscope  Zeiss Axio Observe A.1, 
Germany 
PowerGen 125 Homogenize Fisher Scientific 
Refrigerated laboratory centrifuge, 4K15 Sigma 
Soniprep 150 MSE 
Veriti® Thermal Cycler Life Technologies 
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Table 7-6 Flow cytometry antibodies 
Antibody Isotype Company 
PE/Cy7 anti-mouse/human 
CD44 Antibody (103029) 
Mouse BioLegend 






FITC anti-human CD54 
Antibody (353107) 
Mouse BioLegend 
Alexa Fluor® 647 anti-human 
CD326 (EpCAM) Antibody 
(324212) 
Mouse BioLegend 
CD31/PECAM-1 (PerCP) Mouse BD Bioscience 
VEGF-R2/KDR  (PE) Mouse R&D Systems 
VEGF-R2/KDR  (FITC) Mouse R&D Systems 
 
Table 7-7 Primary antibodies 




Rabbit R&D Systems 
CD31 (PECAM-1) 
Human/mouse 
Rabbit BD BioScience 
Cytochrome P450 enzyme  
CYP3A4 polyclonal  
Rabbit Millipore 
 
Table 7-8 Secondary antibodies 
Antibody Source Company 
Alexa Fluor 488 Anti-rabbit Goat Life Technologies 
Alexa Fluor 488 Anti Mouse Rabbit Life Technologies 








   
199 
 
8 Publication and poster presentations 
  
1. GRACIA-SANCHO, J., MAESO-DIAZ, R., FERNANDEZ-IGLESIAS, A., 
NAVARRO-ZORNOZA, M. & BOSCH, J. 2015. New cellular and molecular 
targets for the treatment of portal hypertension. Hepatol Int. 
 
8.1 Selected conference presentations and published abstracts 
 
1.  M. NAVARRO, L. NELSON, K. BURGESS, O. TURA, K. SAMUEL, J. 
PLEVRIS. Hepatic/ endothelial cell co-culture; establishing optimal conditions for liver 
tissue engineering. British Association for the Study of the Liver, poster – (Liverpool, 2012)   
2.  M. NAVARRO, L. NELSON, O. TURA, K. SAMUEL, P.HAYES, J. PLEVRIS. 
Defining in vitro co-culture systems for human liver tissue engineering – Tissue and Cell 
Engineering Society, poster – (Liverpool 2012)   
3.  M. NAVARRO, O.TURA, K.SAMUEL, L.NELSON, J.PLEVRIS. Liver tissue 
engineering: hepatocytes and endothelial co-culture cross-talk in a liver model – European 
Society for Artificial Organs 2013, Oral communication – (Glasgow 2013)  
4.  M. NAVARRO, L. J. NELSON, P. TRESKES, P.C.HAYES, K. SAMUEL, J. 
N.PLEVRIS. Hepatoprotective effect of HUVECs in an in vitro hepatic co- culture model of 
APAP toxicity", European International Liver Congress (London, 2014)   
5.  M. NAVARRO, L. J. NELSON, P. TRESKES, P.C.HAYES, K. SAMUEL, J. 
N.PLEVRIS. Hepatocytes improve their drug metabolic activity with the presence of 
endothelial cells in an in vitro hepatic co-culture model of APAP toxicity", European 













Abdel-Misih, S. R. & Bloomston, M. 2010. Liver anatomy. Surg Clin North Am, 90, 
643-53. 
Adeva, M., Gonzalez-Lucan, M., Seco, M. & Donapetry, C. 2013. Enzymes involved 
in l-lactate metabolism in humans. Mitochondrion, 13, 615-29. 
Agarwal, R., Hennings, L., Rafferty, T. M., Letzig, L. G., McCullough, S., James, L. 
P., MacMillan-Crow, L. A. & Hinson, J. A. 2012. Acetaminophen-induced 
hepatotoxicity and protein nitration in neuronal nitric-oxide synthase 
knockout mice. J Pharmacol Exp Ther, 340, 134-42. 
Aguer, C., Gambarotta, D., Mailloux, R. J., Moffat, C., Dent, R., McPherson, R. & 
Harper, M. E. 2011. Galactose enhances oxidative metabolism and reveals 
mitochondrial dysfunction in human primary muscle cells. PLoS One, 6, 
e28536. 
Aharoni-Simon, M., Anavi, S., Beifuss, U., Madar, Z. & Tirosh, O. 2012. Nitric 
oxide, can it be only good? Increasing the antioxidant properties of nitric 
oxide in hepatocytes by YC-1 compound. Nitric Oxide, 27, 248-56. 
Ahmed, N., Riley, C., Rice, G. & Quinn, M. 2005. Role of integrin receptors for 
fibronectin, collagen and laminin in the regulation of ovarian carcinoma 
functions in response to a matrix microenvironment. Clin Exp Metastasis, 22, 
391-402. 
Aleksunes, L. M., Campion, S. N., Goedken, M. J. & Manautou, J. E. 2008. 
Acquired resistance to acetaminophen hepatotoxicity is associated with 
induction of multidrug resistance-associated protein 4 (Mrp4) in proliferating 
hepatocytes. Toxicol Sci, 104, 261-73. 
Allen, J. W., Khetani, S. R. & Bhatia, S. N. 2005. In vitro zonation and toxicity in a 
hepatocyte bioreactor. Toxicol Sci, 84, 110-9. 
Allen, P., Melero-Martin, J. & Bischoff, J. 2011. Type I collagen, fibrin and 
PuraMatrix matrices provide permissive environments for human endothelial 
and mesenchymal progenitor cells to form neovascular networks. J Tissue 
Eng Regen Med, 5, e74-86. 
Alva, N., Cruz, D., Sanchez, S., Valentin, J. M., Bermudez, J. & Carbonell, T. 2013. 
Nitric oxide as a mediator of fructose 1,6-bisphosphate protection in 
galactosamine-induced hepatotoxicity in rats. Nitric Oxide, 28, 17-23. 
Amaral, S. S., Oliveira, A. G., Marques, P. E., Quintao, J. L., Pires, D. A., Resende, 
R. R., Sousa, B. R., Melgaco, J. G., Pinto, M. A., Russo, R. C., Gomes, A. K., 
Andrade, L. M., Zanin, R. F., Pereira, R. V., Bonorino, C., Soriani, F. M., 
Lima, C. X., Cara, D. C., Teixeira, M. M., Leite, M. F. & Menezes, G. B. 
2013. Altered responsiveness to extracellular ATP enhances acetaminophen 
hepatotoxicity. Cell Commun Signal, 11, 10. 
Aninat, C., Piton, A., Glaise, D., Le Charpentier, T., Langouet, S., Morel, F., 
Guguen-Guillouzo, C. & Guillouzo, A. 2006. Expression of cytochromes 
P450, conjugating enzymes and nuclear receptors in human hepatoma 
HepaRG cells. Drug Metab Dispos, 34, 75-83. 
Aritomi, K., Ishitsuka, Y., Tomishima, Y., Shimizu, D., Abe, N., Shuto, T., Irikura, 
M., Kai, H. & Irie, T. 2014. Evaluation of three-dimensional cultured HepG2 
   
201 
 
cells in a nano culture plate system: an in vitro human model of 
acetaminophen hepatotoxicity. J Pharmacol Sci, 124, 218-29. 
Arrowsmith, J. & Miller, P. 2013. Trial watch: phase II and phase III attrition rates 
2011-2012. Nat Rev Drug Discov. England. 
Atlante, A., Giannattasio, S., Bobba, A., Gagliardi, S., Petragallo, V., Calissano, P., 
Marra, E. & Passarella, S. 2005. An increase in the ATP levels occurs in 
cerebellar granule cells en route to apoptosis in which ATP derives from both 
oxidative phosphorylation and anaerobic glycolysis. Biochim Biophys Acta, 
1708, 50-62. 
Badmann, A., Langsch, S., Keogh, A., Brunner, T., Kaufmann, T. & Corazza, N. 
2012. TRAIL enhances paracetamol-induced liver sinusoidal endothelial cell 
death in a Bim- and Bid-dependent manner. Cell Death Dis, 3, e447. 
Bala, K., Ambwani, K. & Gohil, N. K. 2011. Effect of different mitogens and serum 
concentration on HUVEC morphology and characteristics: implication on use 
of higher passage cells. Tissue Cell, 43, 216-22. 
Bale, S. S., Golberg, I., Jindal, R., McCarty, W. J., Luitje, M., Hegde, M., Bhushan, 
A., Usta, O. B. & Yarmush, M. 2014a. Long Term Co-culture Strategies for 
Primary Hepatocytes and Liver Sinusoidal Endothelial Cells. Tissue Eng Part 
C Methods. 
Bale, S. S., Vernetti, L., Senutovitch, N., Jindal, R., Hegde, M., Gough, A., McCarty, 
W. J., Bakan, A., Bhushan, A., Shun, T. Y., Golberg, I., Debiasio, R., Usta, 
B. O., Taylor, D. L. & Yarmush, M. L. 2014b. In vitro platforms for 
evaluating liver toxicity. Exp Biol Med (Maywood). 
Berger, D. R., Ware, B. R., Davidson, M. D., Allsup, S. R. & Khetani, S. R. 2014. 
Enhancing the functional maturity of iPSC-derived human hepatocytes via 
controlled presentation of cell-cell interactions in vitro. Hepatology. 
Bhatia, S. N., Balis, U. J., Yarmush, M. L. & Toner, M. 1999. Effect of cell-cell 
interactions in preservation of cellular phenotype: cocultivation of 
hepatocytes and nonparenchymal cells. Faseb j, 13, 1883-900. 
Bhatia, S. N. & Ingber, D. E. 2014. Microfluidic organs-on-chips. Nat Biotechnol, 
32, 760-72. 
Bhogal, R. H., Hodson, J., Bartlett, D. C., Weston, C. J., Curbishley, S. M., 
Haughton, E., Williams, K. T., Reynolds, G. M., Newsome, P. N., Adams, D. 
H. & Afford, S. C. 2011. Isolation of primary human hepatocytes from 
normal and diseased liver tissue: a one hundred liver experience. PLoS One, 
6, e18222. 
Bhushan, A., Senutovitch, N., Bale, S. S., McCarty, W. J., Hegde, M., Jindal, R., 
Golberg, I., Berk Usta, O., Yarmush, M. L., Vernetti, L., Gough, A., Bakan, 
A., Shun, T. Y., DeBiasio, R. & Lansing Taylor, D. 2013. Towards a three-
dimensional microfluidic liver platform for predicting drug efficacy and 
toxicity in humans. Stem Cell Res Ther, 4 Suppl 1, S16. 
Biron-Andreani, C., Raulet, E., Pichard-Garcia, L. & Maurel, P. 2010. Use of human 
hepatocytes to investigate blood coagulation factor. Methods Mol Biol, 640, 
431-45. 
Blachier, M., Leleu, H., Peck-Radosavljevic, M., Valla, D. C. & Roudot-Thoraval, F. 
2013. The burden of liver disease in Europe: a review of available 
epidemiological data. J Hepatol, 58, 593-608. 
   
202 
 
Blouin, A., Bolender, R. P. & Weibel, E. R. 1977. Distribution of organelles and 
membranes between hepatocytes and nonhepatocytes in the rat liver 
parenchyma. A stereological study. J Cell Biol, 72, 441-55. 
Burcham, P. C. & Harman, A. W. 1991. Acetaminophen toxicity results in site-
specific mitochondrial damage in isolated mouse hepatocytes. J Biol Chem, 
266, 5049-54. 
Carmeliet, P. 2000. Mechanisms of angiogenesis and arteriogenesis. Nat Med, 6, 
389-95. 
Cecchelli, R., Berezowski, V., Lundquist, S., Culot, M., Renftel, M., Dehouck, M. P. 
& Fenart, L. 2007. Modelling of the blood-brain barrier in drug discovery and 
development. Nat Rev Drug Discov, 6, 650-61. 
Chalasani, N. & Bjornsson, E. 2010. Risk factors for idiosyncratic drug-induced liver 
injury. Gastroenterology, 138, 2246-59. 
Chan, B. P. & Leong, K. W. 2008. Scaffolding in tissue engineering: general 
approaches and tissue-specific considerations. Eur Spine J, 17 Suppl 4, 467-
79. 
Cheng, J., Ma, X., Krausz, K. W., Idle, J. R. & Gonzalez, F. J. 2009. Rifampicin-
activated human pregnane X receptor and CYP3A4 induction enhance 
acetaminophen-induced toxicity. Drug Metab Dispos, 37, 1611-21. 
Chou, M. J., Hsieh, C. H., Yeh, P. L., Chen, P. C., Wang, C. H. & Huang, Y. Y. 
2013. Application of open porous poly(D,L-lactide-co-glycolide) 
microspheres and the strategy of hydrophobic seeding in hepatic tissue 
cultivation. J Biomed Mater Res A, 101, 2862-9. 
Choucha Snouber, L., Bunescu, A., Naudot, M., Legallais, C., Brochot, C., Dumas, 
M. E., Elena-Herrmann, B. & Leclerc, E. 2013. Metabolomics-on-a-chip of 
hepatotoxicity induced by anticancer drug flutamide and Its active metabolite 
hydroxyflutamide using HepG2/C3a microfluidic biochips. Toxicol Sci, 132, 
8-20. 
Ciociola, A. A., Cohen, L. B. & Kulkarni, P. 2014. How Drugs are Developed and 
Approved by the FDA: Current Process and Future Directions. Am J 
Gastroenterol, 109, 620-3. 
Cole, S. D., Madren-Whalley, J. S., Li, A. P., Dorsey, R. & Salem, H. 2014. High 
Content Analysis of an In Vitro Model for Metabolic Toxicity: Results with 
the Model Toxicants 4-Aminophenol and Cyclophosphamide. J Biomol 
Screen. 
Cox, A. G., Saunders, D. C., Kelsey, P. B., Jr., Conway, A. A., Tesmenitsky, Y., 
Marchini, J. F., Brown, K. K., Stamler, J. S., Colagiovanni, D. B., Rosenthal, 
G. J., Croce, K. J., North, T. E. & Goessling, W. 2014. S-nitrosothiol 
signaling regulates liver development and improves outcome following toxic 
liver injury. Cell Rep, 6, 56-69. 
De Kock, J., Ceelen, L., De Spiegelaere, W., Casteleyn, C., Claes, P., Vanhaecke, T. 
& Rogiers, V. 2011. Simple and quick method for whole-liver 
decellularization: a novel in vitro three-dimensional bioengineering tool? 
Arch Toxicol, 85, 607-12. 
Deavall, D. G., Martin, E. A., Horner, J. M. & Roberts, R. 2012. Drug-induced 
oxidative stress and toxicity. J Toxicol, 2012, 645460. 
Deboux, C., Ladraa, S., Cazaubon, S., Ghribi-Mallah, S., Weiss, N., Chaverot, N., 
Couraud, P. O. & Baron-Van Evercooren, A. 2013. Overexpression of CD44 
   
203 
 
in neural precursor cells improves trans-endothelial migration and facilitates 
their invasion of perivascular tissues in vivo. PLoS One, 8, e57430. 
Deenen, M. J., Cats, A., Beijnen, J. H. & Schellens, J. H. 2011. Part 2: 
pharmacogenetic variability in drug transport and phase I anticancer drug 
metabolism. Oncologist, 16, 820-34. 
Deleve, L. D. 1994. Dacarbazine toxicity in murine liver cells: a model of hepatic 
endothelial injury and glutathione defense. J Pharmacol Exp Ther, 268, 1261-
70. 
DeLeve, L. D. 2013. Liver sinusoidal endothelial cells and liver regeneration. J Clin 
Invest, 123, 1861-6. 
DeLeve, L. D. 2014. Liver sinusoidal endothelial cells in hepatic fibrosis. 
Hepatology. 
DeLeve, L. D., Wang, X., Hu, L., McCuskey, M. K. & McCuskey, R. S. 2004. Rat 
liver sinusoidal endothelial cell phenotype is maintained by paracrine and 
autocrine regulation. Am J Physiol Gastrointest Liver Physiol, 287, G757-63. 
DeLeve, L. D., Wang, X., Kaplowitz, N., Shulman, H. M., Bart, J. A. & van der 
Hoek, A. 1997. Sinusoidal endothelial cells as a target for acetaminophen 
toxicity. Direct action versus requirement for hepatocyte activation in 
different mouse strains. Biochem Pharmacol, 53, 1339-45. 
Diehl, A. M. & Rai, R. M. 1996. Liver regeneration 3: Regulation of signal 
transduction during liver regeneration. Faseb j, 10, 215-27. 
Ding, B. S., Nolan, D. J., Butler, J. M., James, D., Babazadeh, A. O., Rosenwaks, Z., 
Mittal, V., Kobayashi, H., Shido, K., Lyden, D., Sato, T. N., Rabbany, S. Y. 
& Rafii, S. 2010. Inductive angiocrine signals from sinusoidal endothelium 
are required for liver regeneration. Nature, 468, 310-5. 
Donahower, B. C., McCullough, S. S., Hennings, L., Simpson, P. M., Stowe, C. D., 
Saad, A. G., Kurten, R. C., Hinson, J. A. & James, L. P. 2010. Human 
recombinant vascular endothelial growth factor reduces necrosis and 
enhances hepatocyte regeneration in a mouse model of acetaminophen 
toxicity. J Pharmacol Exp Ther, 334, 33-43. 
Donato, M. T., Jover, R. & Gomez-Lechon, M. J. 2013. Hepatic cell lines for drug 
hepatotoxicity testing: limitations and strategies to upgrade their metabolic 
competence by gene engineering. Curr Drug Metab, 14, 946-68. 
Dott, W., Mistry, P., Wright, J., Cain, K. & Herbert, K. E. 2014. Modulation of 
mitochondrial bioenergetics in a skeletal muscle cell line model of 
mitochondrial toxicity. Redox Biol, 2, 224-33. 
Du, K., Williams, C. D., McGill, M. R., Xie, Y., Farhood, A., Vinken, M. & 
Jaeschke, H. 2013. The gap junction inhibitor 2-aminoethoxy-diphenyl-borate 
protects against acetaminophen hepatotoxicity by inhibiting cytochrome P450 
enzymes and c-jun N-terminal kinase activation. Toxicol Appl Pharmacol, 
273, 484-91. 
Elvevold, K., Smedsrod, B. & Martinez, I. 2008. The liver sinusoidal endothelial 
cell: a cell type of controversial and confusing identity. Am J Physiol 
Gastrointest Liver Physiol, 294, G391-400. 
Endo, S., Toyoda, Y., Fukami, T., Nakajima, M. & Yokoi, T. 2012. Stimulation of 
human monocytic THP-1 cells by metabolic activation of hepatotoxic drugs. 
Drug Metab Pharmacokinet, 27, 621-30. 
   
204 
 
Feichtinger, R. G., Sperl, W., Bauer, J. W. & Kofler, B. 2014. Mitochondrial 
dysfunction: a neglected component of skin diseases. Exp Dermatol. 
Feldstein, A. E., Canbay, A., Angulo, P., Taniai, M., Burgart, L. J., Lindor, K. D. & 
Gores, G. J. 
Ferreira, A., Rodrigues, M., Silvestre, S., Falcao, A. & Alves, G. 2014. HepaRG cell 
line as an in vitro model for screening drug-drug interactions mediated by 
metabolic induction: Amiodarone used as a model substance. Toxicol In 
Vitro. 
Filippi, C., Keatch, S. A., Rangar, D., Nelson, L. J., Hayes, P. C. & Plevris, J. N. 
2004. Improvement of C3A cell metabolism for usage in bioartificial liver 
support systems. J Hepatol, 41, 599-605. 
Flecknell, P. 2002. Replacement, reduction and refinement. Altex, 19, 73-8. 
Fomin, M. E., Zhou, Y., Beyer, A. I., Publicover, J., Baron, J. L. & Muench, M. O. 
2013. Production of factor VIII by human liver sinusoidal endothelial cells 
transplanted in immunodeficient uPA mice. PLoS One, 8, e77255. 
Forstermann, U. & Munzel, T. 2006. Endothelial nitric oxide synthase in vascular 
disease: from marvel to menace. Circulation, 113, 1708-14. 
Fransen, M., Nordgren, M., Wang, B. & Apanasets, O. 2012. Role of peroxisomes in 
ROS/RNS-metabolism: implications for human disease. Biochim Biophys 
Acta, 1822, 1363-73. 
Genove, E., Schmitmeier, S., Sala, A., Borros, S., Bader, A., Griffith, L. G. & 
Semino, C. E. 2009. Functionalized self-assembling peptide hydrogel 
enhance maintenance of hepatocyte activity in vitro. J Cell Mol Med, 13, 
3387-97. 
Gerets, H. H., Tilmant, K., Gerin, B., Chanteux, H., Depelchin, B. O., Dhalluin, S. & 
Atienzar, F. A. 2012. Characterization of primary human hepatocytes, HepG2 
cells, and HepaRG cells at the mRNA level and CYP activity in response to 
inducers and their predictivity for the detection of human hepatotoxins. Cell 
Biol Toxicol, 28, 69-87. 
Germano, D., Uteng, M., Pognan, F., Chibout, S. D. & Wolf, A. 2014. Determination 
of Liver Specific Toxicities in Rat Hepatocytes by High Content Imaging 
during 2-Week Multiple Treatment. Toxicol In Vitro. 
Getachew, Y., James, L., Lee, W. M., Thiele, D. L. & Miller, B. C. 2010. 
Susceptibility to acetaminophen (APAP) toxicity unexpectedly is decreased 
during acute viral hepatitis in mice. Biochem Pharmacol, 79, 1363-71. 
Giri, S., Braumann, U. D., Giri, P., Acikgoz, A., Scheibe, P., Nieber, K. & Bader, A. 
2013. Nanostructured self-assembling peptides as a defined extracellular 
matrix for long-term functional maintenance of primary hepatocytes in a 
bioartificial liver modular device. Int J Nanomedicine, 8, 1525-39. 
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., 
Bode, J. G., Bolleyn, J., Borner, C., Bottger, J., Braeuning, A., Budinsky, R. 
A., Burkhardt, B., Cameron, N. R., Camussi, G., Cho, C. S., Choi, Y. J., 
Craig Rowlands, J., Dahmen, U., Damm, G., Dirsch, O., Donato, M. T., 
Dong, J., Dooley, S., Drasdo, D., Eakins, R., Ferreira, K. S., Fonsato, V., 
Fraczek, J., Gebhardt, R., Gibson, A., Glanemann, M., Goldring, C. E., 
Gomez-Lechon, M. J., Groothuis, G. M., Gustavsson, L., Guyot, C., Hallifax, 
D., Hammad, S., Hayward, A., Haussinger, D., Hellerbrand, C., Hewitt, P., 
Hoehme, S., Holzhutter, H. G., Houston, J. B., Hrach, J., Ito, K., Jaeschke, 
   
205 
 
H., Keitel, V., Kelm, J. M., Kevin Park, B., Kordes, C., Kullak-Ublick, G. A., 
LeCluyse, E. L., Lu, P., Luebke-Wheeler, J., Lutz, A., Maltman, D. J., Matz-
Soja, M., McMullen, P., Merfort, I., Messner, S., Meyer, C., Mwinyi, J., 
Naisbitt, D. J., Nussler, A. K., Olinga, P., Pampaloni, F., Pi, J., Pluta, L., 
Przyborski, S. A., Ramachandran, A., Rogiers, V., Rowe, C., Schelcher, C., 
Schmich, K., Schwarz, M., Singh, B., Stelzer, E. H., Stieger, B., Stober, R., 
Sugiyama, Y., Tetta, C., Thasler, W. E., Vanhaecke, T., Vinken, M., Weiss, 
T. S., Widera, A., Woods, C. G., Xu, J. J., Yarborough, K. M. & Hengstler, J. 
G. 2013. Recent advances in 2D and 3D in vitro systems using primary 
hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells 
and their use in investigating mechanisms of hepatotoxicity, cell signaling 
and ADME. Arch Toxicol, 87, 1315-530. 
Godoy, P., Reif, R. & Bolt, H. M. 2012. Alcohol hepatotoxicity: Kupffer cells 
surface to the top. Arch Toxicol, 86, 1331-2. 
Goler-Baron, V. & Assaraf, Y. G. 2011. Structure and function of ABCG2-rich 
extracellular vesicles mediating multidrug resistance. PLoS One, 6, e16007. 
Gomez-Lechon, M. J., Castell, J. V. & Donato, M. T. 2010. The use of hepatocytes 
to investigate drug toxicity. Methods Mol Biol, 640, 389-415. 
Gomez-Lechon, M. J., Donato, M. T., Castell, J. V. & Jover, R. 2004. Human 
hepatocytes in primary culture: the choice to investigate drug metabolism in 
man. Curr Drug Metab, 5, 443-62. 
Gomez-Lechon, M. J., Tolosa, L., Conde, I. & Donato, M. T. 2014. Competency of 
different cell models to predict human hepatotoxic drugs. Expert Opin Drug 
Metab Toxicol, 10, 1553-68. 
Gripon, P., Rumin, S., Urban, S., Le Seyec, J., Glaise, D., Cannie, I., Guyomard, C., 
Lucas, J., Trepo, C. & Guguen-Guillouzo, C. 2002. Infection of a human 
hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A, 99, 15655-
60. 
Gulmez, S. E., Larrey, D., Pageaux, G. P., Lignot, S., Lassalle, R., Jove, J., Gatta, A., 
McCormick, P. A., Metselaar, H. J., Monteiro, E., Thorburn, D., Bernal, W., 
Zouboulis-Vafiadis, I., de Vries, C., Perez-Gutthann, S., Sturkenboom, M., 
Benichou, J., Montastruc, J. L., Horsmans, Y., Salvo, F., Hamoud, F., Micon, 
S., Droz-Perroteau, C., Blin, P. & Moore, N. 2013. Transplantation for acute 
liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): 
the multinational case-population SALT study. Drug Saf, 36, 135-44. 
Guo, L., Dial, S., Shi, L., Branham, W., Liu, J., Fang, J. L., Green, B., Deng, H., 
Kaput, J. & Ning, B. 2011. Similarities and differences in the expression of 
drug-metabolizing enzymes between human hepatic cell lines and primary 
human hepatocytes. Drug Metab Dispos, 39, 528-38. 
Hadi, M., Westra, I. M., Starokozhko, V., Dragovic, S., Merema, M. T. & Groothuis, 
G. M. 2013. Human precision-cut liver slices as an ex vivo model to study 
idiosyncratic drug-induced liver injury. Chem Res Toxicol, 26, 710-20. 
Hammad, S., Hoehme, S., Friebel, A., von Recklinghausen, I., Othman, A., Begher-
Tibbe, B., Reif, R., Godoy, P., Johann, T., Vartak, A., Golka, K., Bucur, P. 
O., Vibert, E., Marchan, R., Christ, B., Dooley, S., Meyer, C., Ilkavets, I., 
Dahmen, U., Dirsch, O., Bottger, J., Gebhardt, R., Drasdo, D. & Hengstler, J. 
G. 2014. Protocols for staining of bile canalicular and sinusoidal networks of 
human, mouse and pig livers, three-dimensional reconstruction and 
   
206 
 
quantification of tissue microarchitecture by image processing and analysis. 
Arch Toxicol, 88, 1161-83. 
Han, D., Dara, L., Win, S., Than, T. A., Yuan, L., Abbasi, S. Q., Liu, Z. X. & 
Kaplowitz, N. 2013. Regulation of drug-induced liver injury by signal 
transduction pathways: critical role of mitochondria. Trends Pharmacol Sci, 
34, 243-53. 
Harimoto, M., Yamato, M., Hirose, M., Takahashi, C., Isoi, Y., Kikuchi, A. & 
Okano, T. 2002. Novel approach for achieving double-layered cell sheets co-
culture: overlaying endothelial cell sheets onto monolayer hepatocytes 
utilizing temperature-responsive culture dishes. J Biomed Mater Res, 62, 464-
70. 
Harrill, A. H., Watkins, P. B., Su, S., Ross, P. K., Harbourt, D. E., Stylianou, I. M., 
Boorman, G. A., Russo, M. W., Sackler, R. S., Harris, S. C., Smith, P. C., 
Tennant, R., Bogue, M., Paigen, K., Harris, C., Contractor, T., Wiltshire, T., 
Rusyn, I. & Threadgill, D. W. 2009. Mouse population-guided resequencing 
reveals that variants in CD44 contribute to acetaminophen-induced liver 
injury in humans. Genome Res, 19, 1507-15. 
Hart, S. N., Li, Y., Nakamoto, K., Subileau, E. A., Steen, D. & Zhong, X. B. 2010. A 
comparison of whole genome gene expression profiles of HepaRG cells and 
HepG2 cells to primary human hepatocytes and human liver tissues. Drug 
Metab Dispos, 38, 988-94. 
Hastings, R., Qureshi, M., Verma, R., Lacy, P. S. & Williams, B. 2004. Telomere 
attrition and accumulation of senescent cells in cultured human endothelial 
cells. Cell Prolif, 37, 317-24. 
Hinson, J. A., Roberts, D. W. & James, L. P. 2010. Mechanisms of acetaminophen-
induced liver necrosis. Handb Exp Pharmacol, 369-405. 
Ho, C. T., Lin, R. Z., Chen, R. J., Chin, C. K., Gong, S. E., Chang, H. Y., Peng, H. 
L., Hsu, L., Yew, T. R., Chang, S. F. & Liu, C. H. 2013. Liver-cell patterning 
lab chip: mimicking the morphology of liver lobule tissue. Lab Chip, 13, 
3578-87. 
Hoehme, S., Brulport, M., Bauer, A., Bedawy, E., Schormann, W., Hermes, M., 
Puppe, V., Gebhardt, R., Zellmer, S., Schwarz, M., Bockamp, E., Timmel, T., 
Hengstler, J. G. & Drasdo, D. 2010. Prediction and validation of cell 
alignment along microvessels as order principle to restore tissue architecture 
in liver regeneration. Proc Natl Acad Sci U S A, 107, 10371-6. 
Hoekstra, R., Nibourg, G. A., van der Hoeven, T. V., Plomer, G., Seppen, J., 
Ackermans, M. T., Camus, S., Kulik, W., van Gulik, T. M., Elferink, R. P. & 
Chamuleau, R. A. 2013. Phase 1 and phase 2 drug metabolism and bile acid 
production of HepaRG cells in a bioartificial liver in absence of dimethyl 
sulfoxide. Drug Metab Dispos, 41, 562-7. 
Hsieh, S. C., Wu, C. H., Wu, C. C., Yen, J. H., Liu, M. C., Hsueh, C. M. & Hsu, S. 
L. 2014. Gallic acid selectively induces the necrosis of activated hepatic 
stellate cells via a calcium-dependent calpain I activation pathway. Life Sci, 
102, 55-64. 
Hwa, A. J., Fry, R. C., Sivaraman, A., So, P. T., Samson, L. D., Stolz, D. B. & 
Griffith, L. G. 2007. Rat liver sinusoidal endothelial cells survive without 
exogenous VEGF in 3D perfused co-cultures with hepatocytes. Faseb j, 21, 
2564-79. 
   
207 
 
Hynes, R. O. 2007. Cell-matrix adhesion in vascular development. J Thromb 
Haemost, 5 Suppl 1, 32-40. 
Inamori, M., Mizumoto, H. & Kajiwara, T. 2009. An approach for formation of 
vascularized liver tissue by endothelial cell-covered hepatocyte spheroid 
integration. Tissue Eng Part A, 15, 2029-37. 
Ito, Y., Bethea, N. W., Abril, E. R. & McCuskey, R. S. 2003. Early hepatic 
microvascular injury in response to acetaminophen toxicity. 
Microcirculation, 10, 391-400. 
Jaeschke, H., Gores, G. J., Cederbaum, A. I., Hinson, J. A., Pessayre, D. & 
Lemasters, J. J. 2002. Mechanisms of hepatotoxicity. Toxicol Sci, 65, 166-76. 
Jaeschke, H., Knight, T. R. & Bajt, M. L. 2003. The role of oxidant stress and 
reactive nitrogen species in acetaminophen hepatotoxicity. Toxicol Lett, 144, 
279-88. 
Jaeschke, H., McGill, M. R. & Ramachandran, A. 2012a. Oxidant stress, 
mitochondria, and cell death mechanisms in drug-induced liver injury: 
Lessons learned from acetaminophen hepatotoxicity. Drug Metabolism 
Reviews, 44, 88-106. 
Jaeschke, H., McGill, M. R. & Ramachandran, A. 2012b. Oxidant stress, 
mitochondria, and cell death mechanisms in drug-induced liver injury: 
lessons learned from acetaminophen hepatotoxicity. Drug Metab Rev, 44, 88-
106. 
Jaeschke, H., Williams, C. D., McGill, M. R., Xie, Y. & Ramachandran, A. 2013. 
Models of drug-induced liver injury for evaluation of phytotherapeutics and 
other natural products. Food Chem Toxicol, 55, 279-89. 
Jancova, P., Anzenbacher, P. & Anzenbacherova, E. 2010. Phase II drug 
metabolizing enzymes. Biomed Pap Med Fac Univ Palacky Olomouc Czech 
Repub, 154, 103-16. 
Jetten, M. J., Kleinjans, J. C., Claessen, S. M., Chesne, C. & van Delft, J. H. 2013. 
Baseline and genotoxic compound induced gene expression profiles in 
HepG2 and HepaRG compared to primary human hepatocytes. Toxicol In 
Vitro, 27, 2031-40. 
Jungermann, K. & Kietzmann, T. 1996. Zonation of parenchymal and 
nonparenchymal metabolism in liver. Annu Rev Nutr, 16, 179-203. 
Kamel, A. & Harriman, S. 2013. Inhibition of cytochrome P450 enzymes and 
biochemical aspects of mechanism-based inactivation (MBI). Drug Discov 
Today Technol, 10, e177-89. 
Kanzler, I., Seitz-Merwald, I., Schleger, S., Kaczmarek, I., Kur, F. & Beiras-
Fernandez, A. 2013. In vitro effects of ATG-Fresenius on immune cell 
adhesion. Transplant Proc, 45, 1846-9. 
Kao, Y. H., Jawan, B., Goto, S., Pan, M. C., Lin, Y. C., Sun, C. K., Hsu, L. W., Tai, 
M. H., Cheng, Y. F., Nakano, T., Wang, C. S., Huang, C. J. & Chen, C. L. 
2009. Serum factors potentiate hypoxia-induced hepatotoxicity in vitro 
through increasing transforming growth factor-beta1 activation and release. 
Cytokine, 47, 11-22. 
Kaplowitz, N. 2005. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov, 4, 489-
99. 
Kato, T., Ito, Y., Hosono, K., Suzuki, T., Tamaki, H., Minamino, T., Kato, S., 
Sakagami, H., Shibuya, M. & Majima, M. 2011. Vascular endothelial growth 
   
208 
 
factor receptor-1 signaling promotes liver repair through restoration of liver 
microvasculature after acetaminophen hepatotoxicity. Toxicol Sci, 120, 218-
29. 
Kavitha, C. V., Agarwal, C., Agarwal, R. & Deep, G. 2011. Asiatic acid inhibits pro-
angiogenic effects of VEGF and human gliomas in endothelial cell culture 
models. PLoS One, 6, e22745. 
Khodarev, N. N., Yu, J., Labay, E., Darga, T., Brown, C. K., Mauceri, H. J., Yassari, 
R., Gupta, N. & Weichselbaum, R. R. 2003. Tumour-endothelium 
interactions in co-culture: coordinated changes of gene expression profiles 
and phenotypic properties of endothelial cells. J Cell Sci, 116, 1013-22. 
Kim, K., Ohashi, K., Utoh, R., Kano, K. & Okano, T. 2012. Preserved liver-specific 
functions of hepatocytes in 3D co-culture with endothelial cell sheets. 
Biomaterials, 33, 1406-13. 
Kim, P. K., Zamora, R., Petrosko, P. & Billiar, T. R. 2001. The regulatory role of 
nitric oxide in apoptosis. Int Immunopharmacol, 1, 1421-41. 
Kjaergaard, A. G., Dige, A., Krog, J., Tonnesen, E. & Wogensen, L. 2013. Soluble 
adhesion molecules correlate with surface expression in an in vitro model of 
endothelial activation. Basic Clin Pharmacol Toxicol, 113, 273-9. 
Kleinman, H. K. & Martin, G. R. 2005. Matrigel: basement membrane matrix with 
biological activity. Semin Cancer Biol, 15, 378-86. 
Klingenberg, M. 2008. The ADP and ATP transport in mitochondria and its carrier. 
Biochim Biophys Acta, 1778, 1978-2021. 
Knight, T. R., Ho, Y. S., Farhood, A. & Jaeschke, H. 2002. Peroxynitrite is a critical 
mediator of acetaminophen hepatotoxicity in murine livers: protection by 
glutathione. J Pharmacol Exp Ther, 303, 468-75. 
Knudsen, T. B. & Kleinstreuer, N. C. 2011. Disruption of embryonic vascular 
development in predictive toxicology. Birth Defects Res C Embryo Today, 
93, 312-23. 
Kojima, S., Negishi, Y., Tsukimoto, M., Takenouchi, T., Kitani, H. & Takeda, K. 
2014. Purinergic signaling via P2X7 receptor mediates IL-1beta production in 
Kupffer cells exposed to silica nanoparticle. Toxicology, 321, 13-20. 
Kola, I. & Landis, J. 2004. Can the pharmaceutical industry reduce attrition rates? 
Nat Rev Drug Discov, 3, 711-5. 
Kon, K., Kim, J. S., Jaeschke, H. & Lemasters, J. J. 2004. Mitochondrial 
permeability transition in acetaminophen-induced necrosis and apoptosis of 
cultured mouse hepatocytes. Hepatology, 40, 1170-9. 
Kostadinova, R., Boess, F., Applegate, D., Suter, L., Weiser, T., Singer, T., 
Naughton, B. & Roth, A. 2013. A long-term three dimensional liver co-
culture system for improved prediction of clinically relevant drug-induced 
hepatotoxicity. Toxicol Appl Pharmacol, 268, 1-16. 
Kraljevic, S., Stambrook, P. J. & Pavelic, K. 2004. Accelerating drug discovery. 
EMBO Rep, 5, 837-42. 
Kubota, Y., Kleinman, H. K., Martin, G. R. & Lawley, T. J. 1988. Role of laminin 
and basement membrane in the morphological differentiation of human 
endothelial cells into capillary-like structures. J Cell Biol, 107, 1589-98. 
Kunze, A., Huwyler, J., Camenisch, G. & Gutmann, H. 2012. Interaction of the 
antiviral drug telaprevir with renal and hepatic drug transporters. Biochem 
Pharmacol, 84, 1096-102. 
   
209 
 
Lawson, J. A., Farhood, A., Hopper, R. D., Bajt, M. L. & Jaeschke, H. 2000. The 
hepatic inflammatory response after acetaminophen overdose: role of 
neutrophils. Toxicol Sci, 54, 509-16. 
Le Vee, M., Jigorel, E., Glaise, D., Gripon, P., Guguen-Guillouzo, C. & Fardel, O. 
2006. Functional expression of sinusoidal and canalicular hepatic drug 
transporters in the differentiated human hepatoma HepaRG cell line. Eur J 
Pharm Sci, 28, 109-17. 
Le Vee, M., Noel, G., Jouan, E., Stieger, B. & Fardel, O. 2013. Polarized expression 
of drug transporters in differentiated human hepatoma HepaRG cells. Toxicol 
In Vitro, 27, 1979-86. 
LeCluyse, E. L., Witek, R. P., Andersen, M. E. & Powers, M. J. 2012. Organotypic 
liver culture models: meeting current challenges in toxicity testing. Crit Rev 
Toxicol, 42, 501-48. 
LeCouter, J., Moritz, D. R., Li, B., Phillips, G. L., Liang, X. H., Gerber, H. P., 
Hillan, K. J. & Ferrara, N. 2003. Angiogenesis-independent endothelial 
protection of liver: role of VEGFR-1. Science, 299, 890-3. 
Lee, E. J. & Niklason, L. E. 2010. A novel flow bioreactor for in vitro 
microvascularization. Tissue Eng Part C Methods, 16, 1191-200. 
Leong, M. F., Toh, J. K., Du, C., Narayanan, K., Lu, H. F., Lim, T. C., Wan, A. C. & 
Ying, J. Y. 2013. Patterned prevascularised tissue constructs by assembly of 
polyelectrolyte hydrogel fibres. Nat Commun, 4, 2353. 
Li, H., Horke, S. & Forstermann, U. 2013. Oxidative stress in vascular disease and 
its pharmacological prevention. Trends Pharmacol Sci, 34, 313-9. 
Li, L., Zhang, B., Tao, Y., Wang, Y., Wei, H., Zhao, J., Huang, R. & Pei, Z. 2009. 
DL-3-n-butylphthalide protects endothelial cells against oxidative/nitrosative 
stress, mitochondrial damage and subsequent cell death after oxygen glucose 
deprivation in vitro. Brain Res, 1290, 91-101. 
Li, M., Zhou, X., Mei, J., Geng, X., Zhou, Y., Zhang, W. & Xu, C. 2014. Study on 
the activity of the signaling pathways regulating hepatocytes from G0 phase 
into G1 phase during rat liver regeneration. Cell Mol Biol Lett, 19, 181-200. 
Li, R., Oteiza, A., Sorensen, K. K., McCourt, P., Olsen, R., Smedsrod, B. & 
Svistounov, D. 2011. Role of liver sinusoidal endothelial cells and stabilins in 
elimination of oxidized low-density lipoproteins. Am J Physiol Gastrointest 
Liver Physiol, 300, G71-81. 
Li, S., Edgar, D., Fassler, R., Wadsworth, W. & Yurchenco, P. D. 2003. The role of 
laminin in embryonic cell polarization and tissue organization. Dev Cell, 4, 
613-24. 
Limonciel, A., Aschauer, L., Wilmes, A., Prajczer, S., Leonard, M. O., Pfaller, W. & 
Jennings, P. 2011. Lactate is an ideal non-invasive marker for evaluating 
temporal alterations in cell stress and toxicity in repeat dose testing regimes. 
Toxicol In Vitro, 25, 1855-62. 
Linden, J. 2006. New insights into the regulation of inflammation by adenosine. J 
Clin Invest, 116, 1835-7. 
Liu, Y., Bubolz, A. H., Shi, Y., Newman, P. J., Newman, D. K. & Gutterman, D. D. 
2006. Peroxynitrite reduces the endothelium-derived hyperpolarizing factor 
component of coronary flow-mediated dilation in PECAM-1-knockout mice. 
Am J Physiol Regul Integr Comp Physiol, 290, R57-65. 
   
210 
 
Lockman, K. A., Baren, J. P., Pemberton, C. J., Baghdadi, H., Burgess, K. E., 
Plevris-Papaioannou, N., Lee, P., Howie, F., Beckett, G., Pryde, A., Jaap, A. 
J., Hayes, P. C., Filippi, C. & Plevris, J. N. 2012. Oxidative stress rather than 
triglyceride accumulation is a determinant of mitochondrial dysfunction in in 
vitro models of hepatic cellular steatosis. Liver Int, 32, 1079-92. 
Lübberstedt, M., Müller-Vieira, U., Mayer, M., Biemel, K. M., Knöspel, F., 
Knobeloch, D., Nüssler, A. K., Gerlach, J. C. & Zeilinger, K. 2011. HepaRG 
human hepatic cell line utility as a surrogate for primary human hepatocytes 
in drug metabolism assessment in vitro. J Pharmacol Toxicol Methods, 63, 
59-68. 
Maas-Szabowski, N., Fusenig, N. E. & Stark, H. J. 2005. Experimental models to 
analyze differentiation functions of cultured keratinocytes in vitro and in 
vivo. Methods Mol Biol, 289, 47-60. 
Maharjan, S., Oku, M., Tsuda, M., Hoseki, J. & Sakai, Y. 2014. Mitochondrial 
impairment triggers cytosolic oxidative stress and cell death following 
proteasome inhibition. Sci Rep, 4, 5896. 
Maher, S. P., Crouse, R. B., Conway, A. J., Bannister, E. C., Achyuta, A. K., Clark, 
A. Y., Sinatra, F. L., Cuiffi, J. D., Adams, J. H., Kyle, D. E. & Saadi, W. M. 
2014. Microphysical space of a liver sinusoid device enables simplified long-
term maintenance of chimeric mouse-expanded human hepatocytes. Biomed 
Microdevices, 16, 727-36. 
Manov, I., Hirsh, M. & Iancu, T. C. 2004. N-acetylcysteine does not protect HepG2 
cells against acetaminophen-induced apoptosis. Basic Clin Pharmacol 
Toxicol, 94, 213-25. 
March, S., Hui, E. E., Underhill, G. H., Khetani, S. & Bhatia, S. N. 2009. 
Microenvironmental regulation of the sinusoidal endothelial cell phenotype in 
vitro. Hepatology, 50, 920-8. 
Marin-Juez, R., Rovira, M., Crespo, D., van der Vaart, M., Spaink, H. P. & Planas, J. 
V. 2014. GLUT2-mediated glucose uptake and availability are required for 
embryonic brain development in zebrafish. J Cereb Blood Flow Metab. 
Marrone, G., Maeso-Diaz, R., Garcia-Cardena, G., Abraldes, J. G., Garcia-Pagan, J. 
C., Bosch, J. & Gracia-Sancho, J. 2014. KLF2 exerts antifibrotic and 
vasoprotective effects in cirrhotic rat livers: behind the molecular 
mechanisms of statins. Gut. 
Marroquin, L. D., Hynes, J., Dykens, J. A., Jamieson, J. D. & Will, Y. 2007. 
Circumventing the Crabtree effect: replacing media glucose with galactose 
increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol 
Sci. United States. 
Martin, E. J., Racz, W. J. & Forkert, P. G. 2003. Mitochondrial dysfunction is an 
early manifestation of 1,1-dichloroethylene-induced hepatotoxicity in mice. J 
Pharmacol Exp Ther, 304, 121-9. 
Matsumoto, K., Yoshitomi, H., Rossant, J. & Zaret, K. S. 2001. Liver organogenesis 
promoted by endothelial cells prior to vascular function. Science, 294, 559-
63. 
Mavri-Damelin, D., Damelin, L. H., Eaton, S., Rees, M., Selden, C. & Hodgson, H. 
J. 2008. Cells for bioartificial liver devices: the human hepatoma-derived cell 
line C3A produces urea but does not detoxify ammonia. Biotechnol Bioeng, 
99, 644-51. 
   
211 
 
McCuskey, R. S. 2008. The hepatic microvascular system in health and its response 
to toxicants. Anat Rec (Hoboken), 291, 661-71. 
McGill, M. R. & Jaeschke, H. 2013. Metabolism and disposition of acetaminophen: 
recent advances in relation to hepatotoxicity and diagnosis. Pharm Res, 30, 
2174-87. 
McGill, M. R., Staggs, V. S., Sharpe, M. R., Lee, W. M. & Jaeschke, H. 2014. Serum 
mitochondrial biomarkers and damage-associated molecular patterns are 
higher in acetaminophen overdose patients with poor outcome. Hepatology. 
McGill, M. R., Yan, H. M., Ramachandran, A., Murray, G. J., Rollins, D. E. & 
Jaeschke, H. 2011. HepaRG cells: a human model to study mechanisms of 
acetaminophen hepatotoxicity. Hepatology, 53, 974-82. 
Mitra, M., Kandalam, M., Harilal, A., Verma, R. S., Krishnan, U. M., Swaminathan, 
S. & Krishnakumar, S. 2012. EpCAM is a putative stem marker in 
retinoblastoma and an effective target for T-cell-mediated immunotherapy. 
Mol Vis, 18, 290-308. 
Moir, L. M., Black, J. L. & Krymskaya, V. P. 2012. TSC2 modulates cell adhesion 
and migration via integrin-alpha1beta1. Am J Physiol Lung Cell Mol Physiol, 
303, L703-10. 
Mottino, A. D. & Catania, V. A. 2008. Hepatic drug transporters and nuclear 
receptors: regulation by therapeutic agents. World J Gastroenterol, 14, 7068-
74. 
Moyer, A. M., Fridley, B. L., Jenkins, G. D., Batzler, A. J., Pelleymounter, L. L., 
Kalari, K. R., Ji, Y., Chai, Y., Nordgren, K. K. & Weinshilboum, R. M. 2011. 
Acetaminophen-NAPQI hepatotoxicity: a cell line model system genome-
wide association study. Toxicol Sci, 120, 33-41. 
Mueller, D., Kramer, L., Hoffmann, E., Klein, S. & Noor, F. 2014. 3D organotypic 
HepaRG cultures as in vitro model for acute and repeated dose toxicity 
studies. Toxicol In Vitro, 28, 104-12. 
Mukhopadhyay, P., Rajesh, M., Hasko, G., Hawkins, B. J., Madesh, M. & Pacher, P. 
2007. Simultaneous detection of apoptosis and mitochondrial superoxide 
production in live cells by flow cytometry and confocal microscopy. Nat 
Protoc, 2, 2295-301. 
Nagendra, A. R., Mickelson, J. K. & Smith, C. W. 1997. CD18 integrin and CD54-
dependent neutrophil adhesion to cytokine-stimulated human hepatocytes. 
Am J Physiol, 272, G408-16. 
Nagi, M. N., Almakki, H. A., Sayed-Ahmed, M. M. & Al-Bekairi, A. M. 2010. 
Thymoquinone supplementation reverses acetaminophen-induced oxidative 
stress, nitric oxide production and energy decline in mice liver. Food Chem 
Toxicol, 48, 2361-5. 
Nahmias, Y., Schwartz, R. E., Hu, W. S., Verfaillie, C. M. & Odde, D. J. 2006. 
Endothelium-mediated hepatocyte recruitment in the establishment of liver-
like tissue in vitro. Tissue Eng, 12, 1627-38. 
Nel, A., Xia, T., Madler, L. & Li, N. 2006. Toxic potential of materials at the 
nanolevel. Science, 311, 622-7. 
Nelson, L. J., Walker, S. W., Hayes, P. C. & Plevris, J. N. 2010. Low-shear modelled 
microgravity environment maintains morphology and differentiated 
functionality of primary porcine hepatocyte cultures. Cells Tissues Organs, 
192, 125-40. 
   
212 
 
Newsome, P. N., Tsiaoussis, J., Masson, S., Buttery, R., Livingston, C., Ansell, I., 
Ross, J. A., Sethi, T., Hayes, P. C. & Plevris, J. N. 2004. Serum from patients 
with fulminant hepatic failure causes hepatocyte detachment and apoptosis by 
a beta(1)-integrin pathway. Hepatology, 40, 636-45. 
Nicotera, P. & Melino, G. 2004. Regulation of the apoptosis-necrosis switch. 
Oncogene, 23, 2757-65. 
O'Brien, P. J., Irwin, W., Diaz, D., Howard-Cofield, E., Krejsa, C. M., Slaughter, M. 
R., Gao, B., Kaludercic, N., Angeline, A., Bernardi, P., Brain, P. & 
Hougham, C. 2006. High concordance of drug-induced human hepatotoxicity 
with in vitro cytotoxicity measured in a novel cell-based model using high 
content screening. Arch Toxicol, 80, 580-604. 
Ohno, M., Motojima, K., Okano, T. & Taniguchi, A. 2009. Induction of drug-
metabolizing enzymes by phenobarbital in layered co-culture of a human 
liver cell line and endothelial cells. Biol Pharm Bull, 32, 813-7. 
Ostergaard, S., Olsson, L., Johnston, M. & Nielsen, J. 2000. Increasing galactose 
consumption by Saccharomyces cerevisiae through metabolic engineering of 
the GAL gene regulatory network. Nat Biotechnol, 18, 1283-6. 
Paine, M. F., Hart, H. L., Ludington, S. S., Haining, R. L., Rettie, A. E. & Zeldin, D. 
C. 2006. The human intestinal cytochrome P450 "pie". Drug Metab Dispos, 
34, 880-6. 
Palakkan, A. A., Hay, D. C., Anil Kumar, P. R., Kumary, T. V. & Ross, J. A. 2013. 
Liver tissue engineering and cell sources: issues and challenges. Liver Int, 33, 
666-76. 
Panatto, J. P., Jeremias, I. C., Ferreira, G. K., Ramos, A. C., Rochi, N., Goncalves, C. 
L., Daufenbach, J. F., Jeremias, G. C., Carvalho-Silva, M., Rezin, G. T., 
Scaini, G. & Streck, E. L. 2011. Inhibition of mitochondrial respiratory chain 
in the brain of rats after hepatic failure induced by acetaminophen. Mol Cell 
Biochem, 350, 149-54. 
Parent, R., Marion, M. J., Furio, L., Trepo, C. & Petit, M. A. 2004. Origin and 
characterization of a human bipotent liver progenitor cell line. 
Gastroenterology, 126, 1147-56. 
Pernelle, K., Le Guevel, R., Glaise, D., Stasio, C. G., Le Charpentier, T., Bouaita, B., 
Corlu, A. & Guguen-Guillouzo, C. 2011. Automated detection of hepatotoxic 
compounds in human hepatocytes using HepaRG cells and image-based 
analysis of mitochondrial dysfunction with JC-1 dye. Toxicol Appl 
Pharmacol, 254, 256-66. 
Pessayre, D., Mansouri, A., Berson, A. & Fromenty, B. 2010. Mitochondrial 
involvement in drug-induced liver injury. Handb Exp Pharmacol, 311-65. 
Pires, D. A., Marques, P. E., Pereira, R. V., David, B. A., Gomides, L. F., Dias, A. 
C., Nunes-Silva, A., Pinho, V., Cara, D. C., Vieira, L. Q., Teixeira, M. M. & 
Menezes, G. B. 2014. Interleukin-4 deficiency protects mice from 
acetaminophen-induced liver injury and inflammation by prevention of 
glutathione depletion. Inflamm Res, 63, 61-9. 
Pivovarova, N. B. & Andrews, S. B. 2010. Calcium-dependent mitochondrial 
function and dysfunction in neurons. Febs j, 277, 3622-36. 
Pullikotil, P., Chen, H., Muniyappa, R., Greenberg, C. C., Yang, S., Reiter, C. E., 
Lee, J. W., Chung, J. H. & Quon, M. J. 2012. Epigallocatechin gallate 
induces expression of heme oxygenase-1 in endothelial cells via p38 MAPK 
   
213 
 
and Nrf-2 that suppresses proinflammatory actions of TNF-alpha. J Nutr 
Biochem, 23, 1134-45. 
Rahman, I., Kode, A. & Biswas, S. K. 2006. Assay for quantitative determination of 
glutathione and glutathione disulfide levels using enzymatic recycling 
method. Nat Protoc, 1, 3159-65. 
Ramaiahgari, S. C., den Braver, M. W., Herpers, B., Terpstra, V., Commandeur, J. 
N., van de Water, B. & Price, L. S. 2014. A 3D in vitro model of 
differentiated HepG2 cell spheroids with improved liver-like properties for 
repeated dose high-throughput toxicity studies. Arch Toxicol, 88, 1083-95. 
Rashid, K., Sinha, K. & Sil, P. C. 2013. An update on oxidative stress-mediated 
organ pathophysiology. Food Chem Toxicol, 62, 584-600. 
Rauterberg, J., Voss, B., Pott, G. & Gerlach, U. 1981. Connective tissue components 
of the normal and fibrotic liver. I. Structure, local distribution and 
metabolism of connective tissue components in the normal liver and changes 
in chronic liver diseases. Klin Wochenschr, 59, 767-79. 
Ray, S. D. & Jena, N. 2000. A hepatotoxic dose of acetaminophen modulates 
expression of BCL-2, BCL-X(L), and BCL-X(S) during apoptotic and 
necrotic death of mouse liver cells in vivo. Arch Toxicol, 73, 594-606. 
Raynaud, P., Carpentier, R., Antoniou, A. & Lemaigre, F. P. 2011. Biliary 
differentiation and bile duct morphogenesis in development and disease. Int J 
Biochem Cell Biol. Netherlands: 2009 Elsevier Ltd. 
Reardon, S. & Cyranoski, D. 2014. Japan stem-cell trial stirs envy. Nature. England. 
Rebelo, S. P., Costa, R., Estrada, M., Shevchenko, V., Brito, C. & Alves, P. M. 2014. 
HepaRG microencapsulated spheroids in DMSO-free culture: novel culturing 
approaches for enhanced xenobiotic and biosynthetic metabolism. Arch 
Toxicol. 
Reichen, J. 1999. The Role of the Sinusoidal Endothelium in Liver Function. News 
Physiol Sci, 14, 117-121. 
Reliene, R., Fischer, E. & Schiestl, R. H. 2004. Effect of N-acetyl cysteine on 
oxidative DNA damage and the frequency of DNA deletions in atm-deficient 
mice. Cancer Res, 64, 5148-53. 
Ribeiro, M. P., Santos, A. E. & Custodio, J. B. 2014. Mitochondria: The gateway for 
tamoxifen-induced liver injury. Toxicology, 323c, 10-18. 
Rivron, N. C., Liu, J. J., Rouwkema, J., de Boer, J. & van Blitterswijk, C. A. 2008. 
Engineering vascularised tissues in vitro. Eur Cell Mater, 15, 27-40. 
Rohringer, S., Hofbauer, P., Schneider, K. H., Husa, A. M., Feichtinger, G., 
Peterbauer-Scherb, A., Redl, H. & Holnthoner, W. 2014. Mechanisms of 
vasculogenesis in 3D fibrin matrices mediated by the interaction of adipose-
derived stem cells and endothelial cells. Angiogenesis. 
Rotroff, D. M., Beam, A. L., Dix, D. J., Farmer, A., Freeman, K. M., Houck, K. A., 
Judson, R. S., LeCluyse, E. L., Martin, M. T., Reif, D. M. & Ferguson, S. S. 
2010. Xenobiotic-metabolizing enzyme and transporter gene expression in 
primary cultures of human hepatocytes modulated by ToxCast chemicals. J 
Toxicol Environ Health B Crit Rev, 13, 329-46. 
Rowland, T. J., Blaschke, A. J., Buchholz, D. E., Hikita, S. T., Johnson, L. V. & 
Clegg, D. O. 2013. Differentiation of human pluripotent stem cells to retinal 
pigmented epithelium in defined conditions using purified extracellular 
matrix proteins. J Tissue Eng Regen Med, 7, 642-53. 
   
214 
 
Ruan, G. X. & Kazlauskas, A. 2013. Lactate engages receptor tyrosine kinases Axl, 
Tie2, and vascular endothelial growth factor receptor 2 to activate 
phosphoinositide 3-kinase/Akt and promote angiogenesis. J Biol Chem, 288, 
21161-72. 
Sahi, J., Shord, S. S., Lindley, C., Ferguson, S. & LeCluyse, E. L. 2009. Regulation 
of cytochrome P450 2C9 expression in primary cultures of human 
hepatocytes. J Biochem Mol Toxicol, 23, 43-58. 
Saito, C., Zwingmann, C. & Jaeschke, H. 2010. Novel mechanisms of protection 
against acetaminophen hepatotoxicity in mice by glutathione and N-
acetylcysteine. Hepatology, 51, 246-54. 
Salerno, S., Campana, C., Morelli, S., Drioli, E. & De Bartolo, L. 2011. Human 
hepatocytes and endothelial cells in organotypic membrane systems. 
Biomaterials, 32, 8848-59. 
Saragih, H., Zilian, E., Jaimes, Y., Paine, A., Figueiredo, C., Eiz-Vesper, B., 
Blasczyk, R., Larmann, J., Theilmeier, G., Burg-Roderfeld, M., Andrei-
Selmer, L. C., Becker, J. U., Santoso, S. & Immenschuh, S. 2014. PECAM-1-
dependent heme oxygenase-1 regulation via an Nrf2-mediated pathway in 
endothelial cells. Thromb Haemost, 111, 1077-88. 
Saraswati, S., Agrawal, S. S. & Alhaider, A. A. 2013. Ursolic acid inhibits tumor 
angiogenesis and induces apoptosis through mitochondrial-dependent 
pathway in Ehrlich ascites carcinoma tumor. Chem Biol Interact, 206, 153-
65. 
Sassi, N., Mattarei, A., Azzolini, M., Szabo, I., Paradisi, C., Zoratti, M. & Biasutto, 
L. 2014. Cytotoxicity of mitochondria-targeted resveratrol derivatives: 
interactions with respiratory chain complexes and ATP synthase. Biochim 
Biophys Acta, 1837, 1781-9. 
Schafer, C., Schroder, K. R., Hoglinger, O., Tollabimazraehno, S. & Lornejad-
Schafer, M. R. 2013. Acetaminophen changes intestinal epithelial cell 
membrane properties, subsequently affecting absorption processes. Cell 
Physiol Biochem, 32, 431-47. 
Schmelzer, E., Mutig, K., Schrade, P., Bachmann, S., Gerlach, J. C. & Zeilinger, K. 
2009. Effect of human patient plasma ex vivo treatment on gene expression 
and progenitor cell activation of primary human liver cells in multi-
compartment 3D perfusion bioreactors for extra-corporeal liver support. 
Biotechnol Bioeng, 103, 817-27. 
Schmidt, A., Brixius, K. & Bloch, W. 2007. Endothelial precursor cell migration 
during vasculogenesis. Circ Res, 101, 125-36. 
Schneider, F., Poidevin, A., Riehm, S., Herbrecht, J. E. & Guillot, M. 2014. Liver 
transplantation in case of acetaminophen poisoning: importance of 
assessment of the colon if arterial lactate increases despite appropriate care. 
Transplantation. United States. 
Schuppan, D., Ruehl, M., Somasundaram, R. & Hahn, E. G. 2001. Matrix as a 
modulator of hepatic fibrogenesis. Semin Liver Dis, 21, 351-72. 
Seeland, S., Torok, M., Kettiger, H., Treiber, A., Hafner, M. & Huwyler, J. 2013. A 
cell-based, multiparametric sensor approach characterises drug-induced 
cytotoxicity in human liver HepG2 cells. Toxicol In Vitro, 27, 1109-20. 
Sekine, S., Kimura, T., Motoyama, M., Shitara, Y., Wakazono, H., Oida, H. & Horie, 
T. 2013. The role of cyclophilin D in interspecies differences in susceptibility 
   
215 
 
to hepatotoxic drug-induced mitochondrial injury. Biochem Pharmacol, 86, 
1507-14. 
Shah, A. D., Wood, D. M. & Dargan, P. I. 2011. Understanding lactic acidosis in 
paracetamol (acetaminophen) poisoning. Br J Clin Pharmacol, 71, 20-8. 
Shah, R. R., Morganroth, J. & Shah, D. R. 2013. Hepatotoxicity of tyrosine kinase 
inhibitors: clinical and regulatory perspectives. Drug Saf, 36, 491-503. 
Shahidi, M., Barati, M., Hayat, P., Tavasoli, B. & Bakhshayesh, M. 2014. The in 
vitro effects of sodium salicylate on von Willebrand factor and C-reactive 
protein production by endothelial cells. Inflammopharmacology. 
Shuey, D. & Kim, J. H. 2011. Overview: developmental toxicology: new directions. 
Birth Defects Res B Dev Reprod Toxicol, 92, 381-3. 
Shukla, S., Kouanda, A., Silverton, L., Talele, T. T. & Ambudkar, S. V. 2014. 
Pharmacophore Modeling of Nilotinib as an Inhibitor of ATP-Binding 
Cassette Drug Transporters and BCR-ABL Kinase Using a Three-
Dimensional Quantitative Structure-Activity Relationship Approach. Mol 
Pharm, 11, 2313-22. 
Silva, J. M., Morin, P. E., Day, S. H., Kennedy, B. P., Payette, P., Rushmore, T., 
Yergey, J. A. & Nicoll-Griffith, D. A. 1998. Refinement of an in vitro cell 
model for cytochrome P450 induction. Drug Metab Dispos, 26, 490-6. 
Simon-Santamaria, J., Malovic, I., Warren, A., Oteiza, A., Le Couteur, D., 
Smedsrod, B., McCourt, P. & Sorensen, K. K. 2010. Age-related changes in 
scavenger receptor-mediated endocytosis in rat liver sinusoidal endothelial 
cells. J Gerontol A Biol Sci Med Sci, 65, 951-60. 
Sjogren, A. K., Liljevald, M., Glinghammar, B., Sagemark, J., Li, X. Q., Jonebring, 
A., Cotgreave, I., Brolen, G. & Andersson, T. B. 2014. Critical differences in 
toxicity mechanisms in induced pluripotent stem cell-derived hepatocytes, 
hepatic cell lines and primary hepatocytes. Arch Toxicol, 88, 1427-37. 
Skovseth, D. K., Kuchler, A. M. & Haraldsen, G. 2007. The HUVEC/Matrigel assay: 
an in vivo assay of human angiogenesis suitable for drug validation. Methods 
Mol Biol, 360, 253-68. 
Smedsrod, B., Melkko, J., Risteli, L. & Risteli, J. 1990. Circulating C-terminal 
propeptide of type I procollagen is cleared mainly via the mannose receptor 
in liver endothelial cells. Biochem J, 271, 345-50. 
Soldatow, V. Y., Lecluyse, E. L., Griffith, L. G. & Rusyn, I. 2013. models for liver 
toxicity testing. Toxicol Res (Camb), 2, 23-39. 
Soto-Gutierrez, A., Navarro-Alvarez, N., Yagi, H., Nahmias, Y., Yarmush, M. L. & 
Kobayashi, N. 2010. Engineering of an hepatic organoid to develop liver 
assist devices. Cell Transplant, 19, 815-22. 
Stamati, K., Priestley, J. V., Mudera, V. & Cheema, U. 2014. Laminin promotes 
vascular network formation in 3D in vitro collagen scaffolds by regulating 
VEGF uptake. Exp Cell Res. 
Stolz, D. B., Ross, M. A., Ikeda, A., Tomiyama, K., Kaizu, T., Geller, D. A. & 
Murase, N. 2007. Sinusoidal endothelial cell repopulation following 
ischemia/reperfusion injury in rat liver transplantation. Hepatology, 46, 1464-
75. 
Stroka, K. M., Hayenga, H. N. & Aranda-Espinoza, H. 2013. Human neutrophil 
cytoskeletal dynamics and contractility actively contribute to trans-
endothelial migration. PLoS One, 8, e61377. 
   
216 
 
Sullivan, G. J., Hay, D. C., Park, I. H., Fletcher, J., Hannoun, Z., Payne, C. M., 
Dalgetty, D., Black, J. R., Ross, J. A., Samuel, K., Wang, G., Daley, G. Q., 
Lee, J. H., Church, G. M., Forbes, S. J., Iredale, J. P. & Wilmut, I. 2010. 
Generation of functional human hepatic endoderm from human induced 
pluripotent stem cells. Hepatology, 51, 329-35. 
Swartz, M. A. & Fleury, M. E. 2007. Interstitial flow and its effects in soft tissues. 
Annu Rev Biomed Eng, 9, 229-56. 
Takebe, T., Sekine, K., Enomura, M., Koike, H., Kimura, M., Ogaeri, T., Zhang, R. 
R., Ueno, Y., Zheng, Y. W., Koike, N., Aoyama, S., Adachi, Y. & Taniguchi, 
H. 2013. Vascularized and functional human liver from an iPSC-derived 
organ bud transplant. Nature, 499, 481-4. 
Tang, N. H., Wang, X. Q., Li, X. J. & Chen, Y. L. 2008. Ammonia metabolism 
capacity of HepG2 cells with high expression of human glutamine synthetase. 
Hepatobiliary Pancreat Dis Int, 7, 621-7. 
Temple, R. J. & Himmel, M. H. 2002. Safety of newly approved drugs: implications 
for prescribing. Jama. United States. 
Tomizawa, M., Shinozaki, F., Motoyoshi, Y., Sugiyama, T., Yamamoto, S. & Ishige, 
N. 2014. Co-culture of hepatocellular carcinoma cells and human umbilical 
endothelial cells damaged by SU11274. Biomed Rep, 2, 799-803. 
Tourovskaia, A., Fauver, M., Kramer, G., Simonson, S. & Neumann, T. 2014. 
Tissue-engineered microenvironment systems for modeling human 
vasculature. Exp Biol Med (Maywood). 
Toyoda, Y., Tamai, M., Kashikura, K., Kobayashi, S., Fujiyama, Y., Soga, T. & 
Tagawa, Y. 2012. Acetaminophen-induced hepatotoxicity in a liver tissue 
model consisting of primary hepatocytes assembling around an endothelial 
cell network. Drug Metab Dispos, 40, 169-77. 
Tsiaoussis, J., Newsome, P. N., Nelson, L. J., Hayes, P. C. & Plevris, J. N. 2001. 
Which hepatocyte will it be? Hepatocyte choice for bioartificial liver support 
systems. Liver Transpl, 7, 2-10. 
Tsuneki, M. & Madri, J. A. 2014. CD44 regulation of endothelial cell proliferation 
and apoptosis via modulation of CD31 and VE-cadherin expression. J Biol 
Chem, 289, 5357-70. 
Ukairo, O., McVay, M., Krzyzewski, S., Aoyama, S., Rose, K., Andersen, M. E., 
Khetani, S. R. & Lecluyse, E. L. 2013. Bioactivation and toxicity of 
acetaminophen in a rat hepatocyte micropatterned coculture system. J 
Biochem Mol Toxicol, 27, 471-8. 
Ulvestad, M., Nordell, P., Asplund, A., Rehnstrom, M., Jacobsson, S., Holmgren, G., 
Davidson, L., Brolen, G., Edsbagge, J., Bjorquist, P., Kuppers-Munther, B. & 
Andersson, T. B. 2013. Drug metabolizing enzyme and transporter protein 
profiles of hepatocytes derived from human embryonic and induced 
pluripotent stem cells. Biochem Pharmacol, 86, 691-702. 
Vinken, M. 2013. The adverse outcome pathway concept: a pragmatic tool in 
toxicology. Toxicology, 312, 158-65. 
Vrochides, D., Papanikolaou, V., Pertoft, H., Antoniades, A. A. & Heldin, P. 1996. 
Biosynthesis and degradation of hyaluronan by nonparenchymal liver cells 
during liver regeneration. Hepatology, 23, 1650-5. 
Wang, A. G., Xia, T., Yuan, J., Yu, R. A., Yang, K. D., Chen, X. M., Qu, W. & 
Waalkes, M. P. 2004. Effects of phenobarbital on metabolism and toxicity of 
   
217 
 
diclofenac sodium in rat hepatocytes in vitro. Food Chem Toxicol, 42, 1647-
53. 
Wang, L., Wang, X., Chiu, J. D., van de Ven, G., Gaarde, W. A. & Deleve, L. D. 
2012a. Hepatic vascular endothelial growth factor regulates recruitment of rat 
liver sinusoidal endothelial cell progenitor cells. Gastroenterology, 143, 
1555-1563.e2. 
Wang, L., Wang, X., Xie, G., Hill, C. K. & DeLeve, L. D. 2012b. Liver sinusoidal 
endothelial cell progenitor cells promote liver regeneration in rats. J Clin 
Invest, 122, 1567-73. 
Willett, C., Rae, J. C., Goyak, K. O., Minsavage, G., Westmoreland, C., Andersen, 
M., Avigan, M., Duche, D., Hartung, T., Jaeschke, H., Kleensang, A., 
Landesmann, B., Toole, C., Rowan, A., Schultz, T., Seed, J., Senior, J., Shah, 
I., Subramanian, K., Vinken, M. & Watkins, P. 2014. Building Shared 
Experience to Advance Practical Application of Pathway-Based Toxicology: 
Liver Toxicity Mode-of-Action. Altex. 
Williamson, D. H., Lund, P. & Krebs, H. A. 1967. The redox state of free 
nicotinamide-adenine dinucleotide in the cytoplasm and mitochondria of rat 
liver. Biochem J, 103, 514-27. 
Wisse, E., Braet, F., Luo, D., De Zanger, R., Jans, D., Crabbe, E. & Vermoesen, A. 
1996. Structure and function of sinusoidal lining cells in the liver. Toxicol 
Pathol, 24, 100-11. 
Xie, W., Sun, J., Zhang, X. & Melzig, M. F. 2014a. Necrosis factor-alpha (TNF-
alpha) response in human hepatoma HepG2 cells treated with hepatotoxic 
agents. Pharmazie, 69, 379-84. 
Xie, Y., McGill, M. R., Dorko, K., Kumer, S. C., Schmitt, T. M., Forster, J. & 
Jaeschke, H. 2014b. Mechanisms of acetaminophen-induced cell death in 
primary human hepatocytes. Toxicol Appl Pharmacol, 279, 266-274. 
Xin, X., Yang, S., Ingle, G., Zlot, C., Rangell, L., Kowalski, J., Schwall, R., Ferrara, 
N. & Gerritsen, M. E. 2001. Hepatocyte growth factor enhances vascular 
endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J 
Pathol, 158, 1111-20. 
Xiong, S., Mu, T., Wang, G. & Jiang, X. 2014. Mitochondria-mediated apoptosis in 
mammals. Protein Cell. 
Yang, L., Yue, S., Liu, X., Han, Z., Zhang, Y. & Li, L. 2013a. Sphingosine 
kinase/sphingosine 1-phosphate (S1P)/S1P receptor axis is involved in liver 
fibrosis-associated angiogenesis. J Hepatol, 59, 114-23. 
Yang, Y., Li, J., Pan, X., Zhou, P., Yu, X., Cao, H., Wang, Y. & Li, L. 2013b. Co-
culture with mesenchymal stem cells enhances metabolic functions of liver 
cells in bioartificial liver system. Biotechnol Bioeng, 110, 958-68. 
Yehuda-Shnaidman, E., Nimri, L., Tarnovscki, T., Kirshtein, B., Rudich, A. & 
Schwartz, B. 2013. Secreted human adipose leptin decreases mitochondrial 
respiration in HCT116 colon cancer cells. PLoS One, 8, e74843. 
Yoon, M., Kedderis, G. L., Yan, G. Z. & Clewell, H. J., 3rd 2014. Use of in vitro 
data in developing a physiologically based pharmacokinetic model: Carbaryl 
as a case study. Toxicology. 
Yoshida, K., Maeda, K. & Sugiyama, Y. 2012. Transporter-mediated drug--drug 
interactions involving OATP substrates: predictions based on in vitro 
inhibition studies. Clin Pharmacol Ther, 91, 1053-64. 
   
218 
 
Yovchev, M. I., Dabeva, M. D. & Oertel, M. 2013. Isolation, characterization, and 
transplantation of adult liver progenitor cells. Methods Mol Biol, 976, 37-51. 
Yu, K. R., Yang, S. R., Jung, J. W., Kim, H., Ko, K., Han, D. W., Park, S. B., Choi, 
S. W., Kang, S. K., Scholer, H. & Kang, K. S. 2012. CD49f enhances 
multipotency and maintains stemness through the direct regulation of OCT4 
and SOX2. Stem Cells, 30, 876-87. 
Zachary, I. & Gliki, G. 2001. Signaling transduction mechanisms mediating 
biological actions of the vascular endothelial growth factor family. 
Cardiovasc Res, 49, 568-81. 
Zamaraeva, M. V., Sabirov, R. Z., Maeno, E., Ando-Akatsuka, Y., Bessonova, S. V. 
& Okada, Y. 2005. Cells die with increased cytosolic ATP during apoptosis: 
a bioluminescence study with intracellular luciferase. Cell Death Differ, 12, 
1390-7. 
Zanger, U. M. & Schwab, M. 2013. Cytochrome P450 enzymes in drug metabolism: 
regulation of gene expression, enzyme activities, and impact of genetic 
variation. Pharmacol Ther, 138, 103-41. 
Zeisberg, M., Kramer, K., Sindhi, N., Sarkar, P., Upton, M. & Kalluri, R. 2006. De-
differentiation of primary human hepatocytes depends on the composition of 
specialized liver basement membrane. Mol Cell Biochem, 283, 181-9. 
Zhang, Q., Liu, J., Huang, W., Tian, L., Quan, J., Wang, Y. & Niu, R. 2014. oxLDL 
induces injury and defenestration of human liver sinusoidal endothelial cells 
via LOX1. J Mol Endocrinol, 53, 281-93. 
Zhou, S. F., Liu, J. P. & Chowbay, B. 2009. Polymorphism of human cytochrome 
P450 enzymes and its clinical impact. Drug Metab Rev, 41, 89-295. 
Zhu, B. T. 2010. On the general mechanism of selective induction of cytochrome 
P450 enzymes by chemicals: some theoretical considerations. Expert Opin 
Drug Metab Toxicol, 6, 483-94. 
   
